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Summary
Epstein-Barr virus (EBV) is a ubiquitous pathogen that infects most of the adult 
population and persists for life after the initial contact. The extreme success of the virus 
is attributed to its bipartite life cycle, which consists of a dormant-like state of latency, 
with periodical reactivation to the virus producing, lytic phase. Zta (BZLF1, Z, Zebra or 
EB1) is a multifunctional viral protein that belongs to the bZIP family  of transcription 
factors and is known as the master lytic regulator of EBV. Together with transcriptional 
activation, Zta has been shown to be involved in DNA binding-dependent transcrip-
tional repression, particularly of the host class II major histocompatibility complex 
transactivator, CIITA. Distinct protein domains, as well as various post-translational 
modifications, like phosphorylation of Serine 209 by  the viral protein kinase (VPK), 
have been linked to different functional roles of Zta. 
In the present study, it was shown that VPK can partially  inhibit  SUMOylation of 
Zta on Lysine 12, in a manner which was not dependent on Serine 209 phosphorylation. 
However, no direct interaction of VPK and Zta could be observed and no significant 
effect of either proteins on histone H2AX phosphorylation was seen.
Interestingly, in vitro reporter assays revealed that fusion of a SUMO moiety to the 
amine-terminus of Zta inhibited repression of the CIITA promoter, but not the activation 
of the viral BHLF1 promoter, pointing at divergent mechanisms of action of transcrip-
tional repression and activation by Zta. Moreover, truncation of the carboxy-terminal 
dimerisation domain of Zta (crucial for protein-DNA interaction) abrogated BHLF1 
transactivation but not CIITA down-regulation, revealing underlying differences in DNA 
binding requirements for the two processes.
Further in silico sequence analysis, coupled with a mutation approach of the CIITA 
promoter, confirmed that an alternate route to the Zta DNA binding-dependent repres-
sion exists. Finally, no single promoter element could be linked to down-regulation of 
CIITA, suggesting sequestration of a possible, yet unknown cofactor, by Zta.
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1. Introduction.
1.1 Herpesviruses.
Herpesviruses are ubiquitous infectious agents that are found across a wide range of 
various species. According to ICTV (International Committee on Taxonomy of Viruses), 
until recently, all herpesviruses were classified into the family of Herpesviridae with 3 
subfamilies of α-, β- and γ-herpesvirinae, that included viruses occurring in mammals, 
birds and reptiles. These subfamilies differ from each other by their ability to establish 
latency  in different tissues: α-herpesvirinae in neurons, β-herpesvirinae in monocytes 
and γ-herpesvirinae in lymphocytes (Davison, 2007). However, because of their omni-
presence and apparent similarities with other species of viruses, recently an entire new 
Order (the highest taxonomic rank for viruses) called Herpesvirales was created; and to 
the existing family  of Herpesviridae, two more were added, Alloherpesviridae and 
Malacoherpesviridae, which now encompass viruses that also infect amphibians, fish 
and the invertebrate bivalves (Davison, 2010; Davison et al., 2009). Nevertheless, the 
list of known herpesviruses is still considered far from complete. In addition to that, it  is 
widely  believed that the number of current species represents just  a small fraction of the 
total that ever existed. At least in part, this is attributed to the fact that each herpesvirus 
is specific to one type of host, with which along the course of history  they change and 
coevolve. On one hand this brings the risk of coextinction with the host species, but on 
the other, the benefit  of extremely  successful adaptability. Therefore, present-day her-
pesviruses are among the most complex, successful and persistent viruses, with many 
species capable of establishing infection throughout the lifetime of the host (Arvin, 
2007; Davison, 2002).
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Herpesviruses complexity  is reflected in their morphology. The virion particles are 
relatively large, averaging at about 200nm in diameter and are composed of at least four 
distinct parts [Figure 1.1] (McGeoch et al., 2006). The outer part is an envelope consist-
ing of a lipid bilayer with associated viral glycoproteins [Figure 1.1 (1) and (2)]. Tether-
ing of the virus to the cell surface is achieved through attachment glycoproteins, that in 
most cases bind to widespread cell membrane glycosaminoglycans (like heparan sul-
phate), receptors and integrins. Attachment alone is not sufficient  for viral entry and is 
mediated through distinct tissue receptors, providing various herpesviruses with cell 
type specificity. Fusion glycoproteins, gB and gH/gL, that are responsible for the final 
stages of viral entry, on the other hand, are not  species specific and are conserved across 
herpesviruses (Krummenacher et al., 2013). Immediately inside the envelope, is a ma-
trix of diverse herpesviral encoded proteins, named the tegument, that have a wide 
range of functions [Figure 1.1 (3)]. Some of the tegument’s important roles include es-
tablishment of initial viral infection by aiding transport to the nucleus, viral gene ex-
pression and immune evasion, as well as promoting latter stages of viral proliferation by 
assisting virion assembly and nuclear and cellular egress. In addition, the tegument pro-
teins are an integral part of the virion architecture, binding both the viral envelope and 
the viral capsid (Guo et  al., 2010a; Kelly et al., 2009). The herpesviruses capsid [Figure 
1.1 (4)] takes the shape of a regular icosahedron (three-dimensional structure composed 
of 20 equilateral triangles) with the triangulation number (T-number) of 16, implying 
the total makeup of 162 multimeric structural proteins termed capsomers. One of the 
vertices of the icosahedron constitutes a dodecameric portal complex needed for viral 
genome ejection upon infection and encapsidation during virion production. The other 
11 vertices are occupied by pentameric proteins and the remaining 150 capsomers
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5. DNA
3. Tegument
1. Lipid Envelope
4. Capsid
2. Envelope Glycoproteins
Figure 1.1 Graphical representation of a Herpesvirus virion particle.
Herpesvirus virion particles consist of: 1. Phospholipid membrane; with embedded 2. 
Envelope proteins; 3. The tegument; 4. Viral capsid; and the 5. DNA.
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are hexamers of the same protein species (Brown and Newcomb, 2011; Mettenleiter et 
al., 2009). The main function of the capsid is to protect  the viral genetic code until its 
release in the nucleus. In herpesviruses, the genome [Figure 1.1 (5)] is encoded by a lin-
ear double stranded DNA (dsDNA), up to 240kbp in length, made up of unique coding 
regions followed by repeats, which can be either direct, inverted, terminal or a combina-
tion of these. Moreover, the ends of the herpesviral DNA are marked by complementary 
overhangs, that aid circularisation upon reaching the nucleus (Arvin, 2007; McGeoch et 
al., 2006). 
All herpesviruses have a distinct biphasic life cycle, which consists of lytic and la-
tent stages. Initial contact with the host, usually causes a (primary) lytic infection. How-
ever, the resulting high load of viral replication is easily detected and eliminated by  a 
healthy immune system. As viral proteins evoke an immune response, the host immune 
system causes a selection pressure for a small number of cells in which the virus has 
established a successful latent  infection, enabling the infected cells to remain virtually 
undetectable. This is achieved through the expression of a minimal number of viral 
genes, immune evasion strategies, like interference with MHC class I and MHC class II 
antigen presentation, and genome replication only once during cell division, from a cir-
cular episome, during the latent phase. Thus, establishing latency, while intermittently 
reactivating to lytic cycle from a small number of infected cells, makes the host  a reser-
voir of infection and contributes to the success and persistence of herpesviruses (Griffin 
et al., 2010; Wagner, 2008; Zuo and Rowe, 2012). 
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1.2 Epstein-Barr virus.
1.2.1 History of EBV discovery.
Epstein-Barr virus (EBV) belongs to the γ-herpesvirinae subfamily and is one of 
the eight known herpesviruses that infect humans: herpes simplex virus-1 (HSV-1), her-
pes simplex virus-2 (HSV-2), varicella-zoster virus (VZV), EBV, cytomegalovirus 
(CMV), human herpesvirus 6 (HHS-6), human herpesvirus 7 (HHS-7) and Kaposi's 
sarcoma-associated herpesvirus (KSHV). EBV is extremely widespread, with an esti-
mated 90-95% of the total adult population infected, as the virus persists for life after 
the initial contact (Arvin, 2007). Despite this ubiquity, diseases related to EBV were not 
documented by medicine until the 1800s. The formal description of the virus was sum-
marised only by the end of the century, first by  a Russian physician, Filatov, in 1885 and 
then (independently) by a German physician, Pfeiffer, in 1889. However it was only in 
1920 when the actual name for Infectious Mononucleosis (IM) (discussed in chapter 
1.2.3) was given by Evans and Sprunt who identified it as a separate disease from acute 
leukaemia, though unable to link it  to EBV or any other infectious agent. In 1932 an-
other milestone was overcome with the discovery  by  Paul and Bunnell of an immuno-
logical test to check for IM. Nevertheless, until the 1960s attempts to find the cause of 
IM resulted in failure and the discovery of a new disease proved crucial for the break-
through (Tselis and Jenson, 2006). Through the late 1950s and early  1960s, surgeon 
Denis P. Burkitt, who worked with patients in East Africa, published various articles on 
tumours occurring in African children, subsequently  called Burkitt’s lymphoma (BL). 
The discovery of the new disease drew the attention of M. Anthony Epstein who re-
quested some samples from Burkitt and by 1964, with the help of Achong and Barr, 
identified a new herpesvirus in BL tissue using electron microscopy (Epstein et al., 
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1964). Isolation of the virus proved to be difficult, and Epstein turned to spouses Ger-
trude and Werner Henle who almost by chance found a link between EBV and IM. The 
serum of a technician (Elaine Hutkin) in their laboratory was used as negative control 
for EBV antibodies. However, once she developed IM, the serum started to react to the 
antibodies. After further investigation, in 1968 they showed that EBV indeed caused 
IM. Since then a vast array of different diseases have been linked to EBV (discussed in 
more detail in chapter 1.3) (Robertson, 2005; Tselis and Jenson, 2006).
1.2.2 EBV genome.
Like other herpesviruses, EBV has a linear dsDNA encoded genome, that circular-
ises upon infection into a structure called the episome (Odumade et al., 2011). EBV has 
a relatively high (~60%) content of guanine and cytosine base pairings (compared to 
~46% in humans (Romiguier et al., 2010)) and the length of the viral DNA can vary  be-
tween different strains and types of EBV but is around 172kbp (Farrell, 2005). The ge-
nome is composed of 5 unique regions (UR 1-5), separated by four internal repeats (IR 
1-4) and flanked by terminal repeats (TR) [Figure 1.2]. Different strains of EBV vary  in 
the number of repeats and therefore the origin of an EBV infection can be traced using 
these DNA markers (Rickinson and Kieff, 2001). 
In addition to strain variation, 2 different types of EBV have been identified: type 1 
and type 2 (also known as type A and type B) (Rickinson et al., 1987). Individuals can 
be infected with either type of EBV, however, type 1 is more widespread, although type 
2 has been shown to have a relatively  high incidence in New Guinea and some equato-
rial African countries (Abdel-Hamid et al., 1992). The main difference between the two 
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TR TR
A.
B.
C. Zta + EBV replication machinery
EBNA1 + host replication machinery
1x per cell division
kb
EBV genome
Infection and
circularisation 
TR
Latency to lytic
cycle switch
TR
Lytic replication
(from oriLyt)
Latent replication
(from oriP)
Figure 1.2 Schematic representation of the EBV genome.
A. Linear viral genome found in virions, with the relative position of terminal repeats 
(TR), internal repeats (IR 1-4) and uniques regions (U 1-5) is shown. Adapted from 
Straus et al. (1993) B. Latent viral genome replication depends on EBNA 1 protein 
and host replication machinery and happens only once per cell division with creation 
of two daughter episomes. C. Lytic EBV genome replication is dependent on Zta and 
viral DNA replication machinery, with creation of long concatameric DNA, that are 
cleaved and packaged into virions. Can be inhibited by acyclovir.
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types of EBV is found in the EBNA 2, -3A, -3B and- 3C (Epstein-Barr viral nuclear an-
tigen 2, 3A, 3B and 3C) genes (Arrand et al., 1989; Sample et al., 1990). EBNA proteins 
are known to be important in EBV’s ability to establish latent infection in B cells (Co-
hen et al., 1989; Tomkinson et al., 1993). Indeed, experiments in which B lymphocytes 
were transformed with EBV to generate in vitro lymphoblastoid cell lines (LCLs), 
showed that type 1 EBV is more competent at transforming and persisting than type 2 
(Rickinson et al., 1987). Because of the immortalisation experiments, over the years, 
type 1 strain has been studied more, although type 2 is also found in cancers, indicating 
that in vitro immortalisation assays do not fully reflect the process of carcinogenesis in 
man. Type 1 was the first to be sequenced in 1984 by Baer et al. The nomenclature of 
EBV genes was based on the direction (rightward or leftward), number and location of 
each identified open reading frame (ORF) relative to BamHI DNA fragments, that were 
labelled alphabetically  in a descending size order (Baer et al., 1984; Skare and Stromin-
ger, 1980). Thus a gene name like BGLF4 can be deciphered as: BamHI Fragment G 
Leftward (transcript) 4; indicating that  BamHI fragment G contains at least three more 
leftward transcripts. Some gene and protein names have been replaced by  more mean-
ingful ones over time, however the original nomenclature is still widely  used, particu-
larly for gene annotations. It is now known that the EBV genome expresses about a 
hundred mRNA transcripts that also include non-coding EBERs (Epstein-Barr virus-
Encoded Ribonucleic acids) and the still poorly understood BARTs (BamHI rightward 
transcripts), the protein products of which remains to be found (Farrell, 2005). Some 
BARTs have been shown to code for micro RNAs (miRNAs) that can interfere with 
DNA replication (Pfeffer et al., 2004). EBERs on the other hand, were found to possess 
an anti apoptotic function, as well as the ability  to interfere with several host enzymes, 
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however, much remains unknown about these transcripts (Clemens et al., 1994; Nanbo 
et al., 2002).
Upon entry and circularisation, the unmodified EBV genome undergoes extensive 
epigenetic alterations. One such modification is the Cytosine methylation of the CpG 
(Cytosine-phosphate-Guanine) motifs (Kintner and Sugden, 1981). In humans, CpG 
methylation has been linked to decreased promoter activity and gene silencing, usually 
through the recruitment of proteins that bind methyl-DNA and repress gene expression 
(Attwood et al., 2002; Di Croce et al., 2002). It is thought that DNA methylation of 
various viral genomes is an evolutionary adaptation aimed at decreasing viral gene ex-
pression and ultimately viral replication (Ernberg et al., 2011). Interestingly, EBV’s co-
evolution with the host has enabled the virus not only to overcome, but to use the DNA 
methylation to its advantage (Sinclair, 2013; Woellmer and Hammerschmidt, 2013). The 
viral transcription factor Zta, encoded by  the BZLF1 gene (discussed in more detail in 
chapter 1.5) has a unique property of being able to activate methylated promoters. In 
addition to that, a group  of essential lytic genes are directly dependent on CpG methyla-
tion for efficient transcription. Therefore, the lack of EBV DNA methylation during ini-
tial infection prevents full lytic cycle activation and virion production (Bergbauer et al., 
2010; Kalla et al., 2012; Kalla et al., 2010; Ramasubramanyan et al., 2012a; Woellmer 
et al., 2012). Latent  promoters of EBNA genes (Cp, Wp, Qp), on the other hand, utilise 
the host’s transcription machinery and are sensitive to methylation. This allows EBV 
not only  to establish latency in an unmethylated genome environment, but also to 
gradually progress to more silent forms of latency as the Cp and Wp promoters become 
methylated (Paulson and Speck, 1999; Tierney et al., 2000). Since methylation is a pre-
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requisite for successful lytic promoter activity, in its heavily methylated form, the viral 
genome is poised for re-activation and escape from latency (Sinclair, 2013).
Another form of epigenetic modification that EBV encounters upon infection is the 
genome packaging into chromatin, which consists of repeating units known as nucleo-
somes. The structure of a single nucleosome consists of protein octamers called his-
tones, wrapped with approximately 147bp of DNA (Lodish et al., 2008). There are two 
distinct forms of chromatin: tightly packaged heterochromatin, and DNA accessible 
euchromatin. Different post-translational modifications (PTMs) of histones are associ-
ated with different chromatin states. Among the many, acetylation at Lysine 9 or Lysine 
27 of histone H3 (H3K9ac and H3K27ac) is linked to euchromatin. Whereas, hetero-
chromatin is known to have such modifications as Lysine 9 trimethylation of histone H3 
(H3K9me3). Furthermore, polycomb group  of proteins can be recruited by Lysine 27 
trimethylation of histone H3 (H3K27me3), which is also associated with chromatin si-
lencing (Lanzuolo and Orlando, 2012; Richards and Elgin, 2002). Investigation of vari-
ous lytic promoter regions has shown that the heterochromatic H3K9me3 mark is pre-
sent in the viral genes during latency. However, Zta can still bind to promoters contain-
ing H3K9me3 (Ramasubramanyan et al., 2012b). In addition to that, H3K27me3 poly-
coomb proteins associated mark was observed at various EBV genes during latency  and 
did not decrease substantially  during early  lytic cycle. At the same time, viral lytic tran-
scription from the studied promoters exhibited normal kinetics (Woellmer et al., 2012). 
Together these studies suggest that Zta can overcome various repressive marks and acti-
vate lytic promoters regardless of the chromatin state, although the mechanism by 
which Zta achieves this, remains unknown.
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1.2.3 EBV primary infection.
The main route of EBV transmission is through the saliva, which is reflected in the 
common name for IM: kissing disease. It is thought that most EBV infections happen in 
infancy, since young children share various objects like cutlery and toys that might be 
contaminated with salivary secretions. At a young age the primary  viral infection does 
not manifest itself symptomatically, however, as the individual matures to adolescence 
and then adulthood, there is a progressively  higher chance of developing IM  upon the 
first contact with EBV. The incubation period usually lasts around six weeks before IM 
starts to manifest. Among the most common symptoms of IM  are fever, headaches, in-
flated lymph nodes and pharyngitis (throat inflammation), giving another common 
name for IM: glandular fever. IM is linked to the overreaction of the immune system to 
EBV infection in B cells, where the virus establishes latency III program with frequent 
reactivation to lytic replication [Figure 1.3]. This causes the production of abnormally 
high numbers of peripheral blood lymphocytes, particularly T cells, which in turn can 
lead to leukocytosis and anaemia (Kutok and Wang, 2006; Odumade et al., 2011). 
EBV can infect both B cells and epithelial cells. The virus can be found in B lym-
phocytes of patients with such diseases as BL and Hodgkin’s lymphoma (HL) and the 
mentioned above IM (Epstein et al., 1964; Niedobitek et al., 2000; Weiss et al., 1991). 
Epithelial cells are infected in such malignancies as nasopharyngeal carcinoma (NPC) 
or oral hairy  leukoplakia (OHL) (Brooks et al., 1992; Greenspan et al., 1985). However, 
it is still a question of debate whether EBV infects epithelial cells in healthy  individuals 
as well, and not just in the abnormal disease environment. The oro- and nasopharynx 
have a number of lymphoid tissues collectively called the Waldeyer's ring. The tonsils
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Figure 1.3 Differential expression of EBV latent genes in various latent pro-
grams. 
As the EBV latency programs progress, less viral genes are expressed and the immu-
nogenicity of infected cells decrease. Gene products expressed during different la-
tency programs are shown. Some of the diseases associated with each latency pro-
gram are indicated as well. IM: infectious mononucleosis; XLP: X-linked lymphopro-
liferative syndrome; PTLD: post-transplant lymphoproliferative disorder; HL: Hodg-
kin’s lymphoma; NPC: nasopharyngeal carcinoma; BL: Burkitt’s lymphoma.
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that constitute the ring are composed of lymphoepithelial tissues, usually with invagina-
tions called crypts. These protrusions create a large surface area for the tonsils, as they 
are the first line of immunological defence against  exogenous pathogens (Hellings et al., 
2000). Since the epithelium in the crypts can be as thin as a cellular monolayer, it is 
possible that EBV directly migrates to B cells between the cellular gaps or alternatively 
passes through epithelial cells without establishing infection, by  a process called tran-
scytosis. Nevertheless, the predominant model of primary EBV infection at the moment 
is that the epithelial cells become infected transiently and undergo rounds of lytic repli-
cation. This results in the production of a high number of viral particles, which can then 
infect naïve B cells in the oropharynx (Hutt-Fletcher, 2005; Tugizov et al., 2013). 
Infection of B cells requires the binding of a number of cellular and viral receptors 
and subsequent endocytosis. The B cell specificity is mediated through the EBV glyco-
proteins gp350/220 that bind the cell surface receptor CD21 also known as complement 
receptor type 2 or CR2 (Tanner et al., 1988). Gp350 and gp220 are splice variants of the 
same viral gene BBLF1 and are 350 and 220 kDa in size respectively. The smaller 
gp220 protein variant is 197 amino acids shorter than the 907 residues long gp350 but 
retains the CR2 binding domain (Beisel et al., 1985). To complete the fusion with the 
endocytic vesicle membrane, EBV utilises glycoprotein gp42 (BZLF2 gene) that binds 
to major histocompatibility  complex (MHC) class II and recruits other fusion glycopro-
teins gB, gL and gH (Kirschner et al., 2006; McShane et al., 2003). Epithelial cells, on 
the other hand, do not endocytose EBV and usually  do not express a CR2 receptor, with 
exception of some tumour cell lines that were shown to have low levels of CR2. The 
biological significance of this observation in vivo still remains to be established. It is 
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now known however, that the BMRF2 protein can bind to β1 family of integrins and 
facilitate entry into epithelial cells (Fingeroth et al., 1999; Hutt-Fletcher, 2005; Xiao et 
al., 2008).
1.2.4 EBV latent phase.
Unlike their lytic counterparts, latent EBV genes do not have homologues in other 
herpesviruses and are unique to the virus. Latent cycle transcripts include six EBNA 
proteins, EBNA1, -2, -3A, -3B, -3C and -LP; three LMP proteins (latent membrane pro-
teins), LMP1, -2A and -2B; as well as the non-coding BARTs, EBER1 and EBER2 
RNAs. As EBV infects undifferentiated naïve B cells in the tonsillar crypts, the virus 
establishes latency III or ‘growth program’ during which the entire array of the afore-
mentioned latent genes are expressed (Joseph et al., 2000). These viral products push 
the B cells to differentiate into active B cell blasts. Since the latency  III is highly immu-
nogenic due to the number of genes expressed, the immune response creates a selection 
for B cells in which EBV has established latency II or ‘default program’. During latency 
II, the promoter for EBNA genes switches from Wp/Cp  to Qp, causing the shut off of 
most EBNA proteins except EBNA1. B cell blasts are then further pushed into forming 
germinal centres in B cell follicles where they differentiate into long living memory B 
cells that circulate around the body, creating a reservoir for viral infection (Babcock et 
al., 2000; Casola et al., 2004; Yoshioka et al., 2003). In these cells the successful EBV 
infection is in a true latency form (latency 0 or just ‘latency program’), during which 
almost all viral transcription switches off, with probable exception of LMP2A, BARTs 
and EBERs genes (Miyashita et al., 1997). When the resting memory B cells occasion-
ally divide, latency I transcription is initiated, and EBNA1 is upregulated once again, to 
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allow the replication of the viral episome. Minimal protein expression during these later 
forms of latency allows the virus to avoid immune surveillance and persist for life [Fig-
ures 1.3 and 1.4] (Amon and Farrell, 2005; Hochberg et al., 2004; Thorley-Lawson, 
2005).
Differential expression of EBV genes in various forms of latency  is related to the 
function and immunogenicity of each protein, as the cytotoxic T lymphocyte (CTL) re-
sponse creates a constant selective pressure on the infected cells. EBNA1 is present dur-
ing most forms of latency  as it  is responsible for viral episome replication. It does this 
by binding to the origin of plasmid (i.e. latent) replication OriP and recruiting host ori-
gin recognition complex (ORC) that initiates DNA replication (Dhar et al., 2001). EB-
NA1 can also activate gene expression, including transcription from the Cp  promoter 
(Kang et al., 2001). In addition to that, EBNA1 can inhibit the Qp promoter, auto-
regulating its own production. Unlike most latent proteins, EBNA1 possesses low im-
munogenicity due to Glycine-Alanine repeats in the protein sequence, that interfere with 
MHC class I presentation (Frappier, 2012).
The other EBNA proteins do not posses the origin binding ability, but can also 
modulate cellular and viral gene expression. Rather than directly binding to the DNA, 
EBNA 2, -3A, -3B, -3C and -LP interact with cellular factors to regulate protein synthe-
sis (McClellan et  al., 2012; Robertson et al., 1996). Amongst others, this includes EB-
NA2 upregulation of LMP proteins, which major function is to facilitate B cell differen-
tiation in the absence of normal B cell maturation signals (Johannsen et al., 1995).
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Figure 1.4 EBV life cycle in B cells.
Maturation pathway of B lymphocytes and the associated EBV life cycle programs 
are shown.
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In contrast to the EBNA proteins, LMPs are transmembrane proteins and localise 
mainly in the outer lipid bilayer and lipid rafts (Higuchi et al., 2001). LMP1 is an ana-
logue of CD40 protein, that  binds to T cells through CD154 receptor, a process essential 
for B cell activation and survival. Unlike CD40, however, LMP1 is constitutively active 
and does not require CD154 binding, allowing the infected B cells to avoid apoptosis. 
LMP1 was also shown to be crucial for efficient viral release during the lytic cycle (Ah-
san et al., 2005; D'Souza et al., 2000; Uchida et al., 1999). LMP2 proteins, on the other 
hand, are responsible for preventing reactivation of EBV. Antigen binding to the B cell 
receptor can result  in a super activation of the phospholipase C pathway, ultimately trig-
gering lytic cycle. Nonetheless, the LMP2 intracellular domain mimics that of the inac-
tive B cell receptor and binds Lyn, Fyn and Syk protein kinases. In this bound form, the 
phosphorylation ability  of these proteins is reduced, causing a tonic signal for survival 
but not a full activation of phospholipase C (Cohen, 2006; Miller et al., 1995; Thorley-
Lawson, 2001). 
1.2.4 EBV lytic replication.
Resting memory B cells that undergo terminal differentiation into plasma cells can 
cause reactivation of the lytic cycle, which will result in the production high numbers of 
new virion particles with eventual cell death. Conveniently, plasma cells preferentially 
migrate to the epithelial crypts to combat incoming infection by  antibody  secretion. This 
property  of plasma cells provides a mechanism through which EBV can set a high viral 
load in the mucosa of the mouth, allowing the infection to spread throughout the popu-
lation (Brandtzaeg et al., 1999; Laichalk and Thorley-Lawson, 2005). 
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As EBV switches to the lytic cycle, a cascade of events is initiated, that consist of 
three distinct stages: immediate early, early and late phases of protein expression. The 
main current model used for studying EBV reactivation in vitro utilises Burkitt’s lym-
phoma derived cell lines (like Akata). Activating the B cell receptor (BCR) with such 
agents as IgG immunoglobulins in vitro, mimmics viral reactivation in plasma cells in 
vivo (Takada and Ono, 1989). Stimulation of the BCR in a functioning protein synthesis 
environment, was shown to result in upregulation of the two immediate early  viral 
genes BZLF1 and BRLF1, which encode the transcription factors, Zta and Rta (Fleming-
ton et al., 1991). These proteins modulate the expression of cellular and viral lytic genes 
by either directly  binding to specific recognition sequences on the DNA or through 
other accessory  proteins. Both transcription factors can initiate the lytic cycle since they 
can auto activate their own promoters known as Rp  and Zp, and upregulate each other 
(Adamson et al., 2000; Hsu et al., 2005; Liu and Speck, 2003; Ragoczy et  al., 1998). 
However, in vitro Luciferase assays have shown that only Zp (but not Rp) is directly 
upregulated by BCR activation. This suggests that Zta protein expression is a primary 
event, which is subsequently followed by the activation of the Rp (Amon et al., 2004). 
Binding sites of cellular transcription factors including myocyte enhancer factor-2 
(MEF-2) and X-box binding protein 1 (XBP-1) have been identified in the BZLF1 pro-
moter region, and were shown to be essential for efficient transcription from Zp 
(McDonald et al., 2010). After Zta and Rta are expressed, the two proteins can synergise 
to alter cellular gene expression and cause G0/G1 to S cell cycle transition in B cells 
(Cox et al., 1990; Guo et al., 2010b). G0/G1 cell cycle arrest through inhibition of c-
myc and activation of p21 and p27 is also attributed to Zta (Rodriguez et al., 2001). In 
addition to transcription control, Zta has the ability to bind to the origin of lytic replica-
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tion (oriLyt) and trigger DNA synthesis required for new virions (Gao et al., 1998; 
Schepers et al., 1993a). Furthermore, Zta facilitates the switch from the viral latent 
phase by inhibiting the Cp promoter that drives the expression of the EBNA proteins 
(Sinclair et al., 1992). Nevertheless, both Zta and Rta are essential for the efficient pro-
gression of the lytic cycle (Feederle et al., 2000).
During the early lytic phase, with the help  of Rta and Zta, EBV expresses a wide 
range of various genes. One group includes proteins that replicate the viral genome, al-
lowing EBV to be independent of the cellular DNA polymerase. These are helicase-
primase BBLF2/3, helicase BBLF4, primase BSLF1, DNA polymerase processivity fac-
tor BMRF1, single-stranded DNA binding factor BALF2 and DNA polymerase BALF5. 
Through an elaborate network of interaction with each other, Zta and DNA, the complex 
assembles at the oriLyt and initiates DNA synthesis. BALF5 and BMRF1 then carry  on 
to replicate the EBV genome by rolling circle, creating long, concatameric DNA mole-
cules, that are then cleaved at the terminal repeats and eventually packaged into virions 
[Figure 1.2] (Cohen, 2006). BMRF1 is also a transcription factor and together with an-
other early lytic protein BRRF1, helps Zta and Rta with viral and host gene modulation 
(Holley-Guthrie et al., 2005; Hong et al., 2004). Another group  of proteins in the early 
lytic cycle possesses antiapoptotic capabilities. BHRF1 and BALF1 are both homo-
logues of cellular BCL-2 (B cell lymphoma 2) that is a proto-oncogene (Henderson et 
al., 1993; Marshall et  al., 1999). BCL-2 inhibits BAX and BAK proteins that are found 
upstream of the caspase mediated apoptosis pathway  (Youle and Strasser, 2008). There-
fore BHRF1 and BALF1 can promote B cell survival needed in the highly immunogenic 
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lytic cells. The only EBV encoded protein kinase, BGLF4, is also an early lytic protein, 
whose function is discussed later on (Cohen, 2006; Kenney and Israle, 2005).
Late lytic proteins are classified as products expressed after viral DNA replication. 
Unlike early genes, they do not have Zta and Rta binding sites in their promoter region. 
Late proteins comprise all of the capsid proteins and surface glycoproteins that assem-
ble the final virion particles. In addition to that, a cytokine homologue BCLF1, that 
shares almost 80% of its sequence with interleukin-10 (IL-10), is also expressed. Like 
its cellular counterpart, BCLF1 can stop the CTL response and stimulate B cell growth. 
It has been suggested that the secretion of BCLF1 from lytic cells can support the 
growth of the surrounding latently  infected B cells (Hsu et al., 1990; Kenney  and Israle, 
2005; Salek-Ardakani et al., 2002). 
1.3 EBV associated diseases.
Unlike other herpesviruses, most  EBV associated diseases are linked to the latent 
phase rather than lytic viral replication. It is widely believed that causing a disorder is 
not a strategy actively  pursued by EBV, as so much of the viral effort is dedicated to 
immune system avoidance, and persistence in the host. Therefore, some additional mo-
lecular aberrations must occur in the infected cells in order for a disease phenotype to 
develop. EBV related malignancies have been linked to different latency programs, with 
concomitant viral expression patterns (Thorley-Lawson, 2005).
The main affliction connected to the latency I program of EBV is Burkitt’s lym-
phoma. BL is a B cell malignant tumour identified by over-expression of the oncogene 
 20
c-myc, that is a transcription factor involved, amongst other things, in apoptosis and cell 
proliferation. A translocation event of the c-myc ORF on chromosome 8 to highly active 
immunoglobulin promoter regions on either chromosome 2, 14 or 22, is thought to be a 
main driving event towards BL. What part EBV plays in the establishment of BL is not 
yet fully understood, but the extremely high rate of association of the virus with BL link 
them together. One possibility  of EBV’s involvement in BL, is the potential prevention 
of apoptosis and increased survival conferred by  the viral EBER transcripts, that would 
allow the tumorigenic events to accumulate in the cells. On the other hand, EBV is 
thought to have the potential to cause chromosomal instability, that would lead to the c-
myc translocation (Gruhne et al., 2009; Young and Rickinson, 2004).
Two major latency II associated diseases are Hodgkin’s lymphoma and nasopha-
ryngeal carcinoma. HL is a lymph node cancer thought to arise from overreaction of the 
immune system to the proliferation of malignant germinal centre B lymphocytes, called 
Hodgkin/Reed Sternberg cells. Up  to 99% of the neoplasm volume consists of high 
numbers of various immune response cells like T lymphocytes, neutrophils, plasma 
cells, granulocytes, etc. NPC on the other hand, is an epithelial cancer most common is 
southeast Asia. Both HL and NPC use the growth promoting functions of LMP proteins 
discussed earlier (Thorley-Lawson, 2005; Young and Rickinson, 2004).
Latency  III on the other hand, is related to EBV disorders that are found mostly in 
immunocompromised individuals. These include X-linked lymphoproliferative syn-
drome (XLP), post-transplant  lymphoproliferative disorder (PTLD) and acquired im-
munodeficiency syndrome (AIDS) associated lymphomas. Without the appropriate T 
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cell response, B cells infected with EBV in the latency III program are not eliminated 
and the growth signals conferred by latency III genes are not  restricted. Thus, B cells 
infected with EBV, in individuals with deficient immunity, are prone to lymphoprolif-
eration (Kutok and Wang, 2006; Macsween and Crawford, 2003).
Oral hairy  leukoplakia is also found in immunocompromised patients, but unlike 
most EBV diseases is associated with active lytic replication of the virus. OHL is a be-
nign cell lesion found in epithelium of the mouth. It is not clear if the lytic cycle is reac-
tivated in persistently  infected epithelial cells due to decreased immune response or if 
the epithelium becomes more susceptible to the B cells amplification of EBV during 
immune suppression. Nonetheless, because OHL is linked to lytic replication, the le-
sions can be treated with acyclovir, which blocks the DNA synthesis in infected cells 
(Kutok and Wang, 2006; Macsween and Crawford, 2003). 
1.4 Viral protein kinase
Viral Protein Kinase (VPK) is a early lytic protein encoded by the BGLF4 gene. 
VPK is a serine/threonine kinase, 429 amino acids in length, that was discovered by 
homologous comparison (amino acid alignment) to the UL13 of HSV which is a con-
served kinase throughout many herpesviruses. Other homologues of VPK include UL97 
of human cytomegalovirus, gene 47 of varicella-zoster virus, 15R of human herpesvirus 
6 and ORF36 of human herpesvirus-8 (Gershburg and Pagano, 2008). VPK was shown 
to be capable of autophosphorylation using ATP as well as GTP as substrate. Lysine 102 
is a crucial residue for phosphorylation and the mutation of this site renders VPK kinase 
dead (Kato et al., 2003). VPK is mainly found in the nucleus with only a small amount 
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present in the cytoplasm. The nuclear localisation signal (NLS) of VPK is located 
within the 55aa of the C-terminus of the protein, which is different from the NLS of 
other herpesvirus kinases [Figure 1.5]. VPK is an early lytic gene whose expression 
rises during the progression of the lytic cycle and the protein co-localises in the viral 
replication compartments in the nucleus. However, VPK is also found in the tegument 
of the EBV virions from which it  can detach through phosphorylation (Asai et al., 2006; 
Gershburg et al., 2004; Wang et al., 2005). VPK can phosphorylate numerous viral and 
host proteins (Zhu et al., 2009). The full range of potential targets is still unknown, and 
the studied interactions show involvement in diverse molecular processes that make it 
hard to identify a clear role for VPK. One of the early studies on VPK suggested that it 
mimicked the action of cyclin dependent kinase-1 (CDK1) by phosphorylating EBNA-
LP and EF-1δ at the same residues. EF-1δ is an elongation factor required for the trans-
lation of cellular proteins. The ability of VPK to phosphorylate this factor suggest an 
involvement in protein synthesis in the cells (Kato et al., 2001; Kato et al., 2003; Kawa-
guchi et al., 2003). Moreover, both VPK and CDK1 can phosphorylate the viral DNA 
polymerase processivity  factor BMRF1. This phosphorylation by VPK is thought to 
help  the recruitment of Zta to the oriLyt ensuring efficient lytic replication (Chen et al., 
2000; Yang et al., 2008). Another indication of CDK1 mimicry is the creation by  VPK 
of mitosis-like conditions in the nucleus. Specifically, VPK can induce the condensation 
of the nuclear DNA by phosphorylating and activating topoisomerase II and condensin, 
which is thought to be useful for EBV as it creates more space for viral DNA replication 
(Lee et al., 2007). Additionally, VPK can also induce nuclear lamina disassembly by 
phosphorylating Lamin A protein essential for nuclear integrity. This is thought to help 
virions to egress from the nucleus, and is further supported by the fact that VPK can 
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control the disassembly of microtubules, another cytoskeletal component (Chen et al., 
2010; Lee et al., 2008). Nevertheless, VPK does not fully mimic CDK1. A study aimed 
at finding VPK substrates using a protein array  phosphorylation assay, identified a range 
of latent and lytic proteins, some of which were not CDK1 targets (Zhu et  al., 2009). 
VPK was also shown to be involved in immune suppression by  inhibiting interferon 
regulatory factor 3 (IRF3). In the presence of VPK, IRF3 has a diminished ability to 
bind to DNA and upregulate interferon production. The inhibition is thought to be 
through phosphorylation of  Serines 123 and 173, and Threonine 180 of IRF3 (Wang et 
al., 2009). Furthermore, VPK involvement in the DNA damage response is highlighted 
by direct phosphorylation of the histone acetyltransferase TIP60 (Li et  al., 2011). Zta is 
another protein known to be targeted by  VPK. Zta is phosphorylated at Serine 209 
which is also a non-CDK1 site but rather similar to a casein kinase 2 (CK2) site. After 
phosphorylation VPK and Zta can form a stable complex which might lead to their co-
localization. In their study, Asai et al. also observed some down-regulation of Zta trans-
activation activity of its own Zp  promoter when VPK was present. They  suggested that 
this might be a control mechanism to decrease Zta levels in later stages of lytic cycle 
(Asai et al., 2006; Asai et al., 2009).
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Figure 1.5 Graphical representation of VPK’s primary structure.
The catalytic Lysine 102 (K102) as well as the first 26 residues (NT) required for 
(auto)phosphorylation are shown. The domains homologous to other Herpesvirus 
protein kinases are indicated by roman numerals, with number II predictively being 
the ATP binding site; the terminal 55aa responsible for nuclear localisation are 
marked as NLS. Based on Chen et al. (2000) and Gershburg et al. (2004) studies.
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1.5 Zta
Zta, also known as Z, Zebra or EB1 is an immediate-early  lytic protein that is en-
coded by the BZLF1 gene of EBV. Zta is a transactivator that  can also act as a transcrip-
tional repressor or DNA replication factor. Among the many functions of Zta are lytic 
cycle progression, initiation of viral DNA synthesis, cell cycle regulation, immune re-
sponse modulation and inhibition of apoptosis (Sinclair, 2003). 
1.5.1 Zta protein structure.
Zta is a 245 amino acid in length, 35kDa protein that belongs to the basic leucine 
zipper (bZIP) family of transcription factors which include cellular homologues like c-
jun and c-fos. bZIP proteins have a characteristic basic region responsible for DNA con-
tact and a leucine zipper (ZIP) region involved in dimerisation. The basic domain of Zta 
has a high homology  with c-fos while the zipper is somewhat atypical. Both of these 
motifs are found in the carboxy terminal region of the protein [Figure 1.6] (Farrell et al., 
1989). Investigations using electrophoretic mobility shift assays (EMSAs) have shown 
that the C-terminal 134-245aa Zta fragment alone can bind DNA (Farrell et al., 1989). 
The basic domain, located roughly between the residues 175 and 195, is composed of 
two distinct parts termed basic region A (BRA) and basic region B (BRB). Mutagenesis 
experiments of BRA and BRB have shown that these regions are essential for DNA 
binding, as well as, nuclear localisation of Zta (Mikaelian et al., 1993; Packham et al., 
1990). 
The zipper region of Zta is located approximately  between residues 195 and 221 
[Figure 1.6], and is crucial for dimerisation, which in turn is a prerequisite for DNA 
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binding (Hicks et al., 2003). Early studies proposed that the dimerisation of Zta is de-
pendent on a coiled coil helix formation. However, unlike other bZIP proteins, Zta’s 
bZIP domain does not contain heptad leucine repeats but rather repeats of hydrophobic 
amino acids. This in part explains the inability  of Zta to efficiently heterodimerise with 
other bZIP proteins like c-jun and c-fos. Mutational evaluation of the zipper region 
demonstrated that the amino acids on the inside of the predicted helix are necessary  for 
dimerisation, whereas the substitution of the outside residues does not elicit an effect 
(Flemington and Speck, 1990). Indeed, crystallographic analysis of a dimerised 175 to 
236 amino acid portion of Zta bound to DNA, confirmed that both basic and zipper re-
gions form a helix. The basic part of the protein fits in the major groove of the DNA, 
but unlike other bZIP transcriptions factors, binds with a higher affinity. This allows Zta 
to interact with a larger variety  of DNA sequences in comparison to other bZIP proteins. 
In addition, Zta’s zipper region does form a coiled coil but is shorter than that of c-jun 
or c-fos. A proline residue at position 223, allows the short C-terminal helix to fold back 
onto itself and interact with the coiled coil structure, contributing to the stability of the 
homodimer (Petosa et al., 2006). Further biophysical and biochemical investigations 
questioned the importance of the carboxy terminus of Zta. Schelcher et al. (2007) gen-
erated short peptides of the bZIP domain (196-231aa of Zta) or bZIP with 10 extra adja-
cent C-terminal residues (196-221aa of Zta), and subjected them to analytical centrifu-
gation and circular dichroism spectroscopy. The addition of 10 CT amino acids consid-
erably increased the dimer and helical structure formation in the studied fragments. In 
addition, the group also produced a series of carboxy terminal truncation mutants of Zta. 
Cross-linking experiments showed that deletions past residue 230 (1-227aa fragments or 
shorter), prevents Zta from forming protein dimers. While EMSA and reverse transcrip-
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tion quantitative PCR (qPCR) demonstrated that Zta must be at least 230 residues long 
to interact with DNA in vitro or transactivate the BMRF1 gene in vivo (Schelcher et al., 
2007). Interestingly, in a separate study, truncating just the three CT residues (243-
245aa) proved to be sufficient for the inhibition of viral genome replication in vivo and 
Zta binding to p53-binding protein 1(53BP1) in vitro (Bailey et al., 2009). Thus, Zta is a 
unique member of bZIP family of proteins which has evolved an uncommon helix motif 
and carboxy terminal region, allowing it to predominantly  form homodimers and to bind 
a wider range of DNA and protein targets. 
Zta
basic ZIP C-ter
1 245
K12 S209S186S173
TFIID binding
TA
Figure 1.6 Graphical representation of Zta’s primary structure.
The key residues are shown: K12 - Lysine 12 at which sumoylation occurs and S173, 
S186 and S209 - Serines 173, 186 and 209 at which phosphorylation by CK2, PKC 
and VPK occurs. The main known domains are also shown: TA - transactivation do-
main; DNA - basic DNA contact region; bZIP - basic zipper domain; C-ter - Carboxy 
terminal region. TFIID binding region associated with highest transactivation loss 
upon mutation is also shown.
The rest of the (amine adjacent) Zta protein is a much less structured region than 
the bZIP domain and has not yet been crystallised. Even though the first  174 amino ac-
ids are not involved in the DNA binding ability of Zta, the amine terminus is known to 
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be important for the transcription activity of the protein and is therefore called the trans-
activation domain (TA) (Packham et al., 1990). A hybrid protein consisting of the first 
167 residues of Zta joined to the dimerisation and DNA binding regions of Gal4 can ac-
tivate a promoter with Gal4 binding sites in vitro. In the same study, a sequential muta-
tional analysis of the TA region revealed that several elements are responsible for the 
transactivation function of Zta. Mutating the protein past amino acid 153 and up to resi-
due 167 abolishes its DNA binding ability, possibly due to close proximity to the bZIP 
region. The highest loss in the transcriptional activity  (80% decrease) of the Zta variants 
is associated with deletion of 27-53aa and 52-78aa regions. Removing other short TA 
sections however, also correlates with a decrease in transcription activation, albeit to a 
lesser extent (40% decrease) (Flemington et al., 1992). Point mutation experiments 
showed that  various amino acid groups in the first 78 residues of Zta have cell type spe-
cific and functional differences. One group is the negatively charged residues, aspartic 
acid 28 and 35 together with glutamic acid 54 (D28 D25 E54); the other consists of 
aromatic amino acids, phenylalanine 22, 26 and 75 with tryptophan 49 and 74 (F22 F26 
F75 W49 W74). The acidic D28, D25 and E54 residues are involved in the transcription 
of the BMRF1 and BRLF1 promoters as well as Zta dependent reactivation of the lytic 
cycle in both epithelial and B-cells. Whereas the hydrophobic F22, F26, F75, W49 and 
W74 residues are needed for Zta’s transcription of a range of viral promoters in epithe-
lial cells and interaction with CREB-binding protein (CBP) and TFIIA-TFIID transcrip-
tion factors. Additionally, the acidic residues play  a role in stabilising Zta, whereas mu-
tating the aromatic amino acids cause a decrease in protein levels (Deng et al., 2001). 
As a result, it  is thought that the diverse amino acid composition and the flexibility of 
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the TA domain allows Zta to bind a range of various targets and exhibit a plethora of 
effects.
1.5.2 Post-translational modifications of Zta.
Zta is post-translationally  modified in several different ways. One type of PTM  as-
sociated with Zta is the phosphorylation on a range of different residues. Point muta-
tions of the protein, in conjunction with various biochemical techniques, have revealed 
several critical phospho-modified residues involved in the function of Zta. By employ-
ing in vitro kinase assays, Baumann et al. (1998) demonstrated that Protein kinase C 
(PKC) can phosphorylate Zta on Serine 186. This phosphorylation was also achieved in 
vivo, by induction with a PKC activator, 12-O-tetradecanoylphorbol-13-acetate. Addi-
tionally, EMSAs showed that the S186A mutant significantly reduces the ability  of Zta 
to bind DNA in vitro. The same mutant did not activate BHLF1 and Rp  Luciferase pro-
moter constructs. Interestingly, in vitro DNA interaction of Zta was enhanced by incu-
bating the phosphorylated protein with cellular extracts. Therefore, S186 phosphoryla-
tion is required for efficient promoter activation and DNA binding, but is possibly  de-
pendent on the interaction with other cellular factors (Baumann et al., 1998). Further-
more, western blot analysis showed that a phosphomimmic mutation S186E, but not the 
phosphorylation incapable S186A, interferes with Zta’s inhibition of c-myc, suggesting 
that the unphosphorylated S186 residue might also have the ability  to recruit other pro-
teins (Rodriguez et al., 2001). Another phosphorylation site on Zta is Serine 173. Kol-
man et al. (1993), employed a radiolabelling in vitro kinase assay to demonstrate that 
CK2 can phosphorylate Zta on this residue (Kolman et  al., 1993). Further immunoblot, 
EMSA and quantitative PCR performed with S173A mutants revealed that  Serine 173 is 
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crucial for the ability  of Zta to induce lytic EBV replication, associate with DNA and 
transactivate late lytic genes (like BFRF3 and BLFR2). Nevertheless, the S173A mutant 
does not completely  abolish DNA interactions and has no effect on transcription of early 
lytic genes (like Rta or the viral replication machinery proteins) by Zta. This implies 
that Serine 173 phosphorylation might have a higher relevance in the later stages of the 
lytic cycle (El-Guindy et al., 2007). As mentioned before, Zta is also phosphorylated by 
VPK on Serine 209, which causes a decrease in auto-activation of the Zp promoter con-
struct. In addition to that, diminishing BZLF1 mRNA levels correlate with increasing 
VPK protein presence during the lytic cycle progression in vivo (Asai et al., 2009). El-
Guindy et al. (2006) employed radiolabelling of Zta point mutants in combination with 
tryptic digestion and two dimensional gel electrophoresis to demonstrate that Zta can 
also be phosphorylated on Serine residues 6, 8 and 167, as well as Threonine residues 7, 
14 and 159. However, the significance and role of these PTMs in vivo still remains to be 
appreciated (El-Guindy et al., 2006).
Zta can also be post-translationally  modified by  SUMO conjugation (Adamson and 
Kenney, 2001). SUMOs or Small Ubiquitin-like Modifiers are a family of proteins that 
are approximately 20% homologous to Ubiquitin, and consist of four family members. 
SUMO2 and 3 are very similar in function and amino acid sequence, and share about 
50% homology with SUMO1. SUMO4 on the other hand is rarely observed in vivo, and 
its role still remains much less understood than the other three proteins. SUMO is cova-
lently attached to Lysine amino acids in a range of target proteins and can results in 
various effects, including altered cellular localisation or modification of transcription 
ability. In addition, SUMO can block other Lysine PTMs and associated effects. In this 
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manner, by occupying a Lysine residue that can also be Ubiquitylated, SUMO can pro-
tect a protein from Ubiquitin-dependent proteasomal degradation (Hay, 2005). Zta is 
SUMOylated on Lysine 12. Mutating this residue abrogates higher molecular weight 
forms of Zta that react to SUMO antibodies. Introduction of Zta into cells can cause a 
decrease in SUMOylation of Promyelocytic Leukemia (PML) protein through competi-
tion. SUMO does not influence the localisation or stability  of Zta in the cells. However, 
SUMO co-transfection with Zta in HeLa cells decreases the transcription of Rp and 
BMRF1, but not Zp promoters cloned into a Luciferase vector. Additionally, BMRF1 
promoter activation can be rescued by expressing Rta together with SUMO and Zta 
(Adamson, 2005; Adamson and Kenney, 2001). Moreover, mutating Lysine 12 and 
Phenylalanine 13 residues, is associated with severely decreased production of infec-
tious virions, suggesting a significant role of Zta SUMOylation in the EBV’s lifecycle 
(Deng et al., 2001).
1.5.3 Zta and DNA binding. 
As a transcription factor, Zta can directly bind to the DNA and modulate gene ex-
pression. Zta response elements (ZREs) are seven nucleotide long sequences that medi-
ate DNA binding with the protein and are found across many viral and cellular promot-
ers (Flower et al., 2010). Karlsson et al. (2008) proposed that the ZREs could be 
grouped into three distinct classes: class I, class II and class III. Class I ZREs lack CpG 
motifs and are inherently independent of DNA methylation for Zta binding. Class II and 
class III ZREs on the other hand, do contain CpG dinucleotides and are affected by cy-
tosine methylation. While class III ZREs can bind Zta only in the methylated form, class 
II can recruit Zta regardless of the methylation state (Karlsson et al., 2008). Nonethe-
less, an increasing amount of evidence suggests that Zta binds more efficiently  and 
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therefore prefers methyl-ZREs. Recently, chromatin immunoprecipitation coupled with 
next generation sequencing (ChIP-seq) studies have shown that Zta interacts with in vi-
tro methylated EBV DNA with a higher affinity than the unmethylated genome. Valida-
tion of several crucial lytic promoters with EMSA and Luciferase assays showed that 
Zta binds and activates ZREs that contain CpG motifs with greater efficiency when they 
are in a methylated state (Bergbauer et al., 2010). Kalla et al. (2012) confirmed these 
observations at the mRNA level by  reverse transcription qPCR. Together, these findings 
explain the absence of virion production during primary EBV infection when the viral 
genome is unmethylated (Kalla et  al., 2010). As latency progresses, the viral genome 
becomes methylated and stays so until the early lytic cycle, allowing Zta mediated re-
activation (Woellmer et al., 2012). Another ChIP-seq study, however, revealed that dur-
ing the transition from early to late lytic cycle, the fall in viral genome methylation cor-
relates with reduced amounts of Zta bound to CpG ZREs, while methylation-
independent ZREs exhibit higher Zta occupancy. This suggests that Zta’s functional role 
might change with the progression of the lytic cycle (Ramasubramanyan et al., 2012a). 
Whether the demethylation of the viral genome during the later stages of the lytic phase 
is an active process is not  yet known. Nevertheless, it  is becoming evident that Zta’s 
ability  to differentially bind and activate three classes of ZREs is intimately linked to 
the control of EBV’s life cycle.
1.5.4 Zta and the viral lytic replication.
At the oriLyt, Zta brings together the viral DNA polymerase complex and aids the 
de novo DNA synthesis. Zta is essential for initiation of the viral lytic replication and 
plays the role of the origin binding protein (Fixman et al., 1995). It is thought that a 
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DNA hairpin formation by  the two ZREs found in the upstream essential element of the 
oriLyt, is needed for efficient Zta binding (Rennekamp et al., 2010). Zta also directly 
interacts with EBV’s primase-helicase complex and viral polymerase processivity fac-
tor, linking oriLyt binding to initiation of EBV lytic replication (Gao et  al., 1998; Zhang 
et al., 1996). 
1.5.5 Transcriptional activation by Zta.
To numerous viral and cellular promoters that contain ZREs, Zta recruits transcrip-
tion factors, thereby initiating mRNA synthesis. Among the most studied is the ability of 
Zta to assemble the TFIIA-TFIID transcription machinery on the DNA. Zta can directly 
bind to the TATA binding TFIID, and increase its promoter affinity. This protein-protein 
interaction is dependent on amino acids 25 to 86 of Zta (Ellwood et  al., 1999; Lieber-
man and Berk, 1991). The mentioned ChIP-seq studies have also identified many viral 
promoters associated with Zta. Apart from validating Zta occupancy on the previously 
established Rp, Zp and early lytic promoters in vivo, a whole range of early and late 
EBV genes bound to Zta have been discovered. The evidence suggests that Zta has viral 
genome-wide effects during the lytic cycle (Bergbauer et al., 2010; Ramasubramanyan 
et al., 2012a). Zta can also induce transcription of cellular genes to create potentially 
favourable conditions for EBV lytic replication. Accordingly, Zta is known to upregu-
late the transcription of IL-10, a cytokine capable of suppressing both MHC class I and 
class II antigen presentation. Indeed, EMSAs showed that Zta can directly bind to the 
ZREs found in the IL-10 promoter. Mutating the TA domain or the basic region of Zta 
abolishes IL-10 transactivation (Mahot et  al., 2003). On the other hand, Zta is also 
found in the promoter region of an EBV encoded IL-10 homologue, BCRF1, highlight-
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ing the importance of this protein for the viral lytic phase (Ramasubramanyan et al., 
2012a). Although the exact  cell cycle conditions suitable for the lytic replication remain 
debated, Zta can arrest the cells in the G1 stage by activating a CDK1 inhibitor, p21. 
The upregulation of p21 is dependent on Zta directly  binding to another bZIP transcrip-
tion factor, CCAAT/Enhancer Binding Protein α (C/EBPα). The two proteins can then 
act together to transactivate p21, as well as C/EBPα and BZLF1 gene expression. How-
ever, Zta and C/EBPα do not seem to heterodimerise but rather interact with each other 
as homodimers (Wu et al., 2003; Wu et al., 2004). 
1.5.6 Transcriptional repression by Zta.
The process of transcriptional repression of Zta by direct DNA binding is contro-
versial and not well understood. By employing EMSAs, Sato et al. (1992) showed that 
Zta can bind to the c-jun promoter sequence in vitro. In addition to that, Chloram-
phenicol AcetylTransferase (CAT) assays revealed that when co-transfected with c-jun, 
Zta can inhibit activation of the collagenase and c-jun promoter constructs. Therefore, 
repression seems to be dependent on competition of Zta with c-jun for the promoter re-
gion occupancy  (Sato et al., 1992). On the other hand, Zta can also down-regulate the 
class II major histocompatibility complex transactivator (CIITA) pIII promoter. Li et al. 
(2009) showed that Zta can bind to the transcription start  site (TSS) proximal ZRE 
found in the pIII of CIITA in vivo. The DNA binding dependent repression is substanti-
ated by the fact that mutating the proximal ZRE sequence, or the basic region of the 
transiently  expressed Zta, abrogates the downregulation of the CIITA promoter con-
struct. However, no further steps into investigating the exact  mechanism of action of Zta 
mediated repression were taken (Li et  al., 2009). Additionally, no known transcription 
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factor binding sites overlap  with the ZRE in the pIII (Ghosh et al., 1999; van der Stoep 
et al., 2004; van der Stoep  et al., 2002). Therefore it is unlikely that the competition 
model is relevant to the repression of the CIITA promoter by Zta.
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1.6 Thesis aims.
To investigate the effects of VPK on Zta’s post-translational modifications and the in-
volvement of both proteins in the DNA damage response, particularly phosphorylation 
of H2AX.
To identify protein coding regions and post-translational modifications of Zta implicated 
in CIITA pIII repression and BHLF1 promoter activation.
To determine which DNA elements in the CIITA promoter are required for Zta repres-
sion. 
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2. Materials and Methods.
2.1 Materials.
2.1.1 Plasmids.
(backbone) Plasmid Name Purpose Origin
pcDNA3 WB (western blotting), Lu-
ciferase assays, ChIP
Invitrogen
(pcDNA3) his-Zta WB, Luciferase assays, ChIP (Bailey et al., 2009)
(pcDNA3) his-Zta K12R WB, Luciferase assays, ChIP Generated myself
(pcDNA3) his-Zta S209A WB, Luciferase assays Generated myself
(pcDNA3) his-Zta S209D WB, Luciferase assays Generated myself
(pcDNA3) his-SUMO1-Zta WB, Luciferase assays, ChIP Generated myself
(pcDNA3) his-SUMO2-Zta WB, Luciferase assays, ChIP Generated myself
(pcDNA3) his-Zta ΔTA WB, Luciferase assays Generated myself
(pcDNA3) his-Zta 243ter WB, Luciferase assays Provided by the lab
(pcDNA3) his-Zta AAA WB, Luciferase assays Provided by the lab
(pcDNA3) his-Zta 199ter WB, Luciferase assays Generated myself
(pcDNA3) his-Zta 134ter WB, Luciferase assays Generated myself
(pcDNA3) his-Zta 166ter WB, Luciferase assays Generated myself
(pcDNA3) his-Zta 26-199ter WB, Luciferase assays Generated myself
(pcDNA3) his-Zta 56-199ter WB, Luciferase assays Generated myself
(pcDNA3) his-Zta 81-199ter WB, Luciferase assays Generated myself
(pcDNA3) VPK WB, Flag pulldowns Provided by the lab
pBabe WB, Flag pulldowns (Morgenstern and 
Land, 1990)
(pBabe) Zta WB, Flag pulldowns (Bailey et al., 2009)
(pBabe) Zta K12R WB, Flag pulldowns Generated myself
(pBabe) Zta S209A WB, Flag pulldowns Generated myself
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(backbone) Plasmid Name Purpose Origin
(pBabe) Zta S209D WB, Flag pulldowns Generated myself
pCpGL Luciferase assays (Klug and Rehli, 
2006)
(pCpGL) BHLF1 Luciferase assays (Bergbauer et al., 
2010)
pGL3 control Luciferase assays Promega
pGL3 enhancer Luciferase assays Promega
(pGL3 enh.) CIITA Luciferase assays Generated myself
(pGL3 enh.) CIITA null ZRE Luciferase assays Generated myself
(pGL3 enh.) CIITA ZRE 3/4 Luciferase assays Generated myself
(pGL3 enh.) CIITA -199+44 Luciferase assays Generated myself
(pGL3 enh.) CIITA -199+52 Luciferase assays Generated myself
(pGL3 enh.) CIITA -214+44 Luciferase assays Generated myself
(pGL3 enh.) CIITA mut H Luciferase assays Generated myself
(pGL3 enh.) CIITA p50 mut Luciferase assays Generated myself
(pGL3 enh.) CIITA downstream 
mut
Luciferase assays Generated myself
(pGL3 enh.) CIITA 1-40 mut Luciferase assays Generated myself
(pGL3 enh.) CIITA 41-80 mut Luciferase assays Generated myself
(pGL3 enh.) CIITA 81-121 mut Luciferase assays Generated myself
(pGL3 enh.) CIITA 121-160 
mut
Luciferase assays Generated myself
(pGL3 enh.) CIITA 161-214 
mut
Luciferase assays Generated myself
Table 2.1 List of plasmids used in the experiments.
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2.1.2 Oligonucleotides
Primer name Purpose Sequence
K12R_F Generating his-Zta K12R and 
Zta K12R mutants by site-
directed mutagenesis
CTCGACTTCTGAAGATGTAAG 
ATTTACACCTGACCCATACC
K12R_R Generating his-Zta K12R and 
Zta K12R mutants by site-
directed mutagenesis
GGTATGGGTCAGGTGTAAATC
TTACATCTTCAGAAGTCGAG
S209A_F Generating his-Zta S209A 
and Zta S209A mutants by 
site-directed mutagenesis
GGCTGCTGCCAAATCAGCTG 
AAAATGACAGGCTGCGCC
S209A_R Generating his-Zta S209A 
and Zta S209A mutants by 
site-directed mutagenesis
GGCGCAGCCTGTCATTTTCAG 
CTGATTTGGCAGCAGCC
S209D_F Generating his-Zta S209D 
and Zta S209D mutants by 
site-directed mutagenesis
GGCTGCTGCCAAATCAGATG 
AAAATGACAGGCTGCGCC
S209D_R Generating his-Zta S209D 
and Zta S209D mutants by 
site-directed mutagenesis
GGCGCAGCCTGTCATTTTCAT 
CTGATTTGGCAGCAGCC
his-Zta_F_ 
normal
Generating his-Zta 243ter, 
his-Zta AAA and his-Zta 
199ter mutants for subcloning 
into pcDNA3 vector.
CTGCACACCGGGGATCCATGC
ATCATCATCATCATCATATGAT
GGACCCAAACTCGACTTCT  
his-Zta_R_ 
normal
Generating his-Zta 199ter 
mutant for subcloning into 
pcDNA3 vector.
CTGCACACCGGGGAATTCTTA
GAAATTTAAGAGATCCTCGTG
TAA
his-Zta_R_ 
243ter
Generating his-Zta 243ter 
mutant for subcloning into 
pcDNA3 vector.
CTGCACACCGGGGAATTCTTA
GAAATTTAACTAGAGATCCTC
GTG
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Primer name Purpose Sequence
his-Zta_R_ 
AAA
Generating his-Zta AAA mu-
tant for subcloning into 
pcDNA3 vector.
CTGCACACCGGGGAATTCTTA
AGCAGCAGCGAGATCCTCGT
G
CIITA null_F Generating CIITA null plas-
mid by site-directed muta-
genesis
TGAAGGTTCCCCCAACAGAC
TTTCTCCCTTCTTTCTGTCTTC
ACCAAATTCAGTC
CIITA null_R Generating CIITA null plas-
mid by site-directed muta-
genesis
GACTGAATTTGGTGAAGACA
GAAAGAAGGGAGAAAGTCTG
TTGGGGGAACCTTCA
CIITA B3/4_F Generating CIITA B3/4 plas-
mid by site-directed muta-
genesis
AAGGTTCCCCCAACAGACTT
TCTGACACACTTTCTGTCTTC
ACCAAATTCAG
CIITA B3/4_R Generating CIITA B3/4 plas-
mid by site-directed muta-
genesis
CTGAATTTGGTGAAGACAGA
AAGTGTGTCAGAAAGTCTGT
TGGGGGAACCTT
CIITA +44 Generating CIITA -199+44 
and CIITA -214+44 promot-
ers for subcloning
GCCCCAAGCTTCCCAGCTCA
GAAGCACAC
CIITA +52 Generating CIITA -199+52 
and CIITA -214+52 promot-
ers for subcloning
GCCGGAAGCTTTTCGGATGCC
CAG
CIITA -199 Generating CIITA -199+52 
and CIITA -199+44 promot-
ers for subcloning
GCCGGTACCAAATTCAGTCCA 
CAGTAAGGAAGTG
CIITA -214 Generating CIITA -214+52 
and CIITA -214+44 promot-
ers for subcloning
GCCGGTACCCTTTCTGTCTTC
ACCAAATTCAGTCC
Rp3_F qPCR GGCTGACATGGATTACTGGTC
Rp3_R qPCR TGATGCAGAGTCGCCTAATG
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Primer name Purpose Sequence
oriLyt flank_F qPCR CCGCATGTCCAACCACCACG
oriLyt flank_R qPCR ATGCTACCTAGGCCTGCGTCC
Rp_F (+biotin) DNA affinity chromatography ATATTGCGATTGCCCGCCCTAT
GCCAATGGCTCATAA + biotin
Rp_R DNA affinity chromatography TTATGAGCCATTGGCATAGGG 
CGGGCAATCGCAATAT
Rp mut_F 
(+biotin)
DNA affinity chromatography ATATTGCGATTGCCCGCCCTAT
GCCAAGACTGCATAA + biotin
Rp mut_R DNA affinity chromatography TTATGCAGTCTTGGCATAGGG
CGGGCAATCGCAATAT
Table 2.2 List of ordered oligonucleotides.
2.1.3 Antibodies.
Antibody (order) Purpose Species, clonality Origin
anti-Flag M2 (primary) WB Mouse, monoclonal Sigma
anti-γH2AX (primary) WB Mouse, monoclonal Upstate
anti-β actin (primary) WB Rabbit, polyclonal Sigma
BZ1 (primary) WB Mouse, monoclonal Young el al. (1991)
DO1 (primary) WB Mouse, monoclonal Santa Cruz Biotech
anti-Rta (primary) WB Mouse, monoclonal Argene
anti-Cdk2 (primary) WB Mouse, monoclonal Santa Cruz Biotech
ScZ (primary) WB, ChIP Goat, polyclonal Santa Cruz Biotech
HRP-linked anti-mouse IgG 
(secondary)
WB Horse GE Healthcare
HRP-linked anti-rabbit IgG 
(secondary)
WB Goat GE Healthcare
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Antibody (order) Purpose Species, clonality Origin
HRP-linked anti-goat IgG 
(secondary)
WB Rabbit DAKO
IRDye 680CW anti-mouse 
IgG (secondary)
WB Goat Li-Cor
IRDye 800CW anti-rabbit 
IgG (secondary)
WB Goat Li-Cor
IRDye 680CW anti-goat 
IgG (secondary)
WB Donkey Li-Cor
Table 2.3 List of antibodies used for western blotting and chromatin immunopre-
cipitation.
2.1.4 Purchased reagents and materials.
Reagents and materials Purpose Supplier
Luria-Bertani (LB) agar pow-
der
Bacterial cell culture (after 
re-suspension)
Invitrogen
Luria-Bertani (LB) broth 
powder
Bacterial cell culture (after 
re-suspension)
Invitrogen
Penicillin Plasmid amplification GIBCO
Zeocin Plasmid amplification Invitrogen
Low melting point agarose Plasmid amplification Sigma
10x Pfx enhancer solution PCR Invitrogen
10x Pfx amplification buffer PCR Invitrogen
Platinum Pfx DNA po-
lymerase
PCR Invitrogen
dNTP mix (10mM each) PCR New England BioLabs
DpnI restriction enzyme (RE) PCR New England BioLabs
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Reagents and materials Purpose Supplier
KpnI high fidelity RE Subcloning New England BioLabs
HindIII high fidelity RE Subcloning New England BioLabs
EcoRI high fidelity RE Subcloning New England BioLabs
BamHI RE Subcloning Roche
RE buffer 4 PCR, Subcloning New England BioLabs
T4 DNA ligase Subcloning Invitrogen
5x T4 ligase buffer Subcloning Invitrogen
DMSO Cell Culture GIBCO
DMEM Cell Culture GIBCO
RPMI 1640 Cell Culture GIBCO
Foetal calf serum (FCS) Cell Culture Sigma
Penicillin, Streptomycin, L-
Glutamine (PSG)
Cell Culture GIBCO
Antimycotic, antibiotic (AA) Cell Culture GIBCO
Hygromycin B Cell culture Invitrogen
L-glutamine Cell Culture GIBCO
DPBS Cell Culture, Transfec-
tions, Benzonase lysis
GIBCO
Effectene Transfections Qiagen
Enhancer Transfections Qiagen
Buffer EC Transfections Qiagen
6-well plate (3.5cm diameter) Transfections NUNC
25cm² small flask Transfections NUNC
75cm² medium flask Transfections NUNC
4mm gap electroporation cu-
vettes
Transfections VWR
NuPAGE Bis-Tris Precast Gels SDS-PAGE Invitrogen
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Reagents and materials Purpose Supplier
NuPAGE SDS MOPS running 
buffer
SDS-PAGE Invitrogen
Odyssey blocking buffer WB Li-Cor
PBS (100 tablets) WB Oxoid
Tween 20 WB Fisher BioReagents
2x protein sample buffer 
(2xPSB)
WB Sigma
SeeBlue Pre-stained markers WB Invitrogen
Luminol WB Sigma
P-Coumaric acid WB Sigma
Hydrogen peroxide 30% WB Sigma
Complete™ EDTA-free prote-
ase inhibitor cocktail 
Flag pulldowns, ChIP Roche
Benzonase nuclease Flag pulldowns Novagen
EZview Red anti-Flag M2 Af-
finity Gel
Flag pulldowns Sigma
Luciferase assay substrate Luciferase assays Promega
Luciferase assay buffer Luciferase assays Promega
5xPassive Lysis Buffer (PLB) Luciferase assays Promega
Protein assay Luciferase assay quantifi-
cation
Bio-Rad
Protein A-Sepharose 4B, Fast 
Flow
ChIP Sigma
Protein G-Sepharose, Fast 
Flow
ChIP Sigma
Salmon sperm DNA (10mg/
ml)
ChIP Invitrogen
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Reagents and materials Purpose Supplier
Triton X-100 ChIP Sigma
Proteinase K (10mg/ml) ChIP Sigma
GoTaq qPCR master mix ChIP Promega
M-270 Streptavidin Dyna-
beads
DNA affinity chromatog-
raphy
Invitrogen
2x B&W buffer DNA affinity chromatog-
raphy
Invitrogen
5x gel shift binding buffer DNA affinity chromatog-
raphy
Promega
Table 2.4 List of reagents and materials purchased from various suppliers.
2.1.5  Solutions.
Solution Purpose Composition
Buffer I Generating competent 
cells
10mM CaCl₂, 50mM 
MnCl₂•4H₂O, 30mM 
KOAc, 100mM RbCl, 
15% v/v glycerol; pH 5.8
Buffer II Generating competent 
cells
10mM RbCl, 10mM 
MOPS, 75mM CaCl₂, 
15% v/v glycerol; pH 6.8
ECL solution I WB 10mM Tris HCl pH8.5, 
0.4mM p-Coumaric acid, 
2.5mM Luminol
ECL solution II WB 10mM Tris HCl pH8.5, 
0.02% Hydrogen Peroxide
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Solution Purpose Composition
PPI (50x) Benzonase lysis, Flag 
pulldowns
50mM NaF, 10mM 
Na₃VO₄, 50mM EGTA, 
500mM Na₄P₂O₇, 100mM 
β glycerophosphate
Benzonase lysis buffer Benzonase lysis, Flag 
pulldowns
50mM Tris (pH7.5), 2mM 
MgCl₂, 50mM NaCl, 
1mM NEM, 0.5% NP40, 
EDTA-free protease in-
hibitors, 1xPPI
Cell lysis buffer ChIP 85mM KCl, 0.5% NP-40, 
5mM PIPES pH8, 1mM 
PMSF, EDTA-free prote-
ase inhibitor cocktail 
SDS lysis buffer ChIP 1% SDS, 10mM EDTA, 
50mM Tris pH8, 1mM 
PMSF, EDTA-free prote-
ase inhibitor cocktail
ChIP dilution buffer ChIP 0.01% SDS, 1.1% Triton 
X-100, 1.2mM EDTA, 
16.7mM Tris pH 8, 
167mM NaCl, 1mM 
PMSF, EDTA-free prote-
ase inhibitor cocktail
Low salt buffer ChIP 0.1% SDS, 1% Triton X-
100, 2mM EDTA, 20mM 
Tris pH 8, 150mM NaCl, 
1mM PMSF, EDTA-free 
protease inhibitor cocktail
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Solution Purpose Composition
High salt buffer ChIP 0.1% SDS, 1% Triton X-
100, 2mM EDTA, 20mM 
Tris pH 8, 500mM NaCl, 
1mM PMSF, EDTA-free 
protease inhibitor cocktail
LiCl buffer ChIP 250mM LiCl, 1% NP-40, 
1% Na-deoxycholate, 
1mM EDTA, 10mM Tris 
pH8, 1mM PMSF, EDTA-
free protease inhibitors
TE buffer ChIP 10mM Tris, 1mM EDTA, 
1mM PMSF, EDTA-free 
protease inhibitor cocktail
Elution buffer ChIP 10mM Tris, 5mM EDTA, 
1mM PMSF, 1% SDS, 
EDTA-free protease in-
hibitor cocktail
Binding buffer DNA affinity chromatog-
raphy
1.5x promega gel shift 
binding buffer, 6mM DTT, 
72ng/ml poly(dI-dC),  
D150 DNA affinity chromatog-
raphy
20mM HEPES pH 7.9, 
20% Glycerol, 0.2mM 
EDTA, 0.05% NP40, 
150mM KCl, 
Table 2.5 List of Solutions made in the laboratory.
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2.2 Methods
2.2.1 Generation of competent prokaryotic cells.
All plasmids used in the present study were amplified in two competent prokaryotic 
cell types: for most  plasmids, Top10 E.coli were used and for pCpGL plasmids, DH5α 
(containing the Pir gene) E.coli. To generate a stock of these bacterial cells, the follow-
ing protocol was used:
 A single colony of each type of E.coli was picked from an LB agar plate, mixed 
with 5 ml of LB broth and incubated overnight at 37°C with 225rpm shaking. 1ml of the 
cell rich LB broth was then transferred into 200ml LB broth and incubated for 2-3 hours 
at 37°C with 225rpm shaking. To monitor the optical density of the cells, an Eppendorf 
Biophotometer was used. Once the optical density of the culture reached 0.4, the cells 
were placed on ice for 10 minutes. After that, the cells were centrifuged at 4k rpm, 4°C 
for 12min and resuspended in 66.6ml of Buffer I. Another incubation on ice for 15min 
and refrigerated centrifugation at 4k rpm at  4°C followed. The pelleted cells were then 
resuspended in 8ml of Buffer II, split into 200µl aliquots, left on ice for 20 minutes, 
snap frozen using liquid Nitrogen and stored at -80ºC.
2.2.2 Plasmid amplification.
2.2.2.1 Transformation.
A short but efficient method was employed for plasmid transformation into bacte-
rial cells: 100ng of plasmid DNA was mixed with 100µl of competent E.coli and incu-
bated on ice for 5min. Preheated LB broth (37ºC) was added to each sample and heat-
shocked at 42ºC for 30sec. After that the cells were incubated on ice for 2min. The en-
tire mixture was then plated onto preheated (37ºC) LB agar plates containing 100µg/ml 
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ampicillin (TOP10) or 25µg/ml zeocin (DH5α) for positive selection. The plates were 
incubated at 37ºC overnight until colonies had grown. 
2.2.2.2 Amplification and extraction.
Cells from a single colony were transferred to 5ml antibiotic containing (100µg/ml 
ampicillin or 25µg/ml zeocin) LB broth and incubated at 37ºC, 225rpm shaking over-
night. Following the incubation, the 5ml of cell rich LB broth was either harvested for 
low yield plasmid DNA using Qiagen plasmid Mini Prep kit, or was poured into 150ml 
antibiotic containing LB broth (100µg/ml ampicillin or 25µg/ml zeocin), incubated at 
37ºC, 225rpm shaking overnight and then harvested for high yield plasmid DNA using 
Qiagen plasmid Maxi or Midi Prep kit  (according to the manufacturers protocol). The 
obtained plasmid stocks were quantified for dsDNA concentration with an Eppendorf 
Biophotometer, analysed using 1% agarose gel electrophoresis and diluted to 100ng/µl.
2.2.3 Polymerase chain reaction.
Polymerase chain reaction was used for generating short  DNA segments or for site-
directed mutagenesis of the existing plasmids. The following reagents were mixed in 
100µl PCR tubes:
10x Pfx enhancer  solution! 15µl
10x Pfx amplification buffer ! 5µl
Forward primer (100ng/µl)! 1µl
Reverse primer (100ng/µl)! 1µl
dNTPs (10mM each)! 1µl
Pfx DNA Polymerase! 1µl
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MgSO₄ (50mM)! 1µl
Template DNA (100ng/µl)! 1µl
ddH₂O! 24µl
Each mixture was placed in a Techne TC512 PCR machine with a heated lid at 
105℃ and set for an initial denaturation of 95℃ for 30sec, followed by 25 cycles of 
95℃ for 30sec, 55℃ for 1min and 68℃ for 30sec. At the end of the reaction a final ex-
tension of 75℃ for 7min and a final hold at 4℃ was applied. 
Following the PCR, either a short DNA segment or a mutated plasmid was ob-
tained. Short DNA segment PCR products were run on a 1% agarose gel and the appro-
priate band was purified using Promega Gel extraction kit (according to manufacturer’s 
protocol). The purified DNA was then used for subcloning (see chapter 2.2.4). Whereas, 
the plasmid DNA products were amplified at a low yield (see chapter 2.2.2), to first 
check for errors by sequencing at Eurofins MWG Operon. Error-free plasmids were 
then amplified at a high yield (see chapter 2.2.2) and used as stock. 
2.2.4 Subcloning.
Short DNA PCR products or ordered DNA sequences (in parent plasmids), as well 
as the destination plasmids (either pcDNA3 or pGL3 enhancer) were digested with ap-
propriate enzymes at 37℃ for 1 hour, run on a 1% agarose gel and purified using 
Promega Gel extraction kit (according to manufacturers protocol). KpnI and HindIII 
restriction enzymes were used for subcloning into pGL3 enhancer, while, BamHI and 
EcoRI were used for subcloning into pcDNA3 vector. RE buffer 4 was used for all reac-
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tions. Ligation reactions were incubated in an ice-bath placed at a room temperature 
overnight (for a wide range of temperature). 0 (no insert), 1:1, 1:3 or 1:6 molar ratios of 
vector:insert were incubated overnight with 100ng of destination plasmid, 1.5µl of T4 
DNA ligase and 4µl of 5x T4 DNA ligase buffer, in a final reaction volume of 20µl. The 
purified insert’s amount was determined by the formula:
Insert mass = molar ratio of the insert x vector mass x insert length / vector length
Where insert and vector mass is in nanograms, length is in base pairs and the molar 
ration is either 0, 1, 3 or 6. Following the overnight incubation, the ligation mixtures 
were transformed into the appropriate E.coli strain (see chapter 2.2.2.1). Several colo-
nies were picked from a plate that had most colonies compared to no insert (negative 
control) plate. Plasmid DNA was extracted (at a low yield) from selected colonies as 
described previously in chapter 2.2.2 and sent for sequencing to Eurofins MWG 
Operon. Error-free plasmids were then amplified at a high yield (see chapter 2.2.2.2).
2.2.5 Cell culture.
All cells were grown in a humidified incubator with a 5% CO₂ supply  at 37ºC. 
HeLa cells, HEK 293 and HEK 293T cells were cultured in DMEM media with 10% 
FCS, L-Glutamine and AA. HEK 293T EBV ZKO cells (Delecluse et al., 1998) were 
grown in RPMI media with 10% FCS, Hygromycin B and L-Glutamine. Raji and AK31 
cells were maintained in RPMI media with 10% FCS and PSG. For long term storage of 
cell lines, exponentially growing cells were washed and resuspended in 90% Foetal Calf 
Serum supplemented with 10% DMSO at 1x10⁷cells/ml. Cells were frozen at -80°C for 
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several days before long term storage in liquid nitrogen. Frozen cell stocks were 
recovered by  rapid thawing, followed by  a subsequent  wash in 10ml of chilled media 
before culturing.
2.2.6 Transfections.
HeLa, HEK 293, HEK 293T or HEK 293T ZKO adherent cells were transfected 
using the Effectene transfection reagent kit (Qiagen) in a class II microbiology cabinet. 
Cells were washed, re-suspended in PBS, counted and 4x10⁵ cells were added to 3.5cm 
diameter plates (of a 6-well plate) and incubated for 24 hours in 3ml of the appropriate 
media. Following the incubation, the existing media was replaced by 2.2ml of fresh me-
dia containing a total of 1µg of vector DNA (of 100ng/µl stock) mixed (by vortexing) 
with Effectene reagents (2.5µl Effectene, 8µl Enhancer and 100µl Buffer EC). N.B. 
HEK 293T ZKO were grown in medium flasks (75cm²) and the cell numbers, DNA and 
reagents volumes were appropriately  scaled up to 8x of the amounts described above. 
Depending on the experiment, the cells were incubated for 48 or 72 hours before har-
vesting.
Raji and AK31 suspension cells, were transfected by electroporation. The cells 
were counted, spun and resuspended in appropriate media at the concentration of 4x10⁷ 
cells/ml. 0.25ml (1x10⁷ cells) were added to each VWR electroporation cuvette together 
with 10µg of desired plasmids (of 100ng/µl stock), and pulsed at 250V at a capacitance 
of 975Ω on a Bio-Rad Gene Pulser II electroporator. The contents of the cuvettes were 
then transferred to a small flask (25cm²) containing 5ml of RPMI and incubated for 48 
hours before harvesting.
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2.2.7 SDS-PAGE.
Transfected cells were harvested, washed in DPBS, and resuspended in 200µl 8M 
Urea. The resuspended cell pellet was then sonicated 3x10sec at 25% amplitude on a 
Sonics, Vibra Cell sonicator with Branson 250 Microtip. 10µl of each obtained sample 
was mixed with 2xPSB, boiled for 5min and run on a NuPAGE Bis-Tris Precast Gel 
with MOPS buffer. Electrophoresis was carried out for 50min at 200V.
2.2.8 Western blotting.
Following the SDS-PAGE, proteins samples were transferred onto a Protran nitro-
cellulose membrane, which was then blocked with 5% milk or with Odyssey blocking 
buffer. Primary antibody was left to bind at  4°C overnight followed by three washes 
with PBS + 0.1% Tween 20. Two different types of secondary antibodies were used but 
both were left to bind for 1 hour, followed by  three washes with PBS + 0.1% Tween 20. 
If a IRDye infrared fluorescent secondary antibody was applied, the membranes were 
directly  developed on a Li-C or Odyssey Fc Dual-Mode Imaging System. If a HRP-
linked secondary antibody was used, the membranes were washed in 1ml ECL I solu-
tion + 1ml ECL II solution, exposed in the dark room to a photographic film and devel-
oped in a X-ograph Compact X2 developer.
2.2.9 Benzonase lysis.
HEK 293T cells from small 6-well plates were harvested (with a DPBS wash) and 
pelleted, 72h post-transfection. The samples were then resuspended in 100µl of Benzo-
nase buffer with 1µl of Benzonase nuclease and incubated on ice for 30min. 2µl of 5M 
NaCl was then added to each tube and left on ice for 15min. Finally the samples were 
spun for 10min at 13,000rpm, 4ºC and the supernatant retained. 10µl of supernatant was 
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mixed with 2xPSB and analysed by western blotting (see chapter 2.2.7), while the re-
mainder of the sample was used for Flag pulldowns.
2.2.10 Flag pulldowns.
20µl of anti-Flag gel (for each sample) was washed with 500µl of Benzonase 
buffer, and resuspended in 40µl Benzonase buffer. The benzonase lysis samples (see 
2.2.8) were then added to the anti-Flag gel and left rotating overnight at room tempera-
ture (RT). The next day, the samples were centrifuged for 30sec at 13,000rpm and the 
supernatant discarded. Following 2x Benzonase buffer washes, the anti-Flag gel was 
resuspended in 20µl of 2xPSB, boiled for 5min and analysed by  western blotting (see 
chapter 2.2.7). 
2.2.11 Luciferase assays.
All cell lines cultured for the luciferase assay were incubated for 48 hours post-
transfection. Upon harvesting, the cell suspension was centrifuged at 2k for 5min (ad-
herent cells were scraped first). The cell pellet was resuspended and split into 2x500µl 
DPBS. Half of the samples were used for western blotting (see chapter 2.2.7). The other 
half was dissolved in 250µl of Passive Lysis Buffer (provided by Promega) and incu-
bated at room temperature for 15 minutes. The lysed cells were then centrifuged for 
10min at 8k rpm and the supernatant was pipetted into clean tubes and stored at -20ºC if 
needed. For the luciferase activity analysis, 10µl aliquots of each lysate sample were 
pipetted into a 96-well white luminescence plate and analysed using 50µl Promega lu-
ciferase detection kit reagents (luciferase substrate + luciferase buffer) on a Promega 
Glomax multidetection system. For normalisation purposes, 200µl of 1xBio-Rad protein 
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assay was added to 10µl of lysates in a 96-well transparent plate and analysed on the 
same machine. 
2.2.12 Chromatin Immunoprecipitation.
2.2.12.1 Cross-linking and chromatin preparation.
Chromatin immunoprecipitations were carried out from HEK 293T EBV ZKO cells 
which were incubated in medium flasks (75cm²) 48 hours post-transfection. Upon com-
pletion of incubation time, the growth media was carefully replaced with new media 
containing 1% final concentration of formaldehyde (for cross-linking) and left  for 
15min at room temperature. 0.125M final concentration of glycine was then added to 
the cells, which were then scraped, spun and washed with DPBS. (From here on the 
samples were handled on ice). Each sample of pelleted cells were then resuspended in 
600µl Cell Lysis Buffer and left on ice for 10min. The lysates were then centrifuged at 
8k rpm for 5min at 4ºC and the supernatant removed. Obtained nuclei (pellet) were then 
mixed with 200µl SDS lysis buffer and sonicated 10x10sec at 30% amplitude on a Son-
ics, Vibra Cell sonicator with Branson 250 Microtip. Finally, the samples were quanti-
fied for total protein concentration (Warburg-Christian method) with the Eppendorf 
Biophotometer, snap frozen in liquid Nitrogen and stored at -80ºC.
2.2.12.2 Beads preparation.
Both protein A-sepharose and protein G-sepharose beads were used for ChIP. 28µl 
protein A-sepharose slurry  + 28µl protein G-sepharose slurry + 54µl ChIP dilution 
buffer were mixed (per sample of nuclear extract obtained earlier). The beads were then 
washed twice in ChIP dilution buffer prior to the addition of 55µl ChIP dilution buffer 
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supplemented with 55µl of salmon sperm DNA and rotated for 30min at 4°C. Finally 
the beads were washed twice and resuspended in ChIP dilution buffer in a total volume 
of 100µl per sample. 
2.2.11.3 Chromatin precipitation.
50-100µl (proportionate to protein quantification) of each sample prepared in 
chaper 2.2.12.1 was diluted with ChIP dilution buffer to a final volume 1ml, of this 40µl 
was retained and stored at -20°C as Input DNA. 45µl of prepared beads slurry (from 
chapter 2.2.12.2) was then pipetted to each 960µl sample and left rotating for 30min at 
4°C. The samples were centrifuged and the supernatant was pipetted into a tube with 
2µg of ScZ antibody, which was then left rotating for 60min at 4°C. Following incuba-
tion, a new aliquot of 55µl of prepared bead slurry (from chapter 2.2.12.2) was mixed 
with the samples which were again left rotating overnight at 4°C. The following day a 
series of 4 washes of 5min rotating at 4°C followed (in sequence; volume per sample): 
1ml low salt buffer; 1ml high salt buffer; 1ml LiCl buffer and 1ml TE buffer. After the 
washes, the beads were either directly  resuspended in 100µl 2xPSB and analysed using 
SDS-PAGE and western blotting (see chapter 2.2.7 and 2.2.8) or eluted with 100µl elu-
tion buffer. At this point the Input DNA samples were also mixed with 60µl elution 
buffer, and together with eluted samples, were left to cross-link overnight at 65ºC. In the 
morning all the samples (including Input DNA and ChIP samples) were mixed with 
150µl TE buffer, 5µl Proteinase K and incubated for 2h at 55ºC. Finally  the samples 
were stored at -20ºC.
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2.2.11.4 Relative quantification analysis.
 The ChIP samples were analysed on a 7500 Real Time PCR System from Applied 
Biosystems. A standard curve consisting of a serial dilution of Input DNA of one sample 
was run along all the ChIP samples and all Input DNA samples (1/2 diluted), with oriLyt 
flank (7/8) or Rp3 primers. Each well of the PCR plate was filled with the following 
contents:
GoTaq qPCR master mix! 12.5µl
Forward primer! 2.5µl
Reverse primer! 2.5µl
Sample (Input or ChIP)! 2.5µl
ddH₂O! 5µl
Cycling conditions were applied to a qPCR plate: 95°C for 30min, followed by 40 
cycles of 95°C for 30sec, 60°C for 1min and 72°C for 30sec, with a final denaturation 
stage of 95°C for 1min. The obtained data for each ChIP sample was then divided by  its 
corresponding Input DNA value for normalisation.
2.2.12 In vitro transcription.
In vitro transcription was achieved with the help of RiboMax T7 Promega kit ac-
cording to manufacturer’s protocol. The obtained RNA was quantified with the Eppen-
dorf Biophotometer and diluted to 100ng/µl.
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2.2.13 In vitro translation.
In vitro translation was performed using Rabbit Reticulocyte Lysate system 
(Promega). The following components were mixed for each sample:
Rabbit Reticulocytes! 35µl
Amino acid mix 1mM (minus Methionine)! 1µl
[35S] Methionine! 2µl
RNasin! 1µl
RNA substrate! 1µl
ddH₂O! 10µl
The mixture was then incubated at  30°C for 90min. Following the incubation, 10µl 
of each sample were run on a SDS-PAGE gel, transferred onto a nitrocellulose mem-
brane and exposed to a Molecular Dynamics Storage Phosphor screen for 24h. The 
samples were then visualised on a Storm 860 phosphorimager and each protein band 
was quantified. The remaining samples were put through a DNA affinity  chromatogra-
phy.
2.2.14 DNA affinity chromatography.
2.2.14.1 Beads and oligonucleotides preparation.
For each sample, 10µl of M-270 Streptavidin Dynabeads were aliquoted, washed 
three times in the provided 2x B&W buffer (10mM TrisHCl pH7.5, 1mM EDTA, 2M 
NaCl)  and resuspended in 10µl of 2x B&W buffer. In the meantime, 200µM of forward 
Rp-biotin or Rp mut-biotin oligos were incubated together with 400µM reverse com-
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plement primers (unbiotinylated) at 95°C for 2min, 65°C for 10min and 37°C for 
30min. Following the incubation, 5µl of 10x diluted double-stranded primers (20µM) 
were pipetted to each beads sample and left to bind at RT for 15min. Three washes with 
1x B&W buffer followed, and the beads (bound with DNA) were resuspended in 7µl 
binding buffer. 
2.2.14.2 Pulldowns.
In vitro translated proteins from chapter 2.2.13 were added to the beads-biotin-
DNA prepared in chapter 2.2.14.1. The volume of each in vitro sample added was in-
versely proportionate to the band intensity quantified in chapter 2.2.13: 2µl of his-Zta; 
6.26µl of his-Zta K12R and 2.4µl of his-SUMO2-Zta. The proteins were left to bind the 
beads-biotin-DNA for 30min at RT, after which the beads were washed three times with 
100µl D150. Finally, the beads were resuspended in 20µl 2xPSB, boiled at 95°C for min 
and run on a SDS-PAGE. The samples were then transferred to a nitrocellulose mem-
brane and exposed to a Molecular Dynamics Storage Phosphor screen for at least 24h. 
The samples were visualised on a Storm 860 phosphorimager and each protein band 
was quantified.
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3. Molecular interplay between Zta, VPK  and 
the DNA damage response pathway.
3.1 Introduction.
The necessity  to reactivate lytic cycle and produce new virion particles is a trade-
off for EBV. With the switch from latency comes the elevated risk of detection by  cellu-
lar molecular machinery, which in turn can create unfavourable conditions for viral rep-
lication. One such host mechanism is the activation of the DNA damage response 
(DDR) during EBV’s lytic phase (Kudoh et al., 2005). The DDR pathway is able to ac-
tivate cell cycle checkpoints or induce apoptosis, events that would be detrimental to 
efficient EBV replication. One possible reason for activation of the DDR, is that the 
amplified EBV genome could be mistaken as damaged host DNA. This theory is sup-
ported by co-localisation of DDR proteins Mre11 and Nbs1 with EBV replication com-
partments (Kudoh et al., 2005). On the other hand, a number of lytic proteins have been 
identified that can trigger the activation of the DDR pathway  in the absence of viral ge-
nome replication. The immediate-early protein Rta is sufficient to induce typical hall-
marks of the DDR such as histone H2AX phosphorylation and p53 up-regulation in 
epithelial cells (Chen et al., 2009). EBV’s DNase encoded by BGLF5 was shown to 
cause double-strand breaks and increase genomic instability, thus elevating the levels of 
phosphorylated H2AX (γH2AX)  in epithelial cells (Wu et al., 2010). 
Recently, however, it has emerged that there might be an advantage to the activa-
tion of the DDR during EBV lytic cycle. The viral protein kinase (VPK) and its homo-
logue orf36 of murine γ-herpesvirus 68 (γHV68) are able to induce γH2AX levels inde-
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pendently of other viral proteins. Orf36, ATM and H2AX phosphorylation are all re-
quired for genome replication of γHV68 in mice (Tarakanova et al., 2007). VPK was 
also found to be required for efficient production of infectious EBV virions and expres-
sion of some lytic viral genes (Feederle et al., 2009; Gershburg et al., 2007). Li et al. 
(2011) showed that both of these processes are at least in part  reliant on VPK directly 
phosphorylating the histone acetyltransferase TIP60. Phosphorylated TIP60 can then 
acetylate histones or activate the ATM protein, which in turn phosphorylates H2AX. 
Histones with the euchromatic acetylation marks and γH2AX at the EBV lytic promot-
ers and at the oriLyt could aid lytic gene transcription and viral DNA synthesis (Li et al., 
2011). 
EBV can actively recruit parts of the DDR pathway, however, the downstream ef-
fects of DDR might not be favourable for the virus. The programmed DNA repair 
stimulated by the ATM  pathway could adversely modify the viral genome, or alterna-
tively, could trigger p53 mediated apoptosis; both outcomes detrimental to EBV lytic 
replication. A likely  candidate to alleviate these unwanted effects of DDR is Zta. The 
ability  of Zta to bind and label p53 for proteasomal degradation could counteract the 
potential negative impact of ATM  on viral replication (Sato et al., 2009a; Sato et  al., 
2009b). Furthermore, the ability of Zta to activate the lytic cycle was shown to be de-
pendent on its ability to bind 53BP1, a scaffold protein, heavily involved in the ATM 
pathway, suggesting a protective role for this binding (Bailey et al., 2009; Lee et  al., 
2010). Thus, it is plausible to assume that VPK recruits DDR machinery needed for 
efficient EBV replication and viral transcription, whereas Zta inhibits some of its down-
stream effectors to prevent the damaging effects of DDR.
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Interestingly, VPK and Zta were also reported to interact with each other forming a 
stable complex. This complex requires VPK phosphorylation of Zta on Serine 209. 
Moreover, VPK seems to down-regulate the transactivation activity of Zta. An increase 
of VPK protein levels during the lytic cycle also correlates with a decrease in Zta’s 
mRNA levels (Asai et al., 2006; 2009). Finally, it was also shown that Zta can be post-
translationally  modified by  SUMOylation on Lysine 12, adding another possible level 
for the fine tuning of Zta’s function (Adamson and Kenney, 2001).
The aim of this chapter was to investigate the following question:
• How do VPK and Zta affect H2AX phosphorylation in human epithelial cells?
• Is Zta targeted for proteasomal degradation?
• Does VPK affect Zta’s SUMOylation?
• Is VPK phosphorylation and reported binding important for Zta’s SUMOylation?
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3.2 Results.
3.2.1 VPK and Zta have no effect on H2AX phosphorylation in 
HEK 293T.
VPK induced H2AX phosphorylation has been shown to occur in murine fibro-
blasts (Tarakanova et al., 2007) and a human EBV positive Burkitt’s lymphoma cell 
line, Akata (Li et al., 2011). However, it is not known whether this also occurs in human 
epithelial cells. To investigate this, HEK 293T cells were transfected with Flag-VPK, 
the same Flag-tag expression vector used by Tarakanova et al. (2007). This was done to 
allow immunoblot detection by anti-Flag antibody, as there were no available VPK an-
tibodies on the market at  the time of this study. The presence of VPK and phosphory-
lated H2AX were detected after 24, 48 or 72 hours post-transfection. The immunoblot 
data was then quantified and normalised to an actin control, as represented in panel B of 
Figure 3.1. The data [Figure 3.1] show that the levels of β actin remained relatively  con-
stant compared to the levels of Flag-VPK and γH2AX which rose steadily  as the ex-
periment progressed throughout the timecourse. However, no significant increase in 
γH2AX levels in response to VPK could be observed at any of the time points [Figure 
3.1].
To test if the phosphorylation of H2AX was dependent on Flag-VPK plasmid lev-
els, a series of titrations of Flag-VPK from 0.05µg to 1µg was transfected into HEK 
293T. The abundance of the proteins was determined 72 later and the immunoblot data 
[Figure 3.2 (A)] was quantified and normalised in the same manner as before. Once 
again, no significant change of γH2AX at any  VPK level transfected was observed 
[Figure 3.2].
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Figure 3.1 Time-course of VPK effects on H2AX phosphorylation. 
HEK 293T cells were transfected with 1µg Flag-VPK (+) or with an empty vector (-) 
and harvested at 24, 48 or 72 hours (with repeats) post-transfection. The harvested 
cells were then resuspended in 8M Urea and sonicated. A. Western blotting results 
using anti-phospho H2AX (γH2AX), anti-Flag (VPK) and anti-β actin antibodies.    
B. The quantified relative intensity of the bands for each antibody. VPK and γH2AX 
were normalised to the corresponding β actin values.
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Figure 3.2 Effects of VPK titration on H2AX phosphorylation. 
HEK 293T cells were transfected with various amounts Flag-VPK and harvested at 
72 hours (with repeats) post-transfection. The harvested cells were then resuspended 
in 8M Urea and sonicated. A. Western blotting results using anti-phospho H2AX 
(γH2AX), anti-Flag (VPK) and anti-β actin antibodies. B. Quantified relative inten-
sity of the bands for each antibody. VPK and γH2AX are normalised to the corre-
sponding β actin values.
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Figure 3.3 Effects of VPK and Zta titrations on H2AX phosphorylation. 
HEK 293T cells were transfected with various amounts Flag-VPK and his-Zta and 
harvested at 72 hours (with repeats) post-transfection. The harvested cells were then 
resuspended in 8M Urea and sonicated. A. Western blotting using anti-phospho 
H2AX (γH2AX), anti-Flag (VPK), BZ1 (Zta) and anti-β actin antibodies were used. 
B. Quantified relative intensity of the bands for each antibody. VPK, γH2AX and Zta 
are normalised to the corresponding β actin values.
These results to some extent contrast with Tarakanova et al. (2007) and Li et al. 
(2011) publications, which saw an increase in the levels of phosphorylated H2AX in 
response to transfected VPK. However, Tarakanova et al. (2007) studies were performed 
in a murine cell line model and Li et al. (2011) used human lymphocytes, both of which 
differ from the cellular background used in the present study. 
The Li et al. (2011) results suggest a possible involvement of other EBV proteins in 
the induction of H2AX phosphorylation, as the observed increase in γH2AX occurred in 
an EBV infection background (Li et  al., 2011). Since Zta is a major modulator of both 
viral and host transcription, and was shown to directly interact with VPK, it was decided 
to co-transfect the two proteins together to study the effects on H2AX phosphorylation 
in HEK 293T cells. As shown in Figure 3.3, γH2AX levels did not change significantly 
in response to any amount of his-Zta or Flag-VPK transfected, indicating the lack of 
involvement of either or both proteins in manipulation of this part of the DDR pathway 
in HEK 293T cells [Figure 3.3].
3.2.2 Zta is not targeted for proteasomal degradation.
Zta was reported to be post-translationally modified by  Adamson and Kenney 
(2005). To identify these modifications, Zta and his- tagged Zta were transfected into 
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Figure 3.4 Comparison of different Zta PTMs in various cell lines. 
A. Zta’s PTMs in epithelial cells. HEK 293, 293T, 293T EBV-ZtaKO and HeLa cells 
were transfected with 1µg of his-Zta (in pcDNA3 vector) or Zta (in pBabe vector) 
and harvested 72h post-transfection. B. Zta’s PTMs in B-cells. Akata cells were incu-
bated for 48h post induction of lytic cycle with IgG. Raji cells were incubated for 48h 
post-transfection with his-Zta (in pcDNA3 vector). LCL3 cells are spontaneously 
lytic. All the samples were analysed by western blotting using BZ1 antibody. Note the 
three main higher molecular weight forms of Zta marked by the arrows and denoted 
as A, B and C. LCL3 and Akata samples were kindly provided by my lab colleague 
Sharada Ramasubramanyan.
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Figure 3.5 Effects of proteasomal inhibition on Zta in HEK 293 and HEK 293T 
cells.
HEK 293T or HEK 293 cells were transfected with his-Zta (in pcDNA3), after 72h 
half of the samples were incubated with MG132 (10µg/ml final concentration in the 
media) for 8 hours. The cells were then harvested in 8M Urea, sonicated and analysed 
by western blotting using anti-β actin, DO1 (p53) and BZ1 (Zta) antibodies. 
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Figure 3.6 Effects of proteasomal inhibition on Zta in HeLa cells.
HeLa cells were transfected with Zta (in pBabe), after 72h half of the samples were 
incubated with MG132 (10µg/ml final concentration in the media) for 2, 4, 8 or 12 
hours. The cells were then harvested in 8M Urea, sonicated and analysed by western 
blotting using anti-cdk2, DO1 (p53) and BZ1 (Zta) antibodies.
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epithelial and B cells, or the wild type Zta from EBV infected B-cells was observed. 
HeLa cells are a cervical carcinoma derived cell line, whereas HEK293 and HEK293T 
originate from human embryonic kidney cells. These cell lines are a commonly used 
model to study EBV replication. HEK 293T EBV-ZKO, on the other hand, are infected 
with a functional EBV genome; however these cells are not able to undergo lytic cycle, 
as the BZLF1 gene is disrupted by insertional mutagenesis. These cells provide a model 
of EBV infection in epithelial cells and are lytic cycle inducible upon transient transfec-
tion with Zta. LCL3 is a lymphoblastoid cell line that is spontaneously lytic and there-
fore produces Zta at a constant rate. Akata cells can be induced with such agents as IgG 
immunoglobulins to initiate the lytic cycle and Zta expression, providing a convenient 
switch for investigating EBV lifecycle. Raji cells are also a Burkitt’s lymphoma cell line 
that contain an EBV genome with various deletions and can be activated to undergo 
early stages of the lytic cycle by Zta transfection. As can be seen from Figure 3.4, Zta 
has at least 3 different higher molecular weight forms denoted as A, B and C. The fact 
that the PTMs can be observed in both epithelial and B cell lines, irrespective of EBV 
presence, suggests that  the post-translational modifications related to higher molecular 
forms of Zta are not dependent on viral proteins, and are not cell type specific. In addi-
tion to that, the N-terminal 6xhistidine tag had no effect on the levels of the higher mo-
lecular forms of Zta [Figure 3.4]. However, it  is important to note the different relative 
levels of abundance of the A, B and C forms in various cell lines. A higher subset of the 
Zta protein pool seemed to be post-translationally modified HEK 293, HEK 293T and 
HeLa compared to LCL3 and Raji [Figure 3.4]. Nevertheless, Akata cells exhibited con-
siderable amounts of the C form of Zta PTM, which corresponds to a multimeric modi-
fication [Figure 3.4].
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It is possible that at least some of the higher molecular forms of Zta could be 
caused by Ubiquitylation. Because one of the main functions of Ubiquitin is to target 
proteins for proteasomal degradation, it was decided to test if Zta’s turnover is affected 
by this mechanism. The HEK 293T and HEK 293 cells were transiently transfected with 
his-Zta and 72 hours later the cells were incubated with a proteasomal inhibitor MG132 
for 8 hours [Figure 3.5]. By inhibiting the proteasome, MG132 can elevate the levels of 
a protein whose turnover is controlled by proteasomal degradation. p53 is one such pro-
tein and was used as a positive control in our experiments [Figure 3.5, Figure 3.6]. Data 
in Figure 3.5 show that Zta levels were not affected in response to the addition of 
MG132 in HEK 293T or HEK 293 cells. The levels of p53 were also unchanged, sug-
gesting that the MG132 treatment was unsuccessful. [Figure 3.5].  The effect of protea-
somal inhibition on Zta was also examined in another cell line, HeLa [Figure 3.6]. Here 
data show a clear build up of p53 levels in response to incubation with MG132. How-
ever, the protein levels of Zta were unchanged once again. Together, these findings 
strongly suggest that proteasomal degradation is not involved in Zta’s turnover.
3.2.3 Zta’s PTMs are not dependent on the extreme carboxy termi-
nus of the protein.
As Zta’s extreme carboxy terminus (CT) has been shown to be important for viral 
replication and interaction with the DDR (Bailey et al., 2009), it was decided to investi-
gate the whether CT region influenced the post-translational modifications of Zta. Two 
mutant versions, Zta AAA and Zta 243ter [Figure 3.7 (A)] were introduced into HEK 
293 EBV-ZKO cells and 72 hours later the protein and PTM levels were compared. This 
revealed a similar pattern of Zta AAA and Zta 243ter bands compared to unmodified 
 72
AB
38kDa
28kDa
49kDa
49kDa
38kDa
38kDa
Zt
a A
A
A
 
Zt
a 
24
3t
er
 
Zt
a 
em
pt
y 
ve
ct
or
 
Zta 
β actin 
Rta
Zta Zta AAA Zta 243ter
Rta/Zta
C
Figure 3.7 Role of C-terminus in post-translational modification of Zta.
A. Graphical representation of the Zta extreme caboxy terminal mutant constructs 
used. B. HEK 293T EBV Z-KO cells were transfected with 1µg empty pBabe 
vector, wild type Zta, Zta AAA mutant (last 3 residues mutated to alanine) or the 
Zta 243 ter mutant (all in a pBabe plasmid). The cells were then harvested 72 
hours post-transfection and analysed by western blotting using anti β actin (load-
ing control), anti-Rta and BZ1 (Zta) antibodies. C. Quantified Rta levels normal-
ised to Zta protein levels.
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Zta [Figure 3.7 (B)], suggesting that the CT region had no significant effect on the Zta’s 
post-translational modifications. In addition to that, the protein levels of Rta were moni-
tored in all transfections. The data show [Figure 3.7 (B)] that Rta expression levels in-
creased when the Zta 243ter and Zta AAA mutants were transfected, indicating that  the 
C-terminus might play a role in Zta’s ability to initiate the early lytic transcription of 
EBV. Together with Bailey et al. (2009), in which it was shown that the same mutant 
constructs exhibited drastic drops in EBV replication, the data suggest  that the extreme 
carboxy  terminus affects both Zta’s ability  to initiate replication and its effectiveness as 
a transcription factor.
3.2.4 Lysine 12 is the site of Zta’s PTMs.
Adamson and Kenney (2001) showed that mutating Lysine 12 together with Phen-
ylalanine13 of Zta abolished the post-translational modifications of Zta. Lysine residues 
are known to be the typical sites of covalent attachments of small proteins such as 
SUMO and Ubiquitin. A K12R point mutant of Zta was generated [Figure 3.8]. Mutat-
ing Lysine12 alone was sufficient to abrogate the expression of all higher molecular 
forms of Zta [Figure 3.9]. Additionally, Rta protein levels increased when Zta K12R 
was expressed, indicating that Lysine 12 and potentially  Zta’s PTMs have an inhibitory 
effect on Zta’s transactivation.
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ABZLF1 DNA SEQUENCE ATG…TAA (738 NT)
ATGATGGACCCAAACTCGACTTCTGAAGATGTAAAATTTACACCTGACCCATACCAGGT
GCCTTTTGTACAAGCTTTTGACCAAGCTACCAGAGTCTATCAGGACCTGGGAGGGCCAT
CGCAAGCTCCTTTGCCTTGTGTGCTGTGGCCGGTGCTGCCAGAGCCTCTGCCACAAGGC
CAGCTAACTGCCTATCATGTTTCAACCGCTCCGACTGGGTCGTGGTTTTCTGCCCCTCA
GCCTGCTCCTGAGAATGCTTATCAAGCTTATGCAGCACCTCAGCTGTTCCCAGTCTCCG
ACATAACCCAGAATCAACAGACTAACCAAGCCGGGGGAGAAGCACCTCAACCTGGAGAC
AATTCTACTGTTCAAACAGCAGCAGCAGTGGTGTTTGCTTGCCCCGGGGCTAACCAAGG
ACAACAGCTAGCAGACATTGGTGTTCCACAGCCTGCACCAGTGGCTGCCCCGGCACGAC
GCACACGGAAACCACAACAGCCAGAATCGCTGGAGGAATGCGATTCTGAACTAGAAATA
AAGCGATACAAGAATCGGGTGGCTTCCAGAAAATGCCGGGCCAAGTTTAAGCAACTGCT
GCAGCACTACCGTGAGGTGGCTGCTGCCAAATCATCTGAAAATGACAGGCTGCGCCTCC
TGTTGAAGCAGATGTGCCCAAGCCTGGATGTTGACTCCATTATCCCCCGGACACCAGAT
GTTTTACACGAGGATCTCTTAAATTTCTAA
B
                               AGA – ARGININE (R)
5 TGGACCCAAACTCGACTTCTGAAGATGTAAAATTTACACCTGACCCATACCAG 57
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20
T T G G T C A A A G
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C T T G T A C A A A
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A G G C A C C T G G
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T A T G G G T C A G
60
G T G T A A A T C T
70
T A C A T C T T C A
80
G A A G T C G A G T
90
T T G G G T C C A T
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C A T C T T C A G C
110
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140
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T G
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T G C G G G C C A G
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G T G A A A A G A C
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C T T G A T C T T A
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G C C A T C
C G A C
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G T T A A A G G T T
430
G G C C A T T C T G
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C A G A G C A G A A
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G G T A A C C C A A
460
C G T C T C T T C T
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T G A C A T C T A C
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C G A C T G G T T G
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T G A G C G A T C
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Figure 3.8 Zta sequence and the design process for the K12R mutant.
A. Zta ORF sequence. B. The mutagenic primer design. C. An example of the muta-
tion validation chromatograph of his-Zta K12R. Key:        - designed primer;        - 
mutated region;        - primers designed for sequencing. 
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Figure 3.9 Role of Lysine 12 in post-translational modification of Zta.
A. HEK 293T EBV Z-KO cells were transfected with 1µg empty pBabe vector, wild 
type Zta or the K12R mutant (in a pBabe plasmid). The cells were then harvested 72 
hours post-transfection and analysed by western blotting using anti β actin (loading 
control), anti-Rta and BZ1 (Zta) antibodies. B. Quantified Rta levels normalised to 
Zta protein levels.
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3.2.5 VPK inhibits Zta’s PTMs but not through the phosphoryla-
tion of Serine 209.
Previous findings by Asai et al. (2009) suggest  that VPK could interact with Zta to 
modulate its function. To examine the ramifications of that interaction on Zta’s post-
translational modifications, a co-transfection of the 2 proteins into HEK 293T cells was 
performed. The data in Figure 3.10 highlights that VPK has a direct  negative effect on 
Zta’s PTMs, decreasing the abundance of all of the higher molecular forms: A, B and C. 
As Serine 209 of Zta is the proven site of VPK phosphorylation (Asai et al., 2009), two 
point mutants, Zta S209A and Zta S209D were generated (same method as for K12R 
outlined in Figure 3.8). The Zta S209A was designed to act as a phosphorylation inca-
pable mutant, whereas Zta S209D was designed to mimic constitutive phosphorylation 
on residue 209. Both of these mutants however showed no effect on Zta’s PTMs levels 
[Figure 3.11]. The Rta protein levels, on the other hand, showed an increase when the 
same amount of Zta S209A and Zta S209D was transfected compared to WT Zta [Fig-
ure 3.11]. These results indicate that phosphorylation of Serine 209 might have a nega-
tive effect on Zta’s ability to transactivate the BRLF1 gene.
3.2.6 Binding of Zta and VPK.
To test the assumption that VPK and Zta form a stable complex, first a lysis method 
using benzonase nuclease was devised, (as described in materials and methods) to effi-
ciently  extract proteins from HEK 293T cells. Benzonase is a nuclease enzyme that is 
capable of degrading nucleic acids in non-denaturing conditions. This allows extraction 
of nuclear proteins like Zta for further protein affinity  chromatography, which was used 
to assess the protein-protein interaction of Zta and VPK.
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Figure 3.10 VPK inhibits Zta PTMs.
HEK 293T cells were transfected with 0.5µg his-Zta and with or without 0.5µg flag-
VPK (with repeats), harvested 72h post-transfection and analysed by western blotting 
using BZ1 (Zta).
hi
s-
Zt
a
hi
s-
Zt
a 
+ 
fla
g-
V
PK
hi
s-
Zt
a
hi
s-
Zt
a 
+ 
fla
g-
V
PK
em
pt
y 
ve
ct
or
38kDa
28kDa
49kDa
Zta 
B
A
C
 78
38kDa
28kDa
49kDa
38kDa
Zt
a 
em
pt
y 
ve
ct
or
 
Zt
a 
S2
09
A
 
Zt
a 
S2
09
D
 
Zta 
β actin 
Rta
49kDa
38kDa
A B
Zt
a
Zt
a 
S2
09
A
Zt
a 
S2
09
D
Rta/Zta
Figure 3.11 Phosphorylation on Serine 209 and Zta’s PTMs.
A. HEK 293T EBV Z-KO cells were transfected with 1µg empty pBabe vector, wild 
type Zta, Zta S209A mutant and Zta S209D mutant (all in a pBabe plasmid). The 
cells were then harvested 72 hours post-transfection and analysed by western blotting 
using anti β actin (loading control), anti-Rta and BZ1 (Zta) antibodies. B. Quantified 
Rta levels normalised to Zta protein levels.
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Data show [Figure 3.12] that the benzonase lysis was indeed an effective method 
for extracting both Zta and VPK from HEK 293T cells. Therefore, a Flag pull-down ex-
periment was performed with Zta and all the designed point mutants (K12R, S209A and 
S209D). Unexpectedly, Zta did not co-elute with Flag-VPK [Figure 3.13] indicating the 
absence of protein-protein interaction between the Zta and VPK. A reverse pull-down 
using Nickel beads to bind histidine-tagged Zta was also attempted and showed similar 
results (data not shown). 
Figure 3.12 Benzonase lysis.
HEK 293T cells were transfected with Zta or flag-VPK (1µg in total) and harvested 
72h post-transfection using benzonase lysis method. The samples were then analysed 
by western blotting using BZ1 (Zta) and anti-Flag (VPK) antibodies.
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Figure 3.13 Flag pulldowns.
HEK 293T cells were transfected with the corresponding plasmids, harvested 72h 
post-transfection and lysed using benzonase method. An aliquot of the total benzo-
nase lysis was mixed with 2xPSB, loaded onto a gel and analysed by western blotting 
(Lysates). The remaining samples were put though a flag pull-down and analysed by 
western blotting. Anti-flag and BZ1 antibodies were used to visualise the result. 
Marked by asterisks are the heavy chains from the pull-down antibodies. N.B. The 
amount of flag-pulldowns loaded correspond to 5x of the lysates loaded.
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3.3 Chapter discussion.
Over the past decade EBV’s lytic cycle involvement in the ATM mediated part of 
the DDR has become more apparent. Both Zta and VPK have been implicated in modu-
lating the proteins of the DDR signal transduction pathway. Kudoh et al. (2005) noted 
that upon reactivation of the lytic cycle in B95-8 cells with an inducible Zta system, the 
ATM, p53, Chk2 and H2AX proteins become activated and an S-phase like cellular en-
vironment is established (Kudoh et al., 2005). It is possible that ATM  is activated by 
newly replicated viral genomes that might be recognised as double strand breaks. Nev-
ertheless, Li et al. (2011) showed that VPK phosphorylates and switches on the acetyl-
transferase TIP60, which implies an active induction of the DDR by EBV. The virus 
might benefit from upstream effects of DDR like acetylation of histones and phosphory-
lation of H2AX at oriLyt and viral promoters (Li et al., 2011). Moreover, Zta and p53 
co-localise in viral replication compartments in the nucleus. However, the p53 transcrip-
tion targets, MDM2 and p21 exhibit a decreased protein level expression during the 
lytic cycle (Kudoh et al., 2005). Sato et  al. (2009a) showed that inhibition of p53 is di-
rectly mediated by Zta. By acting as an adaptor of the ECS Ubiquitin ligase, Zta can 
target p53 for proteasomal degradation. Furthermore, the DDR induced phosphorylated 
form of p53 is able to bind Zta with a higher affinity. Thus, Zta can inhibit deleterious 
effects downstream of the DDR mediated through p53 (Sato et al., 2009a). 
 Since the correlation of VPK expression and H2AX phosphorylation was observed 
only in B-cells (Li et  al., 2011) or murine fibroblasts (Tarakanova et al., 2007), the pre-
sent study utilised HEK 293T cells to assess the effects VPK and Zta on H2AX phos-
phorylation levels. The data showed that neither VPK, nor additional Zta
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supplementation, affected the γH2AX levels in the absence of other viral proteins in 
HEK 293T cells. This observation suggests that other factors are involved in VPK me-
diated phosphorylation of H2AX. It is therefore important to consider the cellular back-
ground when choosing a cell line to study these proteins, as the results can be cell type 
dependent. However, to confirm these results further investigations are needed that 
should include controls for biological activity of VPK kinase. This can be undertaken 
by utilising a known VPK substrate that can be immunobloted on phosphorylated resi-
dues. In addition, a control for H2AX phosphorylation would also be necessary. This 
could be achieved by DNA damage inducing agents like etoposide.
 
Zta is the master lytic regulator of EBV that can act as a transcription factor, ori-
gin of replication binding protein, or can directly  interact with other proteins to elicit an 
effect in the infected cells. Because of its many roles and importance, fine-tuning Zta’s 
function is essential for EBV. One way  this is achieved is through post-translational 
modifications of the protein. Adamson and Kenney (2001) reported that Zta can be 
modified by SUMO conjugation. In the present study a number of Zta expressing 
epithelial and B-cells were examined for the higher molecular weight variants of Zta. At 
least three different  forms, A, B and C, in addition to the unmodified protein were ob-
served. The A form is most likely a monoSUMOylated Zta, whereas the B and C forms 
are polySUMOylated versions. The presented data suggests that the higher molecular 
weight forms of Zta were not dependent on other viral proteins and were not cell type 
specific. However, it was noticed that B-cell lines had generally lower levels of modifi-
cations compared to the Zta in epithelial cells (with exception of the C form in Akata 
cells). To strengthen these conclusions a titration of Zta in the studied cell lines would 
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be necessary, and together with a loading control (e.g. actin), as well as the use of a sin-
gle gel for all samples would help to better visualise and compare the higher molecular 
weight forms of Zta. Nevertheless, a study by Murata et al. (2010) published during this 
project confirm the presented findings, and together the results suggest that the small 
protein PTMs attached to Zta are at lower abundance in B cells.
The possibility that Zta might be Ubiquitylated has not been questioned in the lit-
erature. Because one of the major roles of Ubiquitylation is signalling for proteasomal 
degradation, here it was tested whether Zta could be targeted for proteolysis. The results 
showed that Zta levels did not  increase upon inhibition of the proteasome in human 
epithelial cells. This suggests that Zta’s turnover is not controlled by Ubiquitin mediated 
proteasomal degradation. To exhaustively prove that Zta is only  SUMOylated and not 
Ubiquitylated further investigations are needed. Tagged versions of SUMO and Ubiq-
uitin proteins could be co-transfected with Zta and subjected to immunoprecipitation  or 
affinity chromatography  with subsequent western blot analysis alongside a wild type 
Zta with observable higher molecular weight forms.
The involvement of the extreme carboxy-terminus of Zta, as well as the Lysine 12 
residue on the SUMOylation of Zta were also investigated in this chapter. The results 
show that Lysine 12 is required for SUMOylation of Zta. The three C-terminal amino 
acids of Zta however, do not play a role in this process. In addition to the effects on Zta 
PTMs, the impact of the mutants on the ability to activate Rta was indirectly observed. 
Rta protein levels increased when Lysine 12 or the carboxy terminus of Zta was mu-
tated, suggesting that these residues have an inhibitory effect on Zta’s ability to transac-
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tivate the immediate early BRLF1 gene. In their publication, Bailey et al. (2009) also 
detected a moderate increase in activation of the BMRF1 gene with the Zta 243ter muta-
tion. While Adamson (2005) found a significant reduction in the Rta promoter activity 
when Zta and SUMO were co-expressed in an in vitro assay.
To investigate the role of VPK in Zta PTMs, Serine 209 mutants of Zta were gen-
erated and protein affinity chromatography was attempted. Unfortunately, neither the 
VPK Flag nor the 6xhistidine tagged Zta Nickel affinity (data not shown) pull-downs 
exhibited any co-elution of Zta and VPK. Even though Asai et al. (2006; 2009) showed 
that VPK and Zta can interact with a resultant phosphorylation on Serine 209, other 
genome wide studies did not reproduce these results. An in vitro protein array kinase 
assay did not identify Zta as a target of VPK (Zhu et al., 2009). Moreover, an EBV 
protein-protein interaction study using a yeast two-hybrid system, could not identify  any 
binding between VPK and Zta (Calderwood et al., 2007). All of these observations 
could be explained by  the fact that the interaction (with the resulting phosphorylation) 
of Zta and VPK is transient and might be affected by the cellular environment. Nonethe-
less, the co-transfection of Zta and VPK in HEK 293T cells showed that VPK can 
markedly decrease the levels of SUMOylated Zta. This inhibition partly explains the 
higher abundance of A, B and C forms of Zta in cells without the EBV infection (e.g. 
HeLa cells). The decrease in SUMO conjugated Zta could be mediated through three 
possible mechanisms: A. VPK phosphorylates intermediate factors, which ultimately 
results in de-SUMOylation of Zta; B. Direct VPK phosphorylation on Serine 209 of Zta, 
acts as a signal for de-SUMOylating enzymes; and C. Phosphorylation dependent inter-
action of Zta and VPK recruits proteins that target  Zta for SUMO de-conjugation [Fig-
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ure 3.14]. These models were tested with the help  of the designed phosphorylation dead 
S209A and phosphomimic S209D Zta mutants. The data revealed that neither of these 
variants could affect the levels of the higher molecular forms of Zta, implying that 
phosphorylation on Serine 209 does not play a role in Zta SUMOylation. Therefore 
VPK mediated inhibition of SUMO-Zta must occur though some as yet unknown, VPK 
regulated intermediaries [Figure 3.14 (A)]. As this study was progressing, the publica-
tions of Hagemeier el al. (2010) and Murata et al. (2010) were released, the results of 
which coincided with the ones described above. They found that a decrease in Zta SU-
MOylation is attributed to VPK, but is independent of the phosphorylation on Serine 
209; whilst Hagemeier et al. (2010) also saw an increase in Rta protein levels whenLy-
sine 12 was mutated, validating the findings presented in this study. Their group showed 
that all three major forms of SUMO (1, 2 and 3) are covalently attached to Zta. SUMO 
was linked to a general decrease in Zta’s ability to activate viral promoters, but had no 
significant effects on the production of new virion particles (Hagemeier et al., 2010). 
Murata et al. (2010) investigated further the SUMO inhibition of Zta’s transcriptional 
capacity. They linked this phenomenon to the ability of SUMO-Zta to bind histone dea-
cetylase 3 (HDAC3). Using chromatin immunoprecipitation they showed that HDAC3 
is recruited by SUMO-Zta to the ZRE containing regions of the viral genome (Murata et 
al., 2010).
Together with the published results, the data herein shows that VPK can affect Zta 
in two distinct and opposing ways. Firstly, independent from the phosphorylation of 
S209, VPK can decrease the levels of Zta’s SUMOylation, thus elevating its
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Figure 3.14 Possible mechanisms of SUMO-Zta inhibition by VPK.
3 possible mechanisms of action of VPK on PTM inhibition of Zta. A. VPK depend-
ent de-SUMOylation of Zta happen via interaction and phosphorylation of intermedi-
ate proteins. B. Phosphorylation on S209 of Zta is a signal for de-SUMOylation.      
C. Phosphorylation dependent VPK and Zta binding signals for the removal of the 
SUMO moiety.
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transactivation potential. Secondly, VPK can directly  phosphorylate Zta on Serine 209, 
hampering its transcription ability [Figure 3.15]. This dual mechanism of action could 
prove to be beneficial for EBV, providing a strategy by  which the virus can regulate 
lytic transcription. Considering that the ChIP data indicates that Zta can also bind to the 
BGLF4 promoter (data not shown), a potential feedback loop  might take place. As the 
lytic cycle progresses and VPK starts to be expressed, low levels of the kinase might be 
beneficial for Zta’s transactivation, since the multistep effect of SUMO inhibition 
through various intermediaries has the potential to be amplified. Once the protein con-
centration of VPK reaches a critical level however, the direct phosphorylation of Zta on 
Serine 209 would start to have a noticeable impact, counteracting the positive effects of 
SUMO inhibition. This would cause a decrease in Zta’s transcriptional ability  and 
would stabilise the expression various lytic proteins, including VPK and Zta. Thus, 
through the positive and negative feedback loops an equilibrium could be established.
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Figure 3.15 VPK’s effects on Zta.
VPK can affect Zta in two distinct ways. A. VPK can inhibit SUMOylation of Zta on 
Lysine 12 through an unknown intermediate, which subsequently causes an increase 
in Zta’s transactivation. B. VPK can directly phosphorylate Zta on Serine 209 to de-
crease its transcription ability.
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4. Comparative analysis of Zta’s contribution 
to promoter activation and repression.
4.1 Introduction.
Zta is known to have various functions in the cell. Among the most significant and 
earliest discovered, is the ability  of Zta to act as a transcription factor (Chevallier-Greco 
et al., 1986). One of the viral genes that has a high reliance on Zta for its transcription, 
is BHLF1 (Hardwick et al., 1988; Lieberman et al., 1989). The BHLF1 gene is high-
lighted by  containing a region of NotI repeats, and is of one the most abundant EBV 
RNA species found in lytically induced cells (Hummel and Kieff, 1982; Jeang and 
Hayward, 1983; Jones and Griffin, 1983). Because of these properties, BHLF1 RNA has 
been used as a marker of lytic infection, detected by in-situ hybridisation (Drut et al., 
1994; Montone et al., 1992; Ryon et al., 1993). Information about the BHLF1 protein is 
scarce and apart from the early studies, much still remains unknown about the gene 
product. All that is known about the protein, is that it  contains tandem polypeptide re-
peats (due NotI repeats in its ORF), has a possible nucleolar localisation, and a high af-
finity for ssDNA (single stranded DNA) (Lieberman et al., 1989; Nuebling and Mueller-
Lantzsch, 1989). The BHLF1 promoter, on the other hand, has been studied in more de-
tail, possibly  because it is found adjacent to the OriLyt and is essential for viral lytic 
replication (Schepers et al., 1993b). The four ZREs found in the BHLF1 promoter [Fig-
ure 4.1 (A)], which are the binding sites for Zta, were shown to be critical for both EBV 
replication and BHLF1 transcription (Schepers et al., 1993a, 1996). Recently, Ren-
nekamp and Lieberman elucidated the processes involved further. They demonstrated 
that the RNA transcript of BHLF1 binds to the NotI repeats on the DNA, creating a so 
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called R-loop, which is essential for the recruitment of the EBV ssDNA Binding Protein 
(BALF2) to the OriLyt (Rennekamp and Lieberman, 2011). They  also confirmed an in-
teraction between BALF2 and Zta, which was previously shown to occur through the 
EBV helicase-primase (BBLF4-BBLF2/3-BSLF1) complex, all of which is essential for 
OriLyt replication (Gao et al., 1998; Rennekamp and Lieberman, 2011). Furthermore, 
viral DNA polymerase processivity factor (BMRF1), immediate-early  transcription fac-
tor Rta, and cellular Ku80 have been shown to interact with Zta and synergistically en-
hance transcription of BHLF1 (Chen et al., 2011; Chen et al., 2005; Zhang et al., 1996). 
Additionally, Bergbauer et al. concluded that the methylation status of the CpG motifs 
in the BHLF1 promoter had no significant effect on the ability  of Zta to bind and acti-
vate the BHLF1 promoter (Bergbauer et al., 2010).
Another gene that has been shown to be regulated by  Zta, is the cellular CIITA (Li 
et al., 2009). The CIITA protein encoded by this gene is often referred to as the master 
activator of the MHC class II expression, which is central in antigen presentation by 
specialised cells in acquired immunity  (Steimle et al., 1993; Steimle et al., 1994). Due 
to its role, CIITA has a highly  complex and regulated promoter region. Four different 
promoters have been identified, that control CIITA gene expression: pI, pII, pIII and pIV 
(Muhlethaler-Mottet et al., 1997). Except for the pII driven transcript, the function of 
which still remains unknown, pI, pIII and pIV, all produce different CIITA isoforms, 
that vary only  at the amine terminus (Muhlethaler-Mottet et al., 1997). Promoter I of 
CIITA is constitutively active in dendritic cells and INF-γ induced macrophages 
(Muhlethaler-Mottet et  al., 1997; Waldburger et al., 2001). Promoter IV is essential for 
the expression of MHC class II in non-hematopoietic cells, where it is either expressed 
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constitutively (thymic epithelial cells), or induced by  INF-γ (astrocytes, epithelial cells, 
etc.) (Waldburger et al., 2003; Waldburger et al., 2001). T cells and B cells on the other 
hand, depend on pIII for the expression of CIITA and consequently their antigen presen-
tation ability (Holling et al., 2002; Muhlethaler-Mottet  et al., 1997). Therefore, it is of 
no surprise, that pIII of CIITA is the site of regulation by Zta. Immune evasion is an im-
portant strategy required for viral survival and the ability to control CIITA expression 
would be highly advantageous for EBV. Indeed, Zta is able to repress the CIITA pro-
moter by binding to the TSS proximal ZRE (Li et al., 2009). This finding is somewhat 
controversial, as direct DNA binding by Zta usually confers activation of a promoter 
and repression is achieved via competition for the binding sites of other transcription 
factors, which does not seem to be the case with CIITA (Li et al., 2009; Sato et al., 
1992). Nonetheless, it would be expected that distinct parts of the Zta protein would be 
responsible for promoter activation as opposed to promoter repression.
The aim of this chapter is to investigate the differences in Zta’s protein coding re-
gion in respect to its ability  to repress and activate gene expression, using BHLF1 and 
CIITA promoters as a model.
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4.2 Results.
4.2.1 BHLF1 and CIITA as model promoters.
BHLF1 has one of the most  extensively studied promoters among EBV genes. Be-
cause it is also highly regulated by Zta, and greatly activated by direct Zta binding to 
DNA, it was decided to use it as a model promoter. Figure 4.1 (A) shows a diagram of 
the promoter region that was used in the Luciferase assay experiments. The cloned pro-
moter contains the TSS (indicated by the arrow) and the four ZREs that are essential for 
transcriptional activation and DNA binding by Zta, as well as the TATA and CCAAT 
boxes (Schepers et al., 1993a, 1996). The construct, subcloned into a pCpGL backbone 
(designed on the basis of pGL3 plasmid by Klug and Rehli (2006)), was kindly  pro-
vided by professor Wolfgang Hammerschmidt and was shown to be activated by  Zta in 
HEK 293T cells, in Bergbauer’s et al. (2010) research. Indeed, the Luciferase assay data 
[Figure 4.2 (A)] show that the BHLF1 promoter was activated up to ~150 times in HEK 
293T cells when his-Zta was co-transfected, providing a suitable assay for further inves-
tigations. A number of ways to control the transfection efficiency of the Luciferase as-
says exist on the market, including pRL-SV40, pRL-TK and pRL-CMV vectors (ac-
cording to Promega manual). However, the in silico investigations of the nucleotide se-
quence of these vectors revealed that all of them contained four to five ZREs in the 
promoter region, which could potentially bind Zta. Indeed, co-transfection trials of Zta 
and pRL-TK (most commonly used control) performed in our laboratory revealed that 
pRL-TK expression levels were affected by  Zta (data not shown). To compensate for the 
lost control it was decided to use Bradford assays in conjunction with western blotting 
of both actin and Zta (or its modified versions) in each Luciferase assay performed.
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Figure 4.1 Graphical representation of the cloned promoters.
A. Graphical representation of the BHLF1 promoter region cloned and used for the 
Luciferase reporter assay system. Position of the four ZREs is shown in green (NB. 
The two ZRE3/4 have identical sequences), as well as the position of the TSS, indi-
cated by the arrow. The location coordinates in the EBV B95-8 strain is also shown 
(52760-53128) (Bergbauer et al., 2010). B. Schematic representation of CIITA’s pos-
sible first exons (numbered grey boxes) and of the zoomed in pIII promoter region 
situated immediately in front of exon III. Two ZREs found in the pIII promoter are 
shown, as well as the TSS and the cloned region used for the Luciferase reporter as-
say system (Li et al., 2009; Muhlethaler-Mottet et al., 1997).
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CIITA on the other hand, is repressed by Zta (Li et al., 2009). A promoter region 
similar to the one used by  Li et al. (-288+52, compared to the published -288+44), con-
taining the TSS and the proximal ZRE [Figure 4.1 (B)] was designed and subcloned into 
a pGL3 enhancer vector using KpnI and HindIII restriction sites. Unlike pGL3 basic, 
pGL3 enhancer contains an SV40 enhancer region downstream of the Luciferase gene. 
Subcloning into this backbone provides a more sensitive system that exhibits a higher 
basal promoter activity  (according to the manufacturers manual). The Luciferase data 
[Figure 4.2 (B)] show a substantial level of repression of the CIITA promoter in Raji 
cells, when his-Zta rather than the empty vector (pcDNA3) were co-transfected. The 
repression was not dependent on the poly-histidine tag, as the untagged Zta (in a pBabe 
backbone) also repressed the promoter to a similar extent  when adjusted to Zta protein 
levels (data not shown). As the pBabe-Zta system exhibited a lower protein expression, 
compared to his-Zta in pcDNA3, the latter was chosen as a more suitable option for fur-
ther assays. In addition, the repression of the CIITA pIII promoter construct was also 
tested in the more viable and manageable HEK 293T cells. However, because pIII of 
CIITA is most likely lymphoid specific, HEK 293T epithelial cells are not expected to 
express the pIII. Indeed, the basal promoter activity of the construct was low and no Zta 
repression was observed in HEK 293T cells either (data not shown).
4.2.3 Repression and activation by Zta is not dependent on viral co-
factors.
Viral co-factors can play an important  role in the process of transcriptional regula-
tion by  Zta (Chen et al., 2005; Zhang et al., 1996). To test if repression and activation by 
Zta is dependent on viral factors, an EBV free Akata cell line, AK31, was used for the 
Luciferase assay system. Data in Figure 4.3 show that even in the absence of other EBV
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Figure 4.2 Zta represses CIITA and activates BHLF1 promoters.
A. Luciferase assay data showing the effects of his-Zta on the empty vector (pCpGL) 
or the BHLF1 promoter in HEK 293T cells. The values were adjusted to total protein 
concentration and normalised to his-Zta + BHLF1. Error bars indicate standard devia-
tion; data from two biological replicates. B. Western blot analysis of the HEK 293T 
cellular extracts using BZ1 (Zta) and anti-β actin antibodies. C. Luciferase assay data 
showing the effects of his-Zta on the empty vector (pGL3 enh.) or the CIITA pro-
moter in Raji cells. The values were adjusted to total protein concentration and nor-
malised to pcDNA3 + CIITA. Error bars indicate standard deviation; data from three 
biological replicates. D. Western blot analysis of the Raji cellular extracts using BZ1 
(Zta) and anti-β actin antibodies. 
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Figure 4.3 Repression and activation by Zta does not require viral proteins.
AK31 cells were transfected with his-Zta or empty vector (pcDNA3) and the CIITA 
or BHLF1 promoters and processed according to Luciferase assay protocol. A. Lu-
ciferase assay data showing the effects of his-Zta on the CIITA promoter. The values 
were adjusted to total protein concentration and normalised to pcDNA3. Error bars 
indicate standard deviation; data from two biological replicates. B. Western blot 
analysis of the CIITA promoter transfections using BZ1 (Zta) and anti-β actin anti-
bodies. C. Luciferase assay data showing the effects of his-Zta on the CIITA pro-
moter. The values were adjusted to total protein concentration and normalised to his-
Zta. Error bars indicate standard deviation; data from two biological replicates. 
D. Western blot analysis of the BHLF1 promoter transfections using BZ1 (Zta) and 
anti-β actin antibodies.
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Figure 4.4 Graphical representation of SUMO-fusion protein primary structure.
Schematic representation of the SUMO-Zta fusion proteins made. A 6xhistidine tag 
followed by either SUMO-1 or SUMO-2 C-ter truncated (-6 and -4 aa respectively) 
proteins and the Zta protein with Lysine 12 mutated that were created is shown.
proteins and transcripts, his-Zta was able to both repress the pIII of CIITA and activate 
the BHLF1 promoters. These results suggest that both positive and negative modulation 
of gene expression of these promoters by Zta is independent of the lytic or latent EBV 
backgrounds.
4.2.4 SUMO-Zta fusion proteins. 
SUMO conjugation to Zta is known to inhibit its transcriptional activity  and a Zta 
Lysine 12 mutant defective in SUMOylation, was shown to transactivate at higher levels 
than the wild type protein in HeLa cells (Adamson, 2005; Hagemeier et  al., 2010). In 
order to further study the effects of the SUMOylation on Zta’s transcriptional ability, 
two fusion proteins, his-SUMO1-Zta and his-SUMO2-Zta were designed. The fusion 
with SUMO3 isoform that was also reported to interact with Zta was not made, as it  has 
high homology and very similar functions with the SUMO2 protein (Saitoh and 
Hinchey, 2000). Since the Lysine 12 at which the conjugation with SUMO was shown 
to occur, is located very close to the amino terminus of Zta, it  was decided to place the 
ORF of SUMO proteins in front of the Zta’s sequence. The constructs were designed 
with a new start codon and 6 histidines at the N-terminus followed by either SUMO1 or 
SUMO2 and Zta ORFs [Figure 4.4]. SUMO1 and SUMO2 sequences had the stop
6xHis K12R
SUMO1/2 Zta
 98
his-Zta
+
Rp Rp mut
0
0.25
0.50
0.75
1.00
hi
s-
Zt
a 
+ 
R
p
hi
s-
Zt
a 
+ 
R
p 
m
ut
R
el
at
iv
e 
ba
nd
 in
te
ns
ity
hi
s-
Zt
a 
K
12
R
 +
 R
p
hi
s-
Zt
a 
K
12
R
 +
 R
p 
m
ut
SU
M
O
2-
Zt
a 
+ 
R
p
hi
s-
SU
M
O
2-
Zt
a 
+ 
R
p 
m
ut
his-Zta K12R
+
Rp Rp mut
his-SUMO2-Zta
+
Rp Rp mut
B
A
Figure 4.5 SUMO fusion protein and Lysine 12 mutant can bind DNA in vitro. 
Corresponding proteins were expressed in the presence of radioactively labeled 
amino acids using rabbit reticulocyte lysate (RRL) system. RRL were quantified and 
equivalent amount of each protein extract was incubated with DNA oligos (Rp and 
Rp mut) in vitro. A. Radiograph of the samples after the binding assay. B. Quantifica-
tion of each radiographic band. Values were normalised protein + Rp promoter levels.
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codon removed and were made shorter by 6 and 4 carboxy-terminal amino acids respec-
tively. This was done to eliminate the di-glycine motif that is used by SUMO specific 
proteases for deconjugation of the SUMO PTM  (Gong et al., 2000; Li and Hochstrasser, 
1999). The Zta sequence was also modified by  the introduction of K12R mutation, to 
avoid multiSUMOylation of Zta [Figure 4.4]. Finally, the full sequences were ordered 
from Eurofins MWG, subcloned into a pcDNA3 expression vector using the BamHI and 
EcoRI restriction sites. The resulting vectors were sequenced for errors and amplified in 
E.coli according to the protocol. 
4.2.5 SUMO-Zta fusion and Zta K12R proteins can bind DNA in 
vitro.
Zta mediated transcriptional control of both BHLF1 and CIITA has been reported to 
be dependent on direct DNA binding to the ZRE sequences (Li et al., 2009; Schepers et 
al., 1993a, 1996). To examine this crucial functionality in the SUMO Zta fusion and the 
earlier mentioned Zta K12R proteins, an in vitro assay  was carried out. First, the mRNA 
of interest  was amplified in vitro from the pcDNA3 containing the protein constructs 
and purified using a Promega kit. Each mRNA species was introduced into a rabbit re-
ticulocyte lysate (RRL) system and translated in the presence of radioactively labelled 
amino acids. The RRLs were then incubated with Dyna beads coupled with DNA oligo-
nucleotides, known to bind (Rp promoter) or not to bind (Rp  mut) Zta. Figure 4.5 (A) 
shows the western blot radiographic analysis of the resuspended Dyna beads. The quan-
tified and normalised data [Figure 4.5 (B)] show that all the tested proteins had similar 
in vitro DNA binding compared to the background binding to the negative control (Rp 
mut), indicating that the amino terminal fusion of SUMO did not impair Zta in its abil-
ity to bind DNA.
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Figure 4.6 SUMO fusion proteins and Lysine 12 mutant can bind DNA in vivo.
Chromatin immunoprecipitation was performed in HEK 293T EBV-ZKO cells ac-
cording to the protocol. A. Schematic representation of the proteins used. B. Western 
blot analysis using BZ1 antibodies to confirm immunoprecipitation of the proteins 
with ScZ antibodies. C. qPCR analysis using Rp3 primers that overlap Rta promoter 
in the EBV genome which contains ZREs and has a high affinity for Zta, and Orilyt 
flank primers, know not to bind Zta. Values were normalised to his-Zta + Rp3. Error 
bars indicate standard deviation; data from two biological replicates.
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4.2.6 SUMO-Zta fusion and Zta K12R proteins can bind DNA in 
vivo.
Having validated the in vitro DNA binding of SUMO fusion and K12R, Zta vari-
ants, an in vivo DNA binding assay was also devised. SUMO1-Zta, his-SUMO2-Zta, 
his-Zta K12R, his-Zta and the empty pcDNA3 expression plasmids were transfected 
into the HEK 293T EBV-ZKO cells and processed according to the ChIP protocol. After 
the immunoprecipitation step  with ScZ antibody (that recognises Zta), a portion of the 
samples were used for western blotting with another Zta binding antibody, BZ1, to con-
firm expression and precipitation of the desired proteins. Figure 4.6 (B) clearly shows 
the expression of all the Zta variants including the his-SUMO1-Zta and his-SUMO2-Zta 
that, as expected, have migrated through the gel the same distance as the band that cor-
responds to the higher molecular weight form of Zta, which is missing in the his-Zta 
K12R mutant. The remaining portion of the samples, were fully processed following the 
ChIP protocol and analysed by  quantitative PCR with primers spanning Rp3 (strong Zta 
binding) and OriLyt flank (background Zta binding) regions of the EBV genome. All of 
the proteins showed considerable DNA binding to the Rp promoter region, compared to 
background (OriLyt flank) [Figure 4.6 (C)]. Together with previous results, these find-
ings showed that the SUMO fusion proteins did not alter the DNA binding ability by Zta 
and could be used as a working model for investigating the effects of SUMOylation on 
Zta.
4.2.7 SUMO inhibits CIITA repression but not BHLF1 activation 
by Zta.
Once the binding ability had been established, the fusion proteins were used in a 
Luciferase assay to study the effects on activation of BHLF1 and repression of CIITA. 
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Figure 4.7 SUMOylation of Zta inhibits repression of the CIITA promoter.
Raji cells were transfected with the corresponding plasmids and processed according 
to Luciferase assay protocol. A. Schematic representation of the proteins used B. 
Western blot analysis using BZ1 (Zta) and anti-β actin antibodies. C. Luciferase as-
say data showing the effects of various his-Zta protein constructs on the CIITA pro-
moter in Raji cells. The values were adjusted to total protein concentration and nor-
malised to pcDNA3. Error bars indicate standard deviation; data from three biologi-
cal replicates.
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Figure 4.8 SUMOylation of Zta does not inhibit activation of BHLF1.
HEK 293T cells were transfected with the corresponding plasmids and processed ac-
cording to Luciferase assay protocol. A. Schematic representation of the proteins 
used B. Western blot analysis using BZ1 (Zta) and anti-β actin antibodies. C. Lucife-
rase assay data showing the effects of various his-Zta protein constructs on the 
BHLF1 promoter in HEK 293T cells. The values were adjusted to total protein con-
centration and normalised to his-Zta. Error bars indicate standard deviation; data 
from three biological replicates.
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The data in Figure 4.7 show that the SUMO fusion proteins have been severely  im-
paired in their ability  to repress the pIII promoter of CIITA in Raji cells, compared to 
wild type Zta. In addition to that, the mutation of Lysine 12 to arginine did not have an 
effect on Zta’s function, indicating that  this residue is not required for repression of the 
CIITA promoter [Figure 4.7 (C)]. 
Interestingly, his-Zta K12R, his-SUMO1-Zta and his-SUMO2-Zta were all able to 
activate the BHLF1 promoter, but at  statistically lower levels than his-Zta in HEK 293T 
cells [Figure 4.8 (C)]. The t-test p-values for his-Zta activation of the BHLF1 promoter 
compared to that of his_Zta K12R, his-SUMO1-Zta and his-SUMO2-Zta activation 
were all lower than 0.01.  These findings add to the overall complexity of the processes 
involved, as previously published data showed that mutation of Lysine 12 increases the 
activation of BMRF1 promoter more than ten fold compared to wild type Zta, and that 
the overexpression of SUMO1 abolishes BMRF1 and BRLF1 promoter transactivation 
by Zta to almost background levels, but does not have an effect on the BZLF1 promoter 
in HeLa cells (Adamson, 2005).
Together, the findings in Figures 4.7 and 4.8 point at differences in the molecular 
mechanisms of promoter activation of BHLF1 and promoter repression of CIITA. The 
evident dissimilarity prompted further investigations.
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Figure 4.9 Serine 209 phosphorylation of Zta does not have an effect on the re-
pression of the CIITA promoter.
Raji cells were transfected with the corresponding plasmids and processed according 
to Luciferase assay protocol. A. Schematic representation of the proteins used B. 
Western blot analysis using BZ1 (Zta) and anti-β actin antibodies. C. Luciferase as-
say data showing the effects of his-Zta and Serine 209 mutants on the CIITA pro-
moter in Raji cells. The values were adjusted to total protein concentration and nor-
malised to pcDNA3. Error bars indicate standard deviation; data from two biological 
replicates.
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Figure 4.10 Serine 209 phosphorylation of Zta does not have an effect on the ac-
tivation of the BHLF1 promoter.
HEK 293T cells were transfected with the corresponding plasmids and processed ac-
cording to Luciferase assay protocol. A. Schematic representation of the proteins 
used B. Western blot analysis using BZ1 (Zta) and anti-β actin antibodies. C. Lucife-
rase assay data showing the effects of his-Zta and Serine 209 mutants on the BHLF1 
promoter in HEK 293T cells. The values were adjusted to total protein concentration 
and normalised to his-Zta. Error bars indicate standard deviation; data from two bio-
logical replicates.
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4.2.8 Zta’s Serine 209 does not play a role in either activation of 
BHLF1 or repression of CIITA.
VPK can phosphorylate Zta on Serine 209 and as a result decrease its capacity to 
transactivate the BZLF1 promoter in COS-1 cells (Asai et al., 2009). To check if Serine 
209 or the phosphorylated version of the residue are important for activation and repres-
sion by Zta, the phosphorylation defective his-Zta S209A and the phosphomimic his-Zta 
S209D, mentioned in the previous chapter, were co-transfected with the model promot-
ers. No significant change in the repression levels of the CIITA promoter in Raji cells 
could be observed by  these mutants compared to wild type Zta, all of which had equal 
levels of protein expression [Figure 4.9]. The data in the Figure 4.10 (C) show that the 
BHLF1 promoter was considerably activated above background by all Zta variants in 
HEK 293T cells [Figure 4.10]. A statistical analysis (t-test) of all the available data 
showed no significant difference in the activation of the BHLF1 promoter by  his-Zta 
and his-Zta Serine 209 mutants. These results imply  that neither Serine 209, nor the 
phosphorylation status of this amino acid, are required for Zta to repress the CIITA pro-
moter, or activate the BHLF1 transcription.
4.2.9 The transactivation domain of Zta is crucial for both pro-
moter repression and activation.
The transactivation (TA) domain of Zta plays a central role in the protein’s ability 
to perform various roles, like activating gene expression and initiating DNA replication 
from OriLyt. The deletion of this part of the protein prevents Zta from performing these 
important functions, but does not stop direct binding to DNA (Flemington et al., 1991; 
Sarisky et al., 1996). Since both repression of CIITA and activation of BHLF1 were 
shown to be dependent on Zta binding to ZREs, a Zta ΔTA mutant was constructed to 
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Figure 4.11 Schematic diagram of Zta, Zta 199ter and Zta ΔTA primary struc-
ture.
The transativation domain (TA), DNA binding region (basic), leucine zipper domain 
(ZIP) and the carboxy terminal region (C-ter), as well as the position of Lysine 12 
and  Serine 209 are shown.
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Figure 4.12 Transactivation domain of Zta is essential for the repression of the 
CIITA promoter.
Raji cells were transfected with the corresponding plasmids and processed according 
to Luciferase assay protocol. A. Schematic representation of the proteins used. B. 
Western blot analysis using BZ1 (Zta) and anti-β actin antibodies. C. Luciferase as-
say data showing the effects of his-Zta and his-Zta ΔTA on the CIITA promoter in 
Raji cells. The values were adjusted to total protein concentration and normalised to 
pcDNA3. Error bars indicate standard deviation; data from two biological replicates.
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Figure 4.13 Transactivation domain of Zta is essential for the activation of the 
BHLF1 promoter.
HEK 293T cells were transfected with the corresponding plasmids and processed ac-
cording to Luciferase assay protocol. A. Schematic representation of the proteins 
used. B. Western blot analysis using BZ1 (Zta) and anti-β actin antibodies. C. Lucife-
rase assay data showing the effects of his-Zta and his-Zta ΔTA on the BHLF1 pro-
moter in HEK 293T cells. The values were adjusted to total protein concentration and 
normalised to his-Zta. Error bars indicate standard deviation; data from two biologi-
cal replicates.
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determine if binding to DNA alone is sufficient to elicit an effect in either of the Lucife-
rase assay model systems. The his-Zta ΔTA was designed to have the first 133 N-
terminal residues truncated. The DNA sequence coding for the required methionine, fol-
lowed by  6 histidines placed in front of the remaining 112 C-terminal amino acids of 
Zta, made up the final ORF [Figure 4.11]. The same procedure undertaken for the 
SUMO fusion proteins was followed to obtain the desired expression vector (also in 
pcDNA3).
When his-Zta ΔTA was transiently  transfected into Raji and HEK 293T cells, it 
proved to be stable enough to have the same expression levels as his-Zta [Figures 4.12 
(B) and 4.13 (B)]. Moreover, the Luciferase assays showed that the transactivation do-
main was essential for transcription activity  of Zta in either of the used Luciferase 
model systems. his-Zta ΔTA was completely incapable of repressing CIITA promoter in 
Raji cells [Figure 4.12 (C)] or activating BHLF1 promoter in HEK 293T cells [Figure 
4.13 (C)].
4.2.10 The effects of C-terminal truncations of Zta on transcrip-
tional control.
Having determined of the effects of N-terminal SUMO fusion and N-terminal trun-
cation on Zta’s transcptional capacity, it was then decided to investigate the effects of 
mutation of the C-terminus of Zta. The protein constructs, Zta 199ter and Zta 243ter 
previously  published in Bailey’s et  al. (2009) work were obtained, together with Zta 
AAA, which was studied in the laboratory  and showed similar properties to Zta 243ter 
(unpublished data). All three protein mutants needed to be subcloned into a pcDNA3 
expression vector and modified to contain the (6x) polyhistidine sequence, to maintain 
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Figure 4.14 The extreme C-terminus of Zta is not required for repression of 
CIITA.
Raji cells were transfected with the corresponding plasmids and processed according 
to Luciferase assay protocol. A. Schematic representation of the proteins used B. 
Western blot analysis using BZ1 (Zta) and anti-β actin antibodies. C. Luciferase as-
say data showing the effects of his-Zta, his-Zta AAA and his-Zta 243ter on the CIITA 
promoter in Raji cells. The values were adjusted to total protein concentration and 
normalised to pcDNA3. Error bars indicate standard deviation; data from two bio-
logical replicates.
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Figure 4.15 The extreme C-terminus of Zta is not required for activation of 
BHLF1.
HEK 293T cells were transfected with the corresponding plasmids and processed ac-
cording to Luciferase assay protocol. A. Schematic representation of the proteins 
used. B. Western blot analysis using BZ1 (Zta) and anti-β actin antibodies. C. Lucife-
rase assay data showing the effects of his-Zta, his-Zta AAA and his-Zta 243ter on the 
BHLF1 promoter in HEK 293T cells. The values were adjusted to total protein con-
centration and normalised to his-Zta. Error bars indicate standard deviation; data 
from three biological replicates.
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consistency with the Zta variants used in previous experiments. This was achieved by 
designing primers that spanned the Zta mutants ORFs, contained the needed restriction 
enzyme sites (BamH1, EcoRI) and incorporated the his-tag in the forward running 
primer. The ORF sequences (in the original pBabe backbones) were then put through a 
PCR reaction, cloned into the pcDNA3 plasmid, sequenced for errors and amplified ac-
cording to the protocol. Data show [Figures 4.14 and 4.15] that the extreme carboxy 
terminal mutants, his-Zta AAA and his-Zta 243ter, did not elicit a noticeable effect on 
repression of the pIII promoter in Raji cells or transactivation of BHLF1 in HEK 293T 
cells, compared to wild type Zta. The overactivation of BHLF1 by his-Zta 243ter could 
be explained by higher protein level expression seen in Figure 4.15 (B).
The 199ter mutant of Zta has the dimerisation zipper domain truncated, [Figure 
4.11] and as such is unable to bind DNA and activate gene expression or initiate lytic 
replication (Bailey et al., 2009). Thus, as expected, the his-Zta 199ter mutant was inca-
pable of activating the BHLF1 in HEK 293T cells [Figure 4.16 (C)]. Surprisingly, the 
CIITA promoter in Raji cells was still repressed by the dimerisation and DNA binding 
incapable his-Zta 199ter [Figure 4.17 (C)]. However, the 199ter mutant could not 
achieve the same level of downregulation as the unmodified Zta. These findings suggest 
that apart from the reported DNA binding dependent pathway, an alternative mechanism 
of the pIII repression by Zta exists.
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Figure 4.16 Zipper domain of Zta is required for activation of BHLF1. 
HEK 293T cells were transfected with the corresponding plasmids and processed ac-
cording to Luciferase assay protocol. A. Schematic representation of the proteins 
used. B. Western blot analysis using ScZ (Zta) and anti-β actin antibodies. C. Lucife-
rase assay data showing the effects of his-Zta and his-Zta 199ter on the BHLF1 pro-
moter in HEK 293T cells. The values were adjusted to total protein concentration and 
normalised to his-Zta. Error bars indicate standard deviation; data from four biologi-
cal replicates.
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Figure 4.17 Zipper domain of Zta is not required for repression of CIITA.
Raji cells were transfected with the corresponding plasmids and processed according 
to Luciferase assay protocol. A. Schematic representation of the proteins used. B. 
Western blot analysis using ScZ (Zta) and anti-β actin antibodies. C. Luciferase assay 
data showing the effects of his-Zta and his-Zta 199ter on the CIITA promoter in Raji 
cells. The values were adjusted to total protein concentration and normalised to 
pcDNA3. Error bars indicate standard deviation; data from three biological replicates.
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4.2.11 An attempt to determine the exact domains of Zta involved 
in CIITA repression.
To pinpoint the exact domains involved in the CIITA DNA binding independent re-
pression, a series of mutants shorter than Zta 199ter were designed. The constructs 
graphically represented in Figure 4.18 (B) were created by  the method described previ-
ously in the chapter 4.2.4. Unfortunately, all of the attempts to express these proteins in 
Raji cells turned out to be unsuccessful [Figure 4.18 (A)]. Various factors could have 
influenced this, including altered protein stability and turnover due to shorter polypep-
tide sequence. It is also important to mention that the studied Zta isoforms [Figure 4.18] 
were designed to have shorter nucleotide sequences than the wild type Zta; unlike Zta 
199ter, which was generated by  site-directed mutagenesis of the full Zta sequence sub-
cloned in an expression vector (Bailey et  al., 2009). Therefore, the mRNA stability of 
these shorter constructs could have been affected in Raji cells. A control for future ex-
periments could include a Zta 199ter also designed with an abrogated sequence, rather 
than with a stop codon in a full Zta sequence.
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Figure 4.18 Inability to express short Zta mutants.
A. Raji cells were transfected with the corresponding plasmids, harvested 48h later in 
8M Urea and analysed using anti-polyhistidine (for Zta) and anti-β actin antibodies.
B. Graphical representation of the primary structure of the short Zta mutants designed
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4.3 Chapter discussion.
The focus of this chapter was to investigate the differences in Zta’s ability to acti-
vate the viral BHLF1 promoter and repress the cellular CIITA promoter, the results of 
which are summarised in Figure 4.19. BHLF1 gene product is one of the most common 
mRNA species expressed during the lytic cycle. It is thought that this mRNA forms an 
R-loop with the NotI repeat region within the BHLF1 gene, allowing BALF2 protein to 
bind to the oriLyt and help initiate viral lytic replication (Rennekamp and Lieberman, 
2011). Additionally, the BHLF1 promoter forms part of the oriLyt, and is crucial for re-
cruiting proteins including Zta, that are essential for efficient DNA replication during 
the lytic cycle (Schepers et al., 1996). CIITA is a cellular transcription factor that is in-
dispensable for the expression of the class II Major Histocompatibility  Complex and the 
subsequent antigen presentation mediated through this pathway (Steimle et al., 1994). 
The CIITA gene has a complex promoter region, with pIII being the principle site of 
transcription initiation in B cells (Muhlethaler-Mottet et al., 1997). Both activation of 
the BHLF1 promoter, and repression of pIII of CIITA by Zta, was shown to be depend-
ent on direct binding to the ZREs found within these promoters (Li et  al., 2009; 
Schepers et al., 1996). 
Zta has a complex protein structure that can be roughly subdivided into the amine 
terminal transactivation domain and the carboxy terminal region that contains the bZIP 
required for dimerisation and DNA contact. Transcriptional activation by Zta is reliant 
on both the bZIP region as well as the TA domain. It  is thought that recruitment of such 
factors as TFIIA-TFIID to the DNA through the TA domain, help Zta initiate gene tran-
scription (Ellwood et al., 1999). Direct transcriptional repression through DNA binding 
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on the other hand, has not been studied in great detail. In addition to a multifunction 
protein structure, Zta’s role can be fine tuned by post-translational modifications like 
SUMOylation or VPK mediated phosphorylation of Serine 209 (Asai et al., 2009; 
Hagemeier et al., 2010).
To investigate if the repression of CIITA or the activation of BHLF1 was dependent 
on other viral co-factors, AK31 cells were used. AK31 are an EBV negative subclone of 
the Akata cell line that provides a suitable B cell model system, free from viral infec-
tion. The data showed that Zta does not require the other EBV genes to either activate 
BHLF1 or repress CIITA. These results indicate that Zta alone is involved in the immune 
evasion, through modulation of the CIITA expression.
As SUMOylation can be an important regulator of Zta’s transcriptional function, 
two SUMO-Zta fusion proteins were designed to mimic constitutive SUMOylation of 
Zta. Together with the S209A, S209D and K12R mutants described in the previous 
chapter, these protein constructs were used to study  the effects of Zta PTMs on the re-
pression of CIITA and activation of BHLF1 promoters. Interestingly, the Lysine 12 mu-
tant did not exhibit  a superactivation of BHLF1, which was reported for such promoters 
as Zp, BALF2 (Murata et al., 2010) and BMRF1 (Adamson, 2005). The data does how-
ever agree with the Deng et al. (2001) publication in which a K12A/F13A Zta could ac-
tivate BHLF1 promoter less than 50% compared to the wild type protein. Lysine 12 
might be involved in the folding of the TA domain required for promoter activation of 
BHLF1 but not  other lytic genes. Murata et al. (2010) showed that a SUMO-Zta fusion 
protein could not activate the Zp promoter above background levels and was unable to 
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induce the expression of BALF2 and BMRF1 proteins. The results presented in this 
chapter, on the other hand, revealed that SUMO-Zta chimeric proteins exhibited a de-
creased activation compared to wild type Zta, but were able to activate the BHLF1 pro-
moter considerably above background. This suggests that SUMOylation could inhibit 
Zta’s transactivation to various degrees, depending on the promoter region involved. It 
is however important to remember that the SUMO-Zta chimeras also had the Lysine 12 
residue mutated, which might have accounted for the decrease in Zta’s transactivation, 
with SUMO having just  a marginal effect. Another indication that the effect of Zta 
PTMs on BHLF1 expression is divergent from that on other viral promoters comes from 
the Serine 209 mutants. Both S209A and S209D Zta variants activated the BHLF1 pro-
moter similar to the wild type protein, while the results in the previous chapter indicated 
that the same mutants were associated with an increase in Rta protein levels. The simi-
larity in the effects of S209A and S209D could be explained by the S209D mutation not 
being able to exhibit a true phosphomimic function and rather acting as a phosphoryla-
tion blocking amino acid. Altogether, these results suggest that Zta transactivation of 
BHLF1 is less susceptible to the inhibition by  SUMOylation and VPK mediated phos-
phorylation than other lytic promoters. Since both the BHLF1 promoter and BHLF1 
mRNA are directly involved viral lytic replication, SUMOylation might be a way in 
which EBV adjusts Zta’s function in the later stages of the lytic cycle: from transcrip-
tion of viral protein-coding genes, towards replication of the EBV genome.
The influence of Zta PTMs on the repression of pIII was also investigated. Neither 
the Lysine 12 nor the Serine 209 residues were required or involved in this process. 
SUMO fusion proteins on the other hand, did have a considerable effect on Zta’s poten-
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tial to repress CIITA. It is plausible that the fusion of SUMO could have affected the 
DNA binding affinity of Zta for the CIITA promoter, however this is unlikely, since 
SUMO-Zta was able to bind DNA both in vivo and in vitro. Therefore, the DNA binding 
dependent repression of the CIITA promoter is not  likely to be due to steric hindrance of 
the Zta protein in the pIII region and might involve recruitment of other co-factors to 
the DNA. This theory is supported by the fact that the ΔTA Zta mutant also lost the abil-
ity  to repress the CIITA promoter, indicating that DNA binding alone is not sufficient for 
the repression.
The most striking results however, came from investigating the carboxy terminus of 
Zta. While the effects of the C-terminus mutants on the activation of BHLF1 promoter 
exhibited a response concurrent  with published data, the impact of the truncated pro-
teins on the repression of CIITA showed some unexpected results. Most importantly, the 
dimerisation and DNA binding incapable Zta 199ter mutant (Schelcher et al., 2007), 
was still able to inhibit the expression from pIII. This suggests that in parallel with the 
published DNA binding dependent repression (Li et al., 2009), an alternate DNA bind-
ing independent mechanism of CIITA downregulation by Zta exists. Furthermore, this 
alternative route of action must be facilitated by a Zta monomer. Unfortunately, the ef-
forts to pin point the exact Zta domains involved have remained elusive.
To investigate the CIITA repression further, a pIII promoter mutagenesis approach 
was employed and described in the subsequent chapter.
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SUMO basicTA ZIP C-ter
S209D
S209A
S209D
S209A
K12R
K12R
BHLF1 cloned promoter (369bp)
ZRE 1
ZRE 2
ZRE 3/4
ZRE 3/452760 53128
CIITA cloned promoter (352bp)
ZRE
Zta modification Repression Activation
SUMO fusion to the N-terminus ✗ ✔
Lysine 12 mutation ✔ ✔
Truncation of the transactivation domain ✗ ✗
Serine 209 mutations ✔ ✔
Zta 243ter and AAA mutants ✔ ✔
Zta 199ter mutant ✔ ✗
Figure 4.19 Schematic diagram of the effects of various modifications and trun-
cations of Zta on its function as a suppressor or activator.
The effects of SUMO-fusion, K12R, S209A and S209D mutations, C-ter and N-ter 
truncations on Zta’s ability to repress the CIITA promoter or activate the BHLF1 
promoter are shown.
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5. Analysis of CIITA’s promoter sequence in-
volved in repression by Zta.
5.1 Introduction.
The necessity  to regulate the CIITA gene stems directly from the need to control the 
expression of MHC class II molecules in a cell type specific and temporal manner. This 
issue is partially resolved by differential expression of various CIITA promoters (pI, pIII 
and pIV) in different cell types (Muhlethaler-Mottet et al., 1997). In B cells, transcrip-
tion initiates mainly from pIII of CIITA. However, other cell types (e.g. T cells) also rely 
on pIII for their CIITA expression (Holling et al., 2002; Muhlethaler-Mottet et al., 
1997). In addition to that, B cells themselves require the ability to silence the pIII pro-
moter, in order to switch off the MHC class II presentation upon achieving terminal dif-
ferentiation into plasma cells (Silacci et  al., 1994). Therefore pIII of CIITA by its nature 
is a highly regulated and complex DNA region.
Epigenetic mechanisms like chromatin remodelling play  an important role in the 
regulation of pIII. Hypermethylation of this promoter region in murine lymphoma cells 
is associated with inhibition of CIITA (Murphy et al., 2002). Indeed, chromatin marks 
linked with the repressed transcription state, like Lysine 9 dimethylation of histone H3, 
are low in relation to pIII from B cells compared to higher levels observed in terminally 
differentiated plasma cells. Moreover, ‘open’ chromatin markers like histone H3 Lysine 
9 and Lysine 27 acetylation are lost in plasma cells (Green et al., 2006). This effect, at 
least in part, might be mediated through Blimp-1 protein binding to pIII of CIITA 
(Piskurich et al., 2000) which is able to recruit histone deacetylases to the DNA, that 
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remove acetyl groups from Lysine residues, ultimately  inhibiting gene expression (Yu et 
al., 2000).
 The importance of the pIII promoter is also highlighted by low levels of small nu-
cleotide polymorphisms (SNPs), indicating potential high sequence conservation (Cas-
tle, 2011; Janitz et al., 2001; Patarroyo et al., 2002; Zhao et al., 2005). A number of 
DNA elements in this promoter region have been confirmed as binding sites for cellular 
proteins. These include two activation response elements, ARE-1 and ARE-2 critical for 
efficient transcription and five non-essential sequences: sites A, B and C, as well as two 
E-box motifs. Moreover, three cAMP responsive elements (CREs) located downstream 
and one immediately upstream of the TSS were also found to be important for promoter 
activity (Ghosh et al., 1999; van der Stoep et al., 2004; van der Stoep et al., 2002). 
ARE-2 also incorporates a CRE motif in its sequence and as such can bind the closely 
related cAMP response element-binding protein (CREB) and ATF-1 transcription fac-
tors, and subsequently recruit  CBP as well. Even though CREB is a ubiquitously ex-
pressed protein, the 5’ UTR CREs of pIII are involved in the CIITA promoter activation 
only in B-cells (Raji) and not in T lymphocytes (Jurkat) (van der Stoep et al., 2002). 
Furthermore, ARE-1, ARE-2 and site C, all need to be free of protein for efficient pro-
moter silencing in plasma cells, which is possibly  achieved through earlier discussed 
chromatin remodelling. It was also demonstrated that ARE-1, site A and site B have an 
affinity for TEF-2, NF-1 and OTF-1 proteins respectively (Ghosh et al., 1999). Site C 
and the E-box motifs on the other hand, have the sequence Ets/interferon stimulated re-
sponse element (ISRE)-consensus element (EICE) and E47 homology site respectively. 
These sequences are critical in recruiting a complex of IRF-4, PU.1 and E47 proteins 
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which together, synergistically transactivate the pIII in B lymphocytes but not in plasma 
or T cells (van der Stoep et al., 2004).
Finally, chromatin conformation capture techniques revealed that a so called HSS1 
(hypersensitive site 1) located about 11kb upstream of pIII can bind PU.1 and subse-
quently pIII, forming a loop structure required for CIITA expression in B cells. The 
HSS1, similar to pIII, also has elevated euchromatic markers in B cells compared to low 
levels found in plasma cells (Yoon and Boss, 2010).
Together, the accumulated evidence suggest that temporal control of pIII is 
achieved through the chromatin remodelling mechanisms. Whereas the cell type spe-
cific activity of the pIII promoter is governed by the expression of different combina-
tions of transcription factors. Interestingly, Zta was reported to directly interact with 
several proteins involved in pIII promoter activation in B cells, like CREB and CBP 
(Adamson and Kenney, 1999). It  is possible that Zta might act through protein-protein 
interactions to repress the pIII of CIITA. 
The object of this chapter is to identify  DNA sequences involved in the process of 
pIII repression by Zta, employing a mutagenic approach of the promoter region. 
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5.2 Results.
5.2.1 CIITA ZRE mutations.
As shown in the previous chapter, his-Zta 199ter, which is unable to bind DNA, 
could also repress pIII of CIITA. This surprising discovery  pointed at an alternative 
mechanism of CIITA repression by Zta. In order to confirm these results at the DNA 
level, a promoter mutagenesis approach was employed. First, the ZRE (TGTGCAA) 
found within the cloned promoter region was substituted for several other sequences. A 
CIITA null ZRE mutant with the sequence of ‘CCCCCTT’ was designed to be unrecog-
nisable by Zta and thus unable to form a DNA-protein complex [Figure 5.2 (A)]. 
Moreover, to assess a potential reversal of repression, the ZRE 3/4 of the BHLF1 pro-
moter, with the sequence of ‘TGACACA’ was exchanged for the original ZRE in the 
pIII [Figure 5.2 (A)]. The constructs were ordered, subcloned into pGL3 enhancer 
plasmid, sequenced for errors, amplified and used in a Luciferase assay. The data show 
[Figure 5.2 (B)] that his-Zta was able to repress both CIITA null ZRE and CIITA ZRE 
3/4 mutant promoters in Raji cells. This confirms that there is a second mechanism of 
CIITA down-regulation by Zta, completely  independent of a ZRE sequence and there-
fore, direct DNA binding.
5.2.2 CIITA promoter truncations.
To establish if the promoter region downstream of the ZRE was important for re-
pression of pIII by Zta, several truncations of the originally cloned CIITA promoter 
were designed. Compared to the model promoter (CIITA -288+52) all of the four trun-
cation mutants were shorter at the 5’ end (downstream of the TSS) terminating either 
immediately before the ZRE sequence (CIITA  -214+52 and CIITA -214+44) or 15bp 
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Figure 5.2 Repression of CIITA null ZRE and CIITA ZRE substitution mutants.
Raji cells were transfected with his-Zta or empty vector (pcDNA3) and the CIITA 
pIII, CIITA null ZRE, CIITA ZRE 3/4 and processed according to Luciferase assay 
protocol. A. Schematic representation of the mutants used. B. Luciferase assay data 
showing the effects of his-Zta on the ZRE mutant CIITA promoters in Raji cells. The 
values were adjusted to total protein concentration and normalised to pcDNA3+ 
CIITA. Error bars indicate standard deviation; data from two biological replicates.    
C. Western blot analysis of Zta levels using BZ1 (Zta) and anti-β actin antibodies.
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CIITA pro-
moter trun-
cated mutants 
(no ZRE)
CIITA -214 +52 mutant (266bp)
CIITA -199 +52 mutant (251bp)
CIITA -214 +44 mutant (258bp)
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EICE ARE-1 ARE-2
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Figure 5.3 CIITA promoter truncated mutants.
Schematic representation of the four CIITA truncation mutants designed. All of the 
mutants are missing the ZRE and the CIITA -199+44 corresponds to the one pub-
lished by Li et al.
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after (CIITA -199+52 and CIITA -199+44). Two mutants, CIITA -214+44 and CIITA 
-199+44, were also shorter at the 3’ end, (upstream of the TSS), so that the CIITA 
-199+44 corresponded to the one published by Li et al. (2009) [Figure 5.3]. The con-
structs were ordered and processed as described earlier. As the data in Figure 5.4 show, 
all of the mutants were repressed by  his-Zta in Raji cells, agreeing with the results men-
tioned earlier, and indicating that the promoter region downstream of the ZRE is not re-
quired for repression. Moreover, the two -199 CIITA promoter mutants exhibited a de-
creased basal activity, indicating that an important, previously unreported DNA element 
could be situated within that region.
5.2.3 Comparative analysis of promoters repressed by Zta.
Bergbauer et al. (2010) reported that at least 3 EBV promoters are repressed by Zta: 
BSLF1, BBLF2/3 and BSLF2/BMLF1. Since repression could be dependent on a spe-
cific nucleotide sequence e.g. mediated through other DNA binding proteins interacting 
with Zta, all four promoters (including CIITA) were screened for common DNA se-
quences. PromoterWise (http://www.ebi.ac.uk/tools/psa/promoterwise) web tool was 
used to find common motifs. However, since the program’s algorithm didn’t allow for 
more than 2 promoter comparisons at a time and incorporated a degree of redundancy in 
the sequence match, after the initial analysis, the data was collated and refined. Only 
exact sequence matches found between CIITA and 2 other mentioned EBV promoters 
that were at least 7bp long were picked out. From this, 3 sequences in the CIITA pro-
moter were identified: ‘TGAAGGT’, ‘TGGGGCCA’ shared with BSLF1 and BSLF2/
BMLF1 and ‘AGCTTGGC’ shared with BSLF1 and BBLF2/3 promoters [Figure 5.5 
(A)]. These sequences, together with the ZRE, were then mutated, and the resulting 
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Figure 5.4 Repression of the CIITA truncated mutants.
Raji cells were transfected with his-Zta or empty vector (pcDNA3) and the CIITA 
-199+52, -214+52, -199+44 or -214+44 and processed according to Luciferase assay 
protocol. A. Luciferase assay data showing the effects of his-Zta on the CIITA pro-
moters in Raji cells. The values were adjusted to total protein concentration and nor-
malised to pcDNA3+CIITA. Error bars indicate standard deviation; data from three 
technical replicates. B. Western blot analysis of the transfected Zta protein levels us-
ing BZ1 (Zta) and anti-β actin antibodies.
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Figure 5.5 Repression of CIITA mutant H.
A. Schematic representation of the CIITA promoter with the crucial regions that were 
mutated in CIITA mut H. The ZRE shown in green was mutated to ‘GGTTCAT’, 
same as in Li et al. (2009). The regions identified by promoter comparison are shown 
in brown and were mutated according to the rule: G=>T; C=>A; A=>C; T=>G. B. 
Raji cells were transfected with his-Zta or empty vector (pcDNA3) and the CIITA or 
CIITA mutant H and processed according to Luciferase assay protocol. The values 
were adjusted to total protein concentration and normalised to pcDNA3+CIITA. Error 
bars indicate standard deviation; data from two biological replicates. C. Western blot 
analysis of Zta protein levels using BZ1 and anti-β actin antibodies.
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construct was designated as CIITA mutant H. Unfortunately, the identified regions were 
not linked to the pIII down-regulation by Zta. As data show [Figure 5.5 (B)], the CIITA 
mut H construct was repressed to the same level as the wild type CIITA (-288+52) by 
his-Zta in Raji cells. Interestingly, the basal promoter activity of CIITA mut H was 
~3.5x that of CIITA (-288+52) which points at a previously unreported possible repres-
sive element in the CIITA promoter sequence that was mutated in the CIITA mut H. Al-
ternatively, the mutation could have created new transcription factor binding sites that 
account for the increase in the promoter activity.
5.2.4 Searching for a Zta binding transcription factor.
To identify any potential factors involved in the regulation of the pIII that  were also 
reported to bind Zta, the UCSC genome browser was used. The ENCODE ChIP-seq 
data overlying the pIII of CIITA was analysed for any potential targets [Figure 5.6]. Out 
of the proteins listed in Figure 5.6, NF-κB was singled out, as it was previously reported 
to bind Zta. A PROMO (http://alggen.lsi.upc.es) search to extract the potential transcrip-
tion factor binding sites found in the pIII -214+52 region was then performed. The 
CTTAGCTTGG sequence was identified as the binding site for NF-κB. It was therefore 
decided to mutate this sequence [Figure 5.7], to analyse the effect on Zta mediated re-
pression.
5.2.5 Systematic approach to CIITA promoter mutation.
In addition to the targeted mutagenic approach described above (in 5.2.4), a sys-
tematic mutation of the CIITA pIII region was also performed. Each part of the CIITA 
-214+52 was sequentially mutated as shown in Figure 5.7. The constructs were de-
signed, ordered and made as described earlier. The data [Figure 5.8] confirmed the    
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Figure 5.6 Identification of novel binding proteins.
Searching UCSC genome browser for ENCODE ChIP-seq identified binding proteins 
to the pIII promoter region. NF-κB is highlighted in red, as Zta was shown to previ-
ously interact with the p65 subunit of this transcription factor.
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 CIITA -214 +52 (266bp)
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Figure 5.7 CIITA -214+52 mutants.
Schematic representation of the mutants made. The red blocks represent the mutated 
region according to the rule mentioned in figure 5.4 (G=>T; C=>A; A=>C; T=>G). 
Downstream mutant has the entire TSS downstream region mutated (52nt). The NF-
κB site mutant has a predicted site (CTTAGCTTGG) 22bp upstream of TSS mutated. 
The rest of the mutants have the corresponding TSS upstream regions modified. The 
summary of results form Figure 5.8 are shown.
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importance of previously published DNA sequences within pIII. CIITA -41-80 mut, 
modified the ARE-2 and site B, CIITA -121-160 mut had the ARE-1 region mutated and 
CIITA -161-214 mut lost the site C sequence. All of these constructs had a significantly 
lower promoter activity  compared to CIITA -214+52 [Figure 5.8]. Nonetheless, his-Zta 
was able to repress every  single mutant made [Figure 5.8], even when the basal pro-
moter activity  was diminished, including the NF-κB binding site CIITA mutant. This 
data suggests that Zta has a general effect on the CIITA promoter and is not DNA se-
quence specific. Additional data show that the effect observed is promoter specific. In-
deed, the BHLF1 promoter was activated in Raji cells [Figure 5.9 (A)], whilst the activ-
ity  of SV40 promoter placed in a pGL3 enhancer vector (but called pGL3 control) was 
not significantly affected by his-Zta in the same cell system [Figure 5.9 (B)]. Together 
the data suggested that  Zta had a general repressive effect on the pIII of CIITA, which 
was not due to a global shut off in transcription in Raji cells.
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Figure 5.8 Repression by Zta is not sequence specific.
Raji cells were transfected with his-Zta or empty vector (pcDNA3) and the corre-
sponding CIITA -214+52 mutants and processed according to Luciferase assay proto-
col. A. The Luciferase data, adjusted to total protein concentration and normalised to 
pcDNA3+CIITA p50 mut. Error bars indicate standard deviation; data from three 
technical replicates. B. Western blot analysis using BZ1 (Zta) and anti-β actin Ab.
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Figure 5.9 Zta does not globally repress transcription in Raji cells.
A. Raji cells were transfected with his-Zta or empty vector (pcDNA3) together with 
empty pCpGL or pCpGL+BHLF1 promoter. After 48h the samples were harvested 
according to Luciferase assay protocol. The values were adjusted to total protein con-
centration and normalised to his-Zta+BHLF1. Error bars indicate standard deviation; 
data from three biological replicates. B. Raji cells were transfected with his-Zta or 
empty vector (pcDNA3) together with SV40 promoter containing vector (pGL3 con-
trol) or the CIITA (-288+52) promoter (in a pGL3 enh. vector). After 48h the samples 
were harvested according to Luciferase assay protocol. The values were adjusted to 
total protein concentration and normalised to pcDNA3+CIITA. Error bars indicate 
standard deviation; data from three biological replicates.
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5.2 Chapter discussion.
CIITA plays a central role in the expression of MHC class II. Because of its impor-
tance in the adaptive immune response, CIITA is tightly spatiotemporally regulated. In-
deed, the complexity of CIITA control is evident at the transcriptional level 
(LeibundGut-Landmann et al., 2004). The CIITA gene has four different promoters, 
which govern protein expression in different  cell types. Promoter III (pIII) is the pri-
mary  site of CIITA transcription initiation in B lymphocytes, and as such is targeted by 
EBV, providing a mechanism by which the virus can mediate inhibition of CIITA (Li et 
al., 2009; Muhlethaler-Mottet  et  al., 1997). A number of regulatory DNA sequences that 
can bind various transcription factors have been identified and validated in pIII. Moreo-
ver, a ZRE found within the pIII promoter region was reported to be essential for Zta 
mediated downregulation of CIITA (Li et al., 2009). Nevertheless, the data in the previ-
ous chapter showed that another route of CIITA expression inhibition must exist, inde-
pendent of the DNA binding ability of Zta. To investigate this further, a mutagenic ap-
proach of the pIII promoter was undertaken.
Modifying the CIITA TSS proximal ZRE to a binding nonsense sequence, or substi-
tuting it for a BHLF1 ZRE, showed similar levels of repression as the wild type pro-
moter in the presence of Zta. Additionally, truncation mutants of pIII, all of which 
lacked the ZRE sequence were also repressed by  Zta. This data validates the observation 
from the previous chapter at a promoter level, and together the results show that the 
DNA binding ability of Zta is not required for all of the repression of CIITA.
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Since the repression of pIII can be mediated independently of the Zta ZIP domain 
and does not require direct DNA binding, the Zta response must be mediated via a 
protein-protein interaction with an unknown transcription factor involved in the expres-
sion of CIITA. Several proteins have been implicated in the promoter control of pIII: 
TEF-2, NF-1, OTF-1, CREB, CBP, PU.1, IRF-4 and E-47 (Ghosh et al., 1999; van der 
Stoep et al., 2004; van der Stoep et al., 2002). Out of these transcription factors only 
CREB and CBP have been shown to directly bind Zta. Nonetheless, because the Zta 
199ter mutant  lacks the amino acids 214 and 218 needed for binding with CBP and 
residue 200 that is required for interaction with CREB (Adamson and Kenney, 1999), it 
is unlikely  that these transcription factors are involved in the Zta inhibition of the CIITA 
promoter.
  To identify the sites of potential Zta binding partners, several in silico techniques 
coupled with a DNA mutagenesis approach were employed: promoter comparison, da-
tabase analysis and systematic pIII mutagenesis. Recent advances by Bergbauer et al. 
(2010) indicate that other lytic genes might be downregulated by Zta. The identified 
promoters include that of BSLF1, BBLF2/3 and BSLF2/BMLF1 genes (Bergbauer et al., 
2010). Nucleotide sequences within these promoters that are shared with pIII of CIITA 
were singled out with the help  of the PromoterWise tool and subsequently mutated. 
However, the generated construct was still repressed by Zta. Interestingly, altering these 
regions allowed for a higher basal activity  for pIII, indicating that previously unreported 
negative regulatory elements within pIII might exist.
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A genome browser ENCODE ChIP-seq scrutiny of the pIII region revealed that 
apart from the documented transcription factors mentioned above, a whole range of 
other proteins can bind the CIITA promoter region. Out of these proteins, NF-kB is 
known to directly interact with Zta (Gutsch et al., 1994). The transcription factor posi-
tion weigh matrix PROMO tool allowed to pinpoint the predicted NF-kB DNA binding 
site within the cloned pIII construct. The mutation of this sequence did not however al-
ter Zta’s ability  to downregulate CIITA, thereby ruling out the role of NF-kB in this 
process.
Finally, the -214+52 pIII was sequentially  mutated in order to determine a potential 
DNA binding region of a transcription factor through which Zta might repress the CIITA 
gene. The data revealed that -161 to -214, -121 to -160 and -41 to -80 fragments were 
all essential for the basal promoter activity of pIII. This is most likely due to the loca-
tion of EICE, ARE-1 and ARE-2 sites within these sequences. Surprisingly, Zta was 
able to repress all of the mutated constructs, even at  lower basal activity. These findings 
suggest that rather than acting through a transcription factor, Zta interacts with a non-
DNA binding co-regulator that acts at multiple sites within the pIII promoter.
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6. General discussion.
The ability to establish a dormant latent phase during which a limited number of 
viral genes are expressed, together with the immune response modulating capabilities of 
these proteins has allowed EBV to become one of the most successful viruses known to 
infect humans (Ning, 2011). Additionally, EBV has developed immune evasion strate-
gies during the lytic cycle. This is particularly  important, as the lytic phase is character-
ised by the expression of a wide range of proteins that can elicit an immune response. 
Studies of donor CD4+ T cells have shown that most tested lytic antigens can cause a 
CD4+ T cell response, independent of the stage of the lytic phase (Long et al., 2011). 
CD8+ cytotoxic T cells, on the other hand, primarily recognise the two immediate early 
proteins, Zta and Rta, as well as some early, but not late lytic proteins. This biased re-
sponse is not due to the avidity of lytic antigens for the surface receptor, but is thought 
to happen because as the lytic cycle progresses, the repression of MHC class I is initi-
ated, thereby inhibiting the activation of CD8+ T cells by  antigens expressed in the later 
stages of the lytic cycle (Pudney et  al., 2005). The evident MHC class I inhibition has 
skewed the research focus towards investigating the EBV suppression of this pathway 
of antigen presentation, rather than lytic downregulation of MHC class II by the virus 
(involved in CD4+ response). This might also be the case because CD8+ T cell response 
historically was thought to play the main role in eliminating viral infections. Cytotoxic 
CD8+ T cells induce apoptosis in the infected cells, while helper T cells were for a long 
time thought to be just accessory in combating the viral infection, by  promoting the 
growth of CD8+ T cells and antibody secreting B cells, through cytokine secretion 
(Heller et al., 2006; Zuo and Rowe, 2012). Nonetheless, recent studies have shown that 
CD4+ T cells that recognise lytic antigens can also have a direct cytolytic effect on EBV 
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infected LCLs (Landais et al., 2004; Long et al., 2011). Moreover, a number of EBV 
lytic proteins have been identified that can interfere with the MHC class II presentation 
pathway, including Zta inhibition of the master regulator of MHC class II, CIITA (Li et 
al., 2009).
The main focus of this study was to investigate the mechanism of action of Zta de-
pendent repression of the CIITA pIII promoter. The results have shown that Zta can 
downregulate CIITA expression in an EBV-free cell line, AK31. This is an important 
finding, as it implies that other viral proteins are not required for Zta mediated repres-
sion of CIITA. Nevertheless, the observation that VPK can inhibit SUMOylation of Zta, 
together with the data from SUMO-Zta chimeras which were severely  impaired for 
CIITA downregulation, suggests that  VPK might play a role in promoting immune eva-
sion through Zta. Therefore, even though EBV factors are not required, they might still 
regulate and fine tune Zta’s ability to affect MHC class II expression.
Most surprisingly however, this study  has demonstrated that apart from the DNA 
binding dependent repression of CIITA, reported by Li et al. (2009), another route of Zta 
mediated CIITA downregulation exists, independent of direct Zta-DNA interaction. The 
experiments have shown that neither the DNA binding incapable 199ter Zta truncation, 
nor the ZRE elimination from the CIITA pIII promoter, could abolish inhibition of this 
gene by Zta. Since the 199ter mutant is missing the ZIP region required for dimerisa-
tion, the action on CIITA must be effected by monomeric forms of Zta. On the other 
hand, it was revealed that  the TA domain of Zta is essential for CIITA repression. Even 
though there are no known catalytic functions associated with the TA domain, this 
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region has been previously implicated in mediating protein-protein interactions. Taken 
together, the data indicate that rather than directly  binding to DNA, monomeric Zta 
achieves CIITA repression via binding to other proteins. 
There are a number of documented factors that were shown to regulate the pIII 
promoter of CIITA: TEF-2, NF-1, OTF-1, CREB, CBP, PU.1, IRF-4 and E-47 (Ghosh et 
al., 1999; van der Stoep  et al., 2004; van der Stoep  et al., 2002). In this study  a targeted 
and a systematic mutagenesis approach of the pIII were employed to identify a binding 
site associated with a transcription factor though which Zta might inhibit CIITA expres-
sion. The data revealed that even though some DNA regions were involved in basal 
promoter activity, Zta could inhibit all pIII mutants made. These results suggest that  Zta 
does not repress CIITA through interaction with a transcription factor that  binds to a sin-
gle site in the pIII. The only  transcription factor known to bind at multiple sites in the 
studied pIII region is CREB (van der Stoep et al., 2002). However, since Zta 199ter 
lacks the amino acid 200 that is required for protein protein interaction with CREB 
(Adamson and Kenney, 1999), it  is unlikely that Zta inhibits CIITA transcription though 
this protein. The ENCODE ChIP seq data of the pIII region, evaluated in this study, 
highlights that apart from the well documented and validated transcription factors, there 
are a number of other proteins that can bind to pIII. This shows that our understanding 
of the pIII regulation is far from complete. Therefore, a novel, yet unknown transcrip-
tion factor could exist that binds at multiple sites within the pIII of CIITA, through 
which Zta might act. Alternatively, Zta could bind and inactivate several transcription 
factors involved in the activation of CIITA transcription. 
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Another group of proteins through which Zta might act to repress CIITA, are tran-
scriptional coactivators. These proteins play an essential part in initiating eukaryotic 
transcription, providing the cells with mechanisms to control gene expression in a tissue 
specific and temporal manner. Coactivators are recruited to promoters by transcription 
factors as they do not possess DNA binding abilities themselves. Once at the DNA, co-
activators can act in several different ways to help initiate gene expression. First  class, 
are coactivators that contribute to the stabilisation of the RNA polymerase II complex 
bound to DNA. Second class, are ATP-dependent chromatin remodelling complexes that 
alter the structure of nucleosomes to allow transcription. The third class of coactivators 
are enzymes that modify  histone tails to create euchromatin needed for efficient gene 
expression (Naar et al., 2001; Rosenfeld et al., 2006). Some coactivators require binding 
to several transcription factors to synergistically activate a promoter. The best example 
of this is the CIITA protein itself. CIITA is a histone acetyltransferase that contains a 
GTP binding domain (Raval et  al., 2001). Recruitment of CIITA to the DNA requires 
the binding of at least three different transcription factors: RFX, NF-Y and CREB (Zhu 
et al., 2000). Mutating the X1, X2 or Y DNA motifs, that  are the binding sites of these 
proteins in the MHC class II promoter, can severely  impair CIITA recruitment and sub-
sequent promoter activation (Masternak et al., 2000). Sequestration of an as yet un-
known coactivator that can act through several transcription factors in the CIITA pro-
moter, in a manner similar to the CIITA protein, could provide the mechanism by  which 
Zta inhibits CIITA gene expression.
To identify  the protein through which Zta represses the CIITA promoter, several 
biochemical techniques could be employed. The first step would be to narrow down the 
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exact protein domain of Zta involved in mediating the inhibition of CIITA transcription. 
This was attempted in the present study, however, expression of lower molecular weight 
forms of Zta in Raji cells remained elusive. It is possible that truncating Zta affects the 
protein’s stability and turnover in the cells. To overcome this, a protein tag such as GST 
or GFP could be fused in front of these Zta constructs. Once the minimal region is es-
tablished, a protein pull-down could be attempted to co-purify associated complexes. 
Followed by mass spectrometry analysis, this technique might yield a number of co-
association partners. To determine which of the identified proteins play a role in the ex-
pression of the pIII promoter, a ChIP assay coupled with qPCR could be undertaken.
Understanding how EBV evades the immune response is critical for developing fu-
ture therapeutic targets. The present study has shed a light on the process of Zta down-
regulation of the CIITA expression, although the exact mechanism of action remains to 
be determined, and further investigations are needed.
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7. Supplementary information.
7.1 Sequences of CIITA promoter constructs.
7.1.1 CIITA (-388+52).
GGTACCAGTGCGGTTCCATTGTGATCATCATTTCTGAACGTCAGACTGTTGAA
GGTTCCCCCAACAGACTTTCTGTGCAACTTTCTGTCTTCACCAAATTCAGTCC
ACAGTAAGGAAGTGAAATTAATTTCAGAGGTGTGGGGAGGGCTTAAGGGAG
TGTGGTAAAATTAGAGGGTGTTCAGAAACAGAAATCTGACCGCTTGGGGCCA
CCTTGCAGGGAGAGTTTTTTTGATGATCCCTCACTTGTTTCTTTGCATGTTGG
CTTAGCTTGGCGGGCTCCCAACTGGTGACTGGTTAGTGATGAGGCTAGTGAT
GAGGCTGTGTGCTTCTGAGCTGGGCATCCGAAAAGCTT
The sequence of the original CIITA pIII cloned promoter region (-388+52) is 
shown. RE sites, KpnI and HindIII, are highlighted in blue and the ZRE in green colour.
7.1.2 CIITA null ZRE.
GGTACCAGTGCGGTTCCATTGTGATCATCATTTCTGAACGTCAGACTGTTGAA
GGTTCCCCCAACAGACTTTCCCCCCTTCTTTCTGTCTTCACCAAATTCAGTCC
ACAGTAAGGAAGTGAAATTAATTTCAGAGGTGTGGGGAGGGCTTAAGGGAG
TGTGGTAAAATTAGAGGGTGTTCAGAAACAGAAATCTGACCGCTTGGGGCCA
CCTTGCAGGGAGAGTTTTTTTGATGATCCCTCACTTGTTTCTTTGCATGTTGG
CTTAGCTTGGCGGGCTCCCAACTGGTGACTGGTTAGTGATGAGGCTAGTGAT
GAGGCTGTGTGCTTCTGAGCTGGGCATCCGAAAAGCTT
The sequence of the ‘CIITA null ZRE’ (-388+52) is shown. RE sites, KpnI and 
HindIII, are highlighted in blue and the mutated ZRE in green colour.
7.1.3 CIITA ZRE 3/4.
GGTACCAGTGCGGTTCCATTGTGATCATCATTTCTGAACGTCAGACTGTTGAA
GGTTCCCCCAACAGACTTTCTGACACACTTTCTGTCTTCACCAAATTCAGTCC
ACAGTAAGGAAGTGAAATTAATTTCAGAGGTGTGGGGAGGGCTTAAGGGAG
TGTGGTAAAATTAGAGGGTGTTCAGAAACAGAAATCTGACCGCTTGGGGCCA
CCTTGCAGGGAGAGTTTTTTTGATGATCCCTCACTTGTTTCTTTGCATGTTGG
CTTAGCTTGGCGGGCTCCCAACTGGTGACTGGTTAGTGATGAGGCTAGTGAT
GAGGCTGTGTGCTTCTGAGCTGGGCATCCGAAAAGCTT
The sequence of the ‘CIITA ZRE 3/4’ (-388+52) is shown. RE sites, KpnI and Hin-
dIII, are highlighted in blue colour, and the ZRE substituted from the BHLF1 promoter 
ZRE 3/4 is shown in green colour.
7.1.4 CIITA -214+52.
GGTACCCTTTCTGTCTTCACCAAATTCAGTCCACAGTAAGGAAGTGAAATTA
ATTTCAGAGGTGTGGGGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGGTGT
TCAGAAACAGAAATCTGACCGCTTGGGGCCACCTTGCAGGGAGAGTTTTTTT
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GATGATCCCTCACTTGTTTCTTTGCATGTTGGCTTAGCTTGGCGGGCTCCCAA
CTGGTGACTGGTTAGTGATGAGGCTAGTGATGAGGCTGTGTGCTTCTGAGCT
GGGCATCCGAAAAGCTT
The sequence of the ‘CIITA -214+52’ is shown. RE sites, KpnI and HindIII, are 
highlighted in blue colour.
7.1.5 CIITA -214+44.
GGTACCCTTTCTGTCTTCACCAAATTCAGTCCACAGTAAGGAAGTGAAATTA
ATTTCAGAGGTGTGGGGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGGTGT
TCAGAAACAGAAATCTGACCGCTTGGGGCCACCTTGCAGGGAGAGTTTTTTT
GATGATCCCTCACTTGTTTCTTTGCATGTTGGCTTAGCTTGGCGGGCTCCCAA
CTGGTGACTGGTTAGTGATGAGGCTAGTGATGAGGCTGTGTGCTTCTGAGCT
GGGAAGCTT
The sequence of the ‘CIITA -214+44’ is shown. RE sites, KpnI and HindIII, are 
highlighted in blue colour.
7.1.6 CIITA -199+52.
GGTACCAAATTCAGTCCACAGTAAGGAAGTGAAATTAATTTCAGAGGTGTGG
GGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGGTGTTCAGAAACAGAAAT
CTGACCGCTTGGGGCCACCTTGCAGGGAGAGTTTTTTTGATGATCCCTCACTT
GTTTCTTTGCATGTTGGCTTAGCTTGGCGGGCTCCCAACTGGTGACTGGTTAG
TGATGAGGCTAGTGATGAGGCTGTGTGCTTCTGAGCTGGGCATCCGAAAAGC
TT
The sequence of the ‘CIITA -199+52’ is shown. RE sites, KpnI and HindIII, are 
highlighted in blue colour.
7.1.7 CIITA -199+44.
GGTACCAAATTCAGTCCACAGTAAGGAAGTGAAATTAATTTCAGAGGTGTGG
GGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGGTGTTCAGAAACAGAAAT
CTGACCGCTTGGGGCCACCTTGCAGGGAGAGTTTTTTTGATGATCCCTCACTT
GTTTCTTTGCATGTTGGCTTAGCTTGGCGGGCTCCCAACTGGTGACTGGTTAG
TGATGAGGCTAGTGATGAGGCTGTGTGCTTCTGAGCTGGGAAGCTT
The sequence of the ‘CIITA -199+44’ is shown. RE sites, KpnI and HindIII, are 
highlighted in blue colour.
7.1.8 CIITA mutant H.
GGTACCAGTGCGGTTCCATTGTGATCATCATTTCTGAACGTCAGACTGTGTCC
TTGTCCCCCAACAGACTTTCGGTTCATCTTTCTGTCTTCACCAAATTCAGTCC
ACAGTAAGGAAGTGAAATTAATTTCAGAGGTGTGGGGAGGGCTTAAGGGAG
TGTGGTAAAATTAGAGGGTGTTCAGAAACAGAAATCTGACCGCTGTTTTAAC
CCTTGCAGGGAGAGTTTTTTTGATGATCCCTCACTTGTTTCTTTGCATGTTGG
 150
CTTCTAGGTTAGGGCTCCCAACTGGTGACTGGTTAGTGATGAGGCTAGTGAT
GAGGCTGTGTGCTTCTGAGCTGGGCATCCGAAAAGCTT
The sequence of the ‘CIITA mutant H’ (-388+52) is shown. RE sites, KpnI and 
HindIII, are highlighted in blue colour, the ZRE substituted from the one reported in Li 
et al. (2009) is shown in green colour, and the mutated crucial regions after Promoter-
Wise comparison are shown in red.
7.1.9 CIITA downstream mutant.
GGTACCCTTTCTGTCTTCACCAAATTCAGTCCACAGTAAGGAAGTGAAATTA
ATTTCAGAGGTGTGGGGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGGTGT
TCAGAAACAGAAATCTGACCGCTTGGGGCCACCTTGCAGGGAGAGTTTTTTT
GATGATCCCTCACTTGTTTCTTTGCATGTTGGCTTAGCTTGGCGGGCTCCCAA
CTGGTGACTGGGGCTGTCGTCTTAGCTGTCGTCTTAGTGTGTAGGAGTCTAGT
TTACGAATCCAAGCTT
The sequence of the ‘CIITA downstream mutant’ (214+52) is shown. RE sites, 
KpnI and HindIII, are highlighted in blue and the mutated region in red colour.
7.1.10 CIITA NF-κB mutant.
GGTACCCTTTCTGTCTTCACCAAATTCAGTCCACAGTAAGGAAGTGAAATTA
ATTTCAGAGGTGTGGGGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGGTGT
TCAGAAACAGAAATCTGACCGCTTGGGGCCACCTTGCAGGGAGAGTTTTTTT
GATGATCCCTCACTTGTTTCTTTGCATGTTGGCTTAGCTTGGATTTAGAAACA
CTGGTGACTGGTTAGTGATGAGGCTAGTGATGAGGCTGTGTGCTTCTGAGCT
GGGCATCCGAAAAGCTT
The sequence of the ‘CIITA NF-κB’ (214+52) is shown. RE sites, KpnI and Hin-
dIII, are highlighted in blue and the mutated region in red colour.
7.1.11 CIITA -1-40 mutant.
GGTACCCTTTCTGTCTTCACCAAATTCAGTCCACAGTAAGGAAGTGAAATTA
ATTTCAGAGGTGTGGGGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGGTGT
TCAGAAACAGAAATCTGACCGCTTGGGGCCACCTTGCAGGGAGAGTTTTTTT
GATGATCCCTCACTTGTTTCTTTGACGTGGTTAGGCTAGGTTATTTAGAAACC
AGTTGTCAGTTTTAGTGATGAGGCTAGTGATGAGGCTGTGTGCTTCTGAGCT
GGGCATCCGAAAAGCTT
The sequence of the ‘CIITA -1-40’ (214+52) is shown. RE sites, KpnI and HindIII, 
are highlighted in blue and the mutated region in red colour.
7.1.12 CIITA -41-80 mutant.
GGTACCCTTTCTGTCTTCACCAAATTCAGTCCACAGTAAGGAAGTGAAATTA
ATTTCAGAGGTGTGGGGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGGTGT
TCAGAAACAGAAATCTGACCGCTTGGGGCCACCTTGACTTTCTCTGGGGGGG
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TCGTCGAAAGACAGGTGGGAGGGTCATGTTGGCTTAGCTTGGCGGGCTCCCA
ACTGGTGACTGGTTAGTGATGAGGCTAGTGATGAGGCTGTGTGCTTCTGAGC
TGGGCATCCGAAAAGCTT
The sequence of the ‘CIITA -41-80’ (214+52) is shown. RE sites, KpnI and HindIII, 
are highlighted in blue and the mutated region in red colour.
7.1.13 CIITA -81-120 mutant.
GGTACCCTTTCTGTCTTCACCAAATTCAGTCCACAGTAAGGAAGTGAAATTA
ATTTCAGAGGTGTGGGGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGTGTG
GACTCCCACTCCCGAGTCAATAGGTTTTAACAAGGTCAGGGAGAGTTTTTTT
GATGATCCCTCACTTGTTTCTTTGCATGTTGGCTTAGCTTGGCGGGCTCCCAA
CTGGTGACTGGTTAGTGATGAGGCTAGTGATGAGGCTGTGTGCTTCTGAGCT
GGGCATCCGAAAAGCTT
The sequence of the ‘CIITA -81-120’ (214+52) is shown. RE sites, KpnI and Hin-
dIII, are highlighted in blue and the mutated region in red colour.
7.1.14 CIITA -121-160 mutant.
GGTACCCTTTCTGTCTTCACCAAATTCAGTCCACAGTAAGGAAGTGAAATTA
ATTTCAGATTGTGTTTTCTTTAGGCCTTTCTGTGTTGCCCCGGCTCTTGTGTTC
AGAAACAGAAATCTGACCGCTTGGGGCCACCTTGCAGGGAGAGTTTTTTTG
ATGATCCCTCACTTGTTTCTTTGCATGTTGGCTTAGCTTGGCGGGCTCCCAAC
TGGTGACTGGTTAGTGATGAGGCTAGTGATGAGGCTGTGTGCTTCTGAGCTG
GGCATCCGAAAAGCTT
The sequence of the ‘CIITA -121-160’ (214+52) is shown. RE sites, KpnI and Hin-
dIII, are highlighted in blue and the mutated region in red colour.
7.1.11 CIITA -161-214 mutant.
GGTACCAGGGAGTGAGGACAACCCGGACTGAACACTGCCTTCCTGTCCCGG
CCGGGACTCGGTGTGGGGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGGT
GTTCAGAAACAGAAATCTGACCGCTTGGGGCCACCTTGCAGGGAGAGTTTTT
TTGATGATCCCTCACTTGTTTCTTTGCATGTTGGCTTAGCTTGGCGGGCTCCC
AACTGGTGACTGGTTAGTGATGAGGCTAGTGATGAGGCTGTGTGCTTCTGAG
CTGGGCATCCGAAAAGCTT
The sequence of the ‘CIITA -161-214’ (214+52) is shown. RE sites, KpnI and Hin-
dIII, are highlighted in blue and the mutated region in red colour.
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